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Abstract 
The optimal therapy for atrial fibrillation (AF) associated with heart failure (HF) is unclear. Drug-based rhythm 
control has not proved clinically beneficial. Catheter ablation-based rhythm control improves cardiac function in 
HF patients, but impact on physiological performance has not been formally evaluated in a randomised trial. 
A randomised trial was designed and conducted, comparing catheter ablation with rate control in adults with 
symptomatic heart failure, radionuclide left ventricular ejection fraction (EF) ≤35%, and persistent AF. The 
primary outcome was change in peak oxygen consumption (VO2) at cardiopulmonary exercise test. Secondary 
endpoints included change in quality of life (Minnesota), 6-minute walk, BNP, and EF. Patients were followed-
up for 12 months, and results analysed by intention-to-treat. 
52 patients (63±9y, EF 24±8%, VO2 17.3±5.1ml/kg/min) were randomised, 26 to each arm.  In the ablation arm, 
at 12 month follow up, 88% maintained SR, with a single procedure success of 69%. In the rate control arm, rate 
criteria were achieved in 96% at 12 months.  At 12 months, peak VO2 had increased by 2.13 (95%CI -0.1 to 
4.36) ml/kg/min in the ablation arm, compared with a decrease (-0.94ml/kg/min, 95%CI -2.21 to 0.32) under rate 
control: mean benefit of ablation +3.07ml/kg/min, 95% CI 0.56-5.59, p=0.018.  The change appeared 
progressive, with a difference of only 0.79ml/kg/min at 3 months (95% CI -1.01 to 2.60, p=0.38).  Compared 
with rate control, ablation reduced 12-month Minnesota score (p=0.019) and BNP (p=0.045), and showed trends 
toward increased 6 min walk distance (p=0.095) and EF (p=0.055). LA size fell significantly after ablation 
(p=0.001). 
Catheter ablation of persistent AF in patients with HF, with the ablation strategy achieving sinus rhythm in the 
majority, improves prognostically important objective cardiopulmonary exercise performance, symptoms and 
neurohormonal status. The effects are clear at 1 year but less distinct earlier, suggesting a period of cardiac 
remodelling and recovery. 
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1 Introduction  
1.1 Background 
In An anatomical disquisition on the motion of the heart and blood in animals (1628),1 
William Harvey wrote: 
“It is...evident that the auricles pulsate, contract...and throw the blood into the ventricles.  
The auricles are prime movers of the blood…whence they are subservient to sending the 
blood into the ventricles, which…more readily and forcibly expel the blood already in 
motion; just as the ball-player can strike the ball more forcibly and further if he takes it on 
the rebound than if he simply threw it” 
Early physiological studies with mammalian heart preparations suggested that the systolic 
contraction of the atria contributed up to 50% of ventricular filling and subsequent ventricular 
stroke volume.2, 3  Although this contribution was found to be nearer 10-15% in vivo with 
early pacing studies,4, 5 it became apparent that the ‘primer pump’ function of the atrium is 
increasingly important in cardiac disease and during exercise, contributing upwards of 30% 
towards cardiac output in these states.6, 7   
Thomas Lewis8 was one of the first to recognise how this ‘primer pump’ function is lost in 
atrial fibrillation (AF) leading to a drop in cardiac output.  In AF, the atria undergo rapid and 
chaotic excitation at rates of 300-600 per minute.  In most circumstances the atrioventricular 
(AV) node prevent conduction of many of these impulses, thereby protecting the ventricles 
from life threatening rapidity.  The ventricles are usually subject, however, to excitation at 
rates higher than normal, particularly during exercise, and to beat-to-beat variability leading 
to an irregular pulse and suboptimal haemodynamics.  It is no surprise therefore that the co-
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existence of this condition with reduced cardiac pump function can have significant 
consequences. 
1.2 Atrial fibrillation in heart failure 
Atrial fibrillation (AF) and chronic heart failure (HF) represent two major cardiovascular 
conditions associated with significant morbidity and mortality,9, 10 and which impose a heavy 
burden on healthcare systems.11, 12  They often coexist (Figure 1-1): AF is present in 10-15% 
of those with mild heart failure (NYHA II-III) and up to 50% of patients severe heart failure 
(NYHA IV).13-19  In the Framingham cohort 22% of heart failure patients, without prior AF, 
developed the arrhythmia within just over 4 years.20   
 
Figure 1-1 Prevalence of AF in major heart failure trials.  
Reproduced with permissions.13, 21 CHF-STAT = Congestive Heart Failure Survival Trial 
of Antiarrhythmic Therapy;16 CONSENSUS = Cooperative North Scandinavian Enalapril 
Survival Study;14 DIAMOND CHF = Danish Investigations of Arrhythmia and Mortality 
on Dofetilide Congestive Heart Failure study;22 GESICA = Grupo de Estudio de la 
Sobrevida en la Insuficiencia Cardiaca en Argentina;17 SOLVD = Studies of Left 
Ventricular Dysfunction;18, 23 V-HeFT = Vasodilator in Heart Failure Trial.15  
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1.2.1 Impact on morbidity and mortality 
The onset of AF in heart failure is associated with detrimental haemodynamic effects, 
increased hospitalisation, and increased mortality.18, 24, 25  Indeed, AF occurring in previously 
normal hearts can in some cases cause a (‘tachycardia-induced’) cardiomyopathy due to 
excessive ventricular rate.26, 27  The interplay between the two conditions can produce a 
vicious cycle of deterioration.28  
It remains unclear whether AF is an independent prognostic marker, or whether it is merely a 
marker of associated co-morbidity and disease severity.  In the Vasodilator in Heart Failure 
trial, AF had no independent effect on mortality,15 and in a study of patients referred for 
transplant assessment, AF was not independently associated with reduced event-free 
survival.29   On the contrary, several studies have shown AF to be an independent prognostic 
marker in heart failure patients.  
In the SOLVD study, baseline atrial fibrillation was an independent predictor of all-cause 
mortality (relative risk 1.34) – predominantly due to pump failure, and of hospitalization for 
heart failure.18  In the COMET study, AF at baseline was a univariate, but not multivariate, 
predictor of mortality (Figure 1-2a).  New onset AF during the study was, however, a strong 
predictor of all-cause mortality in follow-up (Figure 1-2b).25   
Those with preserved systolic function may not fare better:  in patients presenting to the 
emergency department with AF and heart failure, 5 year mortality was similar for those with 
depressed and preserved ejection fraction.30  Indeed, the CHARM data suggested AF was 
associated with a greater risk of major adverse events (cardiovascular death, hospitalization 
for worsening heart failure, and all-cause mortality), compared with sinus rhythm, and the 
effect was greater in those with preserved systolic function (EF>40%).31   
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Figure 1-2  Mortality in the COMET trial 
a) by presence of AF at baseline 
b) by occurrence of new onset AF if sinus rhythm at baseline.   
Reproduced with permission from Swedberg et al.25 
 
 
A further possible indicator of the negative effect of AF is the impact on mortality in the 
SCD-HeFT trial.  In contrast to patients in sinus rhythm, the presence of AF was associated 
a 
b 
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with no mortality benefit from ICD implantation, in addition to being associated with 
increased frequency of both appropriate and inappropriate shocks.32  However, the number of 
patients in the AF sub-group was relatively small to draw definitive conclusions.   
Reassuringly, the development of AF does not appear to negate the mortality reduction seen 
with cardiac resynchronisation therapy (CRT), although CRT does not appear to have a 
beneficial effect in reducing AF occurrence in the heart failure population.33, 34 Restoration of 
sinus rhythm has been associated with improved survival.16  In the DIAMOND trial, which 
enrolled patients with EF <35% in NYHA class III and IV, maintenance of sinus rhythm was 
an independent marker of survival (risk ratio=0.44; 95% CI, 0.30-0.64; p<0.0001). 
Importantly, however, use of dofetilide (active treatment), like all other tried anti-arrhythmic 
agents examined to date, was not in itself associated with improved mortality.35 
1.2.2 Atrial fibrillation promoting heart failure 
The onset of atrial fibrillation is associated with several factors that may impair cardiac 
function.  These include loss of atrial contraction, irregularity of ventricular contraction, and 
rapid heart rate. The rapid heart rate can in itself lead to the development of a tachycardia-
related cardiomyopathy.  There is also evidence that AF leads to a significant decline in peak 
oxygen consumption compared with sinus rhythm.15, 36 
Loss of atrial contraction leads to a reduction in end-diastolic filling and thus lowers stroke 
volume and cardiac output.37  The reduction in stroke volume may be greater than 20% due to 
this alone, and is of even greater significance in patients with low cardiac output at baseline 
and those with impaired diastolic filling. 
Irregularity of ventricular contraction impairs haemodynamics independently of overall heart 
rate,38, 39 and may also increase cardiac sympathetic activity. 40  There are changes in coronary 
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blood flow, with increased resistance and reduced flow reserve.  Together with increased 
cardiac work, all these factors may contribute to the development of angina in some AF 
patients – even in the presence of angiographically normal coronary arteries.10  Regularisation 
of the heart rate has been shown to improve left ventricular function. 41    
Tachycardia is associated with reduced diastolic time and thus left ventricular filling and 
stroke volume.  AF patients may have high resting heart rates, and have suboptimal cardiac 
output with further increases in rate.42  Even in patients with controlled resting rates, there 
may be a disproportionate increase in heart rate on minimal activity, a finding exaggerated in 
those with heart failure – at least in part due to sympathetic drive.43  Prolonged periods of 
tachycardia in atrial fibrillation and other atrial arrhythmias, notably atrial flutter,44 have been 
recognised to lead to development of a cardiomyopathy.  Restoration of sinus rhythm, control 
of ventricular rate by drugs or catheter ablation of the atrioventricular junction, have been 
shown to achieve clinical recovery in patients initially thought to have underlying idiopathic 
cardiomyopathy, ultimately leading to a revision of diagnosis to tachycardia-related 
cardiomyopathy.26, 27 Equally, it is not uncommon for tachycardia to decompensate a pre-
existing cardiomyopathy.    
1.2.3 Heart failure promoting atrial fibrillation 
It is well established that both systolic and diastolic heart failure are risk factors for the 
development of AF, and for the recurrence of AF after electrical cardioversion.9, 45   
The underlying mechanisms that lead to the development of AF are complex, under continued 
investigation, and an area of debate. Our current understanding of the mechanisms of AF 
includes contributions from the following mechanisms: 
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1.2.3.1 Focal initiation 
Rapid atrial activity may arise focally by means of increased automaticity, triggered activity, 
or local re-entry, usually from the region of pulmonary veins. 46, 47 Increased atrial pressure, 
so-called ‘stretch’, is known to increase the frequency of electrical discharge from the 
pulmonary veins, and may contribute to both initiation and maintenance of AF.48 
1.2.3.2 An atrial substrate capable of maintaining AF 
Re-entry of multiple wavelets was first suggested by Moe49 and then validated by Allessie in 
canine then human hearts.50  In this state, there must be multiple simultaneous re-entrant 
wavelets to maintain fibrillation.  Prerequisites for re-entry are: presence of central 
unexcitable tissue, unidirectional conduction block, and maintenance of excitable tissue ahead 
of the wavefront (‘excitable gap’).  Shortening of the local refractory period, and slowing of 
conduction are hence pro-arrhythmic.  In addition, a critical mass of tissue is needed for 
simultaneous wavelet coexistence, so atrial dilatation and/or hypertrophy also lends itself to 
maintenance of AF.  
Electrical rotors,51 which may maintain atrial fibrillation in the presence or absence of 
multiple wavelet re-entry, could contribute, although their existence and nature remains 
debated. 
The autonomic nervous system may play a dominant role both in the process of focal 
initiation of atrial fibrillation, and in the process of maintenance of the arrhythmia. In 
particular, simultaneous sympathetic and parasympathetic discharge to the atrium can 
contribute towards increased automaticity, triggered activity, shortened refractoriness and re-
entry. 
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1.2.3.3 Remodelling 
A change in atrial substrate follows the onset of AF, can be both structural and electrical, and 
encourages its persistence.  This is termed remodelling. 
Reduction of L-type Ca2+ and transient outward K+ currents appear of particular importance in 
electrical remodelling, being associated with more easily inducible and longer-lasting AF in 
animal models, and probably playing a role in the progression from paroxysmal to persistent 
AF that is observed clinically (“AF begets AF”).52  Alterations in gap junctions expression 
and distribution are also observed in patients with AF, which may contribute to 
arrhythmogenesis via changes in intercellular conduction and hence intra-atrial conduction.53  
Atrial dilatation can accompany the increased diastolic pressures in the failing heart.  Acute 
atrial dilatation in the isolated rabbit heart shortens the atrial refractory period and markedly 
increases AF inducibility.54  Conversely, an acute increase in atrial pressure in dogs is 
associated with lengthening of the atrial refractory period.55  This might not be expected to be 
pro-arrhythmic, but further investigation in the canine model has found increased dispersion 
of refractoriness, which was associated with greater AF inducibility.56, 57  Similar changes 
appear to occur in humans,58, and atria in heart failure patients appear to have increased 
refractoriness, regional slowing of conduction, and areas of scar.59  Fibrosis leads to impaired 
cell-cell coupling, causing inhomogeneity of conduction, further contributing to a pro-
fibrillatory state.      
The nature of remodelling differs in heart failure and non-heart failure animal models of AF.  
In the non-heart failure goat and dog model, where repeated bursts of rapid atrial pacing 
(RAP) are used to induce and maintain the arrhythmia, the electrical changes that occur 
appear reversible within a few days,52, 60 and fibrosis appears similar to controls.61  In the 
heart failure-model in dogs, prolonged rapid ventricular pacing is used to induce 
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cardiomyopathy: in one study the effect on AF inducibility in heart failure-dogs at 5 weeks 
was similar to that at 1 week in RAP-dogs (the delayed effect might be expected due to the 
‘indirect’ nature of atrial perturbation in the former), and atrial fibrosis was markedly 
increased.61  In the same model, significant changes in ion current densities occur, but in 
those allowed to recover from ventricular pacing, these electrical changes reverse completely.  
However, the duration of induced AF and fibrosis did not recover, perhaps suggesting a 
primary contribution of structural remodelling to AF maintenance in heart failure.62   
Angiotensin II, along with various protein kinase signalling pathways, has been implicated in 
the structural remodelling process.  Myocardial stretch increases local protein kinase and 
angiotensin II levels, 63, 64 which are associated with development of atrial fibrosis. 65  As 
inhibition of endogenous angiotensin II can prevent the shortening of refractoriness after 
rapid atrial pacing, it may be that angiotensin II is also involved in the mechanism of 
electrical remodelling.66  Either way, this underlies the interest in modulation of this 
angiotensin activity as a means of reducing AF recurrence.  
1.3 Management of atrial fibrillation 
1.3.1 Atrial fibrillation in context 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting 1% of the 
general population. Recent studies indicate that the lifetime risk may exceed 20%.67  
Prevalence increases with age, rising to 8% over 80y,68 with median age 75y.69  It is estimated 
that there are 2.3 million people in the United States, and 4.5 million in the European Union 
with AF.10   The prevalence is increasing – in part due to population aging, but also due to an 
increase in age-adjusted AF incidence – which clearly has significant implications for health 
service planning during this century (Figure 1-3).  
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AF is associated with increased mortality.  In the Framingham Study, AF conferred a relative 
all-cause mortality risk of 1.8.9   Much of this is attributable to stroke, the risk of which is 
increased 5-fold in those with AF – but varies according to age and co-morbidities.   
AF is well known to be associated with several conditions, including hypertension, heart 
failure, coronary artery disease, valvular heart disease, and thyrotoxicosis. Many of these 
conditions can cause mechanical (including stretch and fibrosis) and electrical changes 
(remodelling) that, when coupled with a genetic predisposition70 and triggered by events that 
may be in part mediated by changes in cardiac autonomic activity, can precipitate AF.  AF in 
itself enhances further remodelling, thus encouraging its own perpetuation.52 The 
pathogenesis of AF involves a complex interplay between mechanisms of initiation 
(extremely rapid electrical activity arising from pulmonary veins) and mechanisms of 
perpetuation (reentry or circus movement of electrical waves in the atria).  These are in 
addition influenced by genetic makeup, atrial stretch, fibrosis, changes in the electrical 
properties of the heart, and autonomic nerves.  It is no surprise that AF is highly 
heterogeneous and that attempting to combat it is highly challenging. 
 
 
25 
 
Figure 1-3  Atrial fibrillation – the scale of the problem 
Projected number of persons with AF in the United States between 2000 and 2050, 
assuming no further increase in age-adjusted AF incidence (solid curve) and assuming 
a continued increase in incidence rate as evident in 1980 to 2000 (dotted curve). 
Reproduced with permission from Miyasaka et al. 2006. 71 
  
1.3.2 Medical therapy  
Optimal management requires 
• Recognition of AF 
• Assessment and optimization of thromboembolic risk 
• Treatment of heart failure and its causes 
• Treatment of AF (rate and/or rhythm control) and its causes 
Although AF can be asymptomatic, in the setting of heart failure the onset of AF is often 
associated with significant symptomatic and prognostic decline. Increased recognition of AF 
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is facilitated by more frequent assessment of heart failure patients, and by utilizing the data 
stored in implanted devices.   
Contemporary heart failure therapies already appear to have some impact in reducing AF 
incidence.  Renin-angiotensin system blockade may reduce AF incidence in patients with 
hypertension,10, 72-74 and those with systolic dysfunction.  The effect of renin-angiotensin 
modulation on established AF is not fully established.  Although there appears to be a small 
increase in sinus rhythm maintenance after cardioversion,74  in non-randomized studies of 
patients undergoing catheter ablation, the use of ACE inhibitors or ARBs did not influence 
outcome at 1-year. 
Beta-blockers are now recommended in most heart failure patients, and a recent meta-analysis 
of seven randomized placebo-controlled trials showed a significant reduction in AF 
incidence.75  Possible mechanisms include reduction of adverse ventricular remodelling, 
counteraction of sympathetic hyperactivity,76 ion channel effects,77 and reduction of atrial 
ischemia.78  
1.3.2.1 Anticoagulation 
AF is a major cause of thromboembolic stroke, conferring a five-fold increase in annual risk.  
Stasis in the non-contracting atrium encourages thrombus formation, most commonly in the 
left atrial appendage.  Hypercoagulability and endothelial dysfunction also play a role.10  The 
presence of heart failure further increases the stroke risk 3-fold.79   
Thromboembolic prophylaxis with warfarin reduces the risk of stroke.  Although heart failure 
may increase the risk of major bleeding on anticoagulation,80 the balance of benefit/risk is in 
favour of anticoagulation in the heart failure population as a whole.81    
 
27 
Stroke risk assessment may be performed using the CHADS2 score (based on age, 
hypertension, diabetes, prior stroke or TIA and presence of chronic heart failure).  The current 
recommendations for thromboprophylaxis in AF patients from the ACC/AHA/ESC Task 
force10 advocate warfarin for heart failure patients either aged over 65y, or with LVEF<35%.  
Those with paroxysmal AF should be stratified and treated in the same way as those with 
persistent AF.    
1.3.2.2 Rate control 
Drugs achieve control of the ventricular rate during AF by increasing refractoriness of the 
atrioventricular node.  Ideally, rate-controlling agents should control the heart rate at rest and 
on exercise in a graded manner, but without negative inotropic effect.  
Management of acute heart failure when AF is present is challenging as the two conditions 
may contribute to a vicious cycle of deterioration.  Restoration and maintenance of sinus 
rhythm may be difficult or dangerous. In the absence of anticoagulation, in those without a 
clear history of AF onset within the last 48 hours, cardioversion requires prior 
transoesophageal echocardiography to rule out atrial thrombus – but this may not be feasible 
or appropriate.  Moreover, AF often rapidly recurs in decompensated patients.  In all these 
circumstances, early control of the ventricular rate plays a key role. 
Suggested targets for rate-control are resting heart rate 60-80 beats/min, and 90-115 on 
moderate exercise.10  In the AFFIRM trial, goals were pre-defined as  <80 bpm at rest, and 
<110bpm during 6-minute walk.82  In retrospective analysis of the RACE trial (target 
<100bpm at rest only) and AFFIRM data,83 the primary endpoint of mortality, cardiovascular 
hospitalization, and myocardial infarction did not differ between those who achieved or did 
not achieve rate target.   
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It is uncertain whether goals should be the same in heart failure.  The on-going RACE II 
study,83 prospectively comparing ‘strict’ versus ‘lenient’ rate control (including in heart 
failure patients), may provide further guidance. Rate control during AF is also particularly 
important in patients with implanted devices to allow optimal benefit from cardiac 
resynchronization therapy (CRT) and to reduce inappropriate ICD shocks. 
In heart failure patients, digoxin improves symptoms and reduces hospitalizations, albeit with 
a neutral effect on mortality.84,85  It can control the ventricular rate at rest but not during 
exercise.  Digoxin is usually well tolerated, partly due to its lack of negative inotropic effect, 
may be the safest drug to initiate first, and is currently recommended as part of a rate-control 
strategy for those with LV dysfunction.10 
Beta-blockers control the ventricular rate at rest and on exertion, improve symptoms, and are 
particularly useful as combination therapy with digoxin,86 and are the agents of choice for rate 
control in patients with heart failure.87-91  They may also reduce ectopic triggers of AF.   
Although the principal role of amiodarone in AF is as a rhythm controller, it can provide a 
modest degree of rate-control and may have a role especially where beta-blockers are not 
tolerated. 
The use of non-dihydropyridine calcium blockers in patients with significant systolic heart 
failure is controversial, and caution should be exercised.  The principal concern is the 
negative inotropic effect, which is more marked with verapamil than diltiazem. 92-95   Acutely, 
like beta-blockers, the negatively inotropic effects of calcium blockers may be offset by the 
reduction in heart rate.  Furthermore, diltiazem-related vasodilatation reduces afterload, 
leading to beneficial haemodynamics and may improve overall LV performance.94  
Intravenous diltiazem has been studied in critically ill patients: in patients with significant 
systolic dysfunction, it achieved rate control with no worsening of heart failure, but caused 
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hypotension in 8%.96  In comparison with intravenous amiodarone it could control the heart 
rate faster and more effectively, but hypotension required discontinuation of therapy in 30% 
of patients.97  Long term use appears unsafe: although oral diltiazem has shown some benefit 
in early dilated cardiomyopathy,98 it is associated with poor outcomes in those with ischemic 
systolic heart failure.99   
In the non-heart failure population, oral diltiazem is safe and highly effective, and may be 
superior to beta blockers for exercise rate-control.100 Its use is reasonable in patients with 
relatively preserved systolic function, particularly if intolerant of other drugs, and should be 
considered after beta blockers/digoxin to assist rate control if a tachycardia-cardiomyopathy is 
suspected.   
Combination therapy increases the possibility of significant bradycardia, due to effects on the 
sinus node (paroxysmal AF) or AV node (persistent AF). Nonetheless, combination treatment 
can be useful in selected cases. Conversely, some patients require pacemaker implantation for 
symptomatic bradycardia even without rate controlling drugs, or may have periods of 
tachycardia as well as bradycardia requiring hybrid treatment with rate slowing agents and a 
pacemaker.  
1.3.2.3 Rhythm control 
1.3.2.3.1 Electrical cardioversion 
The presence of even mild-moderate heart failure reduces the likelihood of successful 
cardioversion and maintenance of sinus rhythm. Also, the risks of sedation and/or general 
anaesthetic are increased in those with severe heart failure,81  and attempts should be made to 
control heart failure prior to cardioversion.  
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1.3.2.3.2 Anti-arrhythmic drugs 
Pharmacologic therapy may be preferable to electrical cardioversion in that it avoids general 
anaesthesia and may also help maintain sinus rhythm.  Although restoration and maintenance 
of sinus rhythm is known to be a beneficial prognostic marker, no anti-arrhythmic drug has 
been proven to directly reduce mortality.  The limited efficacy of pharmacologic therapy at 
restoring sinus rhythm means that from a practical perspective, electrical cardioversion with 
adjuvant pharmacologic therapy may be a reasonable approach. 
The class I drugs flecainide, procainamide and propafenone, whilst suitable and often highly 
effective treatments for AF in patients with structurally normal hearts, have important 
negative inotropic effects, are potentially proarrhythmic, and should generally be avoided in 
heart failure patients, particularly those with previous myocardial infarction.101   
Class III agents appear safer in heart failure.  Amiodarone, dofetilide, and sotalol can help 
restore and maintain sinus rhythm.  Dofetilide is effective at restoration and maintenance of 
sinus rhythm and has neutral effect on mortality.35  However, the significant incidence of 
torsade de pointes around the time of initiation necessitates inpatient treatment.  Amiodarone 
reduces incidence of AF in heart failure, and appears similarly neutral on mortality.16, 17, 102 
Significant impairment of LV function is unusual and, although sub-group analysis of SCD-
HeFT trial data suggested a detrimental effect in NYHA III patients,103 amiodarone is 
currently the safest anti-arrhythmic agent available for use in heart failure.   
New antiarrhythmic drugs have been developed – some with multiple ion-channel blocking 
effects that mimic the action of amiodarone, and some with specificity for atrial ion-channels 
(IKAch and IKur).  The most prominent of these is dronedarone, a multi-channel blocker similar 
in chemical structure to amiodarone, but without the iodinated component, was recently 
introduced and looked promising as a potential alternative antiarrhythmic in an early trial.104   
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However the ANDROMEDA study, 105 which evaluated the effect of dronedarone therapy in 
a cohort of patients with symptomatic severe LV dysfunction, showed excess early mortality 
due to worsening heart failure and was terminated early.   In effect this has ruled out its use in 
patients with NYHA III/IV heart failure and/or significant LV impairment.  
1.3.3 Non-medical therapy 
1.3.3.1 Rate control  
1.3.3.1.1 AV node ablation and implantation of permanent pacemaker 
Patients who require rate control but who remain tachycardic despite optimal pharmacological 
treatment, have a further option: radiofrequency catheter ablation of the AV junction.  This 
necessitates implantation of a permanent pacemaker, but achieves rate control and 
regularization of the ventricular rate.106   
This “ablate and pace” strategy is generally effective and well tolerated, with many studies 
showing an improvement in quality of life and left ventricular function.26, 41, 106  However, a 
randomized trial (chronic AF, mean NYHA class 2.7) comparing ablation and VVIR pacing 
with pharmacological treatment showed no benefit on cardiac performance or quality of 
life,107 despite significant improvements in exercise tolerance and symptomatic palpitation.  
Failure of improvement in EF after this treatment may predict a poorer outcome.108   
More recently, the PAVE study looked at the optimal site of ventricular pacing in these 
patients.109  Prompting this were previous studies showing adverse perfusion and 
haemodynamics with long term right ventricular apical pacing (RVP),110 worse clinical 
outcomes from RVP in the DAVID defibrillator trial,111 and symptomatic benefit seen after 
upgrading from RVP to biventricular pacing (BVP) in a small cohort of ablate/pace 
patients.112   PAVE compared BVP with RVP in 184 patients, and suggested BVP preserves 
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EF while RVP is associated with falling EF.  Six minute walk distance was 53% greater with 
BVP at 6 months.  Subgroup analysis showed the main benefit was in NYHA class II and III, 
and with EF <45%.  There was no significant impact on mortality.   
Thus, when heart failure patients are selected for ‘ablate and pace’, implantation of a 
biventricular system should be seriously considered.113  Conversely, patients with permanent 
AF scheduled for implantation of a biventricular device may be considered for ablation of the 
AV node in order to benefit maximally from cardiac resynchronization unless ventricular rate 
control is so good that they are unlikely to conduct to the ventricles, even during exercise.  
However, given the availability of alternative therapies in contemporary era, as discussed 
below, this permanent and essentially irreversible commitment to pacing-dependency might 
more appropriately be deferred until proof exists that medical rate-control or alternative 
rhythm control strategies have failed.  
Polymorphic ventricular tachycardia and sudden death can occur after AV junction ablation, 
but this may be prevented by pacing at a minimum of 80-90 bpm for the first 1-3 months. 114 
1.3.3.2 Rhythm control  
1.3.3.2.1 Surgical and catheter ablation 
A theoretical solution to prevent maintenance of AF is to reduce electrically contiguous atrial 
mass.  Based on the demonstration of multiple wavelet-AF in canine and subsequently human 
hearts,115  the Cox-Maze surgical technique was devised to electrically compartmentalize the 
atria by ‘cut and sew’.  Results from experienced surgical centres are impressive: 5-year AF-
freedom is 80-90%, and 68% in those who underwent concomitant mitral valve surgery.  
Pacemaker implantation rate was 10%, mostly due to underlying sinus node dysfunction, and 
mortality was low (0.9%) despite concomitant coronary or valve surgery in many.116  The 
effect on ventricular function is encouraging: in those with severe preoperative ventricular 
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impairment (EF <35%, n=11), there was an improvement in mean EF (31 to 53%) which was 
sustained at follow up.27  Another potential benefit is amputation of the left atrial appendage 
and theoretical reduction of stroke risk. 
However, many centres have found it difficult to reproduce the results and low complication 
rates initially reported in expert hands with this complex surgical technique.  Alternative 
methods have been developed, avoiding “cut and sew” and sometimes cardiopulmonary 
bypass.  Bipolar radiofrequency, microwave and cryoablation are widely used in specialist 
centres, usually with concomitant cardiac surgery.  Unipolar radiofrequency ablation is now 
used infrequently because of the potential for life-threatening oesophageal damage.  Further 
long-term results are awaited.  
1.3.3.2.2 Radiofrequency Catheter Ablation 
The discovery in the late 1990s that AF could have a focal origin, often in the PV, led to the 
use of catheter ablation techniques to eliminate abnormal foci,47 and later to completely 
isolate the PV from the left atrium.  Subsequently, advancing technology has enabled creation 
of linear atrial lesions similar to those used in surgical maze procedures. In patients with 
advanced AF, a combination of several ablation targets/techniques may be necessary to 
modify atrial electrophysiology enough to restore sinus rhythm and prevent AF.  Possible 
ablation strategies include:  
• Segmental or circumferential PV isolation 
• Linear ablation to partly compartmentalize the atria 
• Ablation in areas of slow, heterogeneous conduction (at sites of complex fractionated 
electrograms) 
• Ablation at sites of ganglionic plexi  
 
34 
• Further linear ablation in refractory cases, but risking exclusion of atrial tissue from 
electrical activation and hence contraction.  
 
These techniques have been greatly facilitated by the development of technologies for non-
fluoroscopic catheter navigation and ablation.  Systems such as CARTO™ (Biosense-
Webster) and NavX™ (St Jude Medical) can localize catheters in a 3-dimensional 
environment and allow creation of a virtual atrial map.  Imaging from CT or MRI can be 
integrated to improve accuracy.  
Importantly, significant complications occur in 2-6% of patients and include transient 
ischaemic attack or stroke (0.5-1.5%), tamponade (0.5-4%), symptomatic PV stenosis (<1%), 
and right phrenic nerve palsy (0.3%, usually transient). Procedures are long (several hours), 
require specialist facilities and expertise, and are modestly more challenging in patients with 
heart failure, and less effective in those with dilated atria.   
There is increasing evidence that restoration of sinus rhythm is desirable, even though studies 
based on pharmacologic therapy have failed to show a mortality advantage: this may be due 
to poor efficacy, or pro-arrhythmic and negatively inotropic effects of these drugs.  It remains 
unclear at present whether catheter ablation offers a prognostic advantage, although some 
small studies have addressed this question in heart failure patients (see section 1.3.4.1).  
1.3.4 Rate versus rhythm control 
Although rate and rhythm control treatments have been available to treat AF for several 
decades, a significant evidence base for applying one or other strategy was not present until 
after the turn of this century.   
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The issue of rate versus rhythm control as initially investigated by large multicentre studies in 
the general AF population.  Five studies compared rate-control with rhythm-control.82, 117-120  
Perhaps surprisingly, none found an advantage from rhythm-control.  In AFFIRM, the largest 
of these trials, rate control appeared non-inferior to rhythm control, and was associated with 
fewer hospitalizations, strokes, and episodes of torsade de pointes.  However, a much greater 
proportion of patients had anticoagulation withdrawn in the rhythm control arm once rhythm 
control was achieved, which may in part explain the increased risk of stroke.  It was felt that 
the observed increase in stroke risk (a major adverse outcome) from rhythm control – 
attributable to cessation of anticoagulation after cardioversion and/or achievement of sinus 
rhythm – may have been avoided if appropriate anticoagulation had been maintained as in 
rate-control patients.121  More encouragingly, recent data have shown a reduced risk of stroke 
in a rhythm-control model.104 
Considering the heart failure population, the AFFIRM data was interesting in that rate control 
was significantly superior in the subgroup of patients without congestive heart failure, whilst 
those with congestive heart failure showed a trend towards superiority of rhythm control 
(Figure 1-4). Physicians are often faced with patients who present with exacerbations of heart 
failure at or soon after the onset of AF.  In addition, although controlling the heart rate may 
counter some of the adverse effects of AF in this population, the loss of atrial contraction 
persists if AF is accepted.  Perhaps on these bases, one might expect that restoring sinus 
rhythm would be superior to rate control. Naturally, conclusion could not been drawn from 
this subgroup analysis, and a clinical trial was needed in the heart failure population.
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The AF-CHF trial was the first to prospectively compare rate and rhythm control specifically 
in a heart failure population.  It randomised 1376 patients with NYHA II-IV functional class 
heart failure, a left ventricular ejection fraction ≤35%, and a history of AF, to rate control 
(mostly beta-blockers and digoxin) or rhythm control (mostly amiodarone; up to 2 DC 
cardioversions could be performed within 3 months of randomisation).  There was no 
difference between the two strategies in terms of death from cardiovascular or all causes, 
stroke, or worsening heart failure (Figure 1-5).122   As in previous studies, rhythm control was 
associated with more hospitalisations, for cardioversion, bradycardia, or adjustment of 
antiarrhythmics.   However, important information such as the effect on quality of life has yet 
to be published. 
This may appear to answer the question of best prognostic treatment strategy for AF in heart 
failure.  Rate control appears a sufficient therapy, and avoids the complications associated 
with rhythm control.  However, another observation, that of the rhythm at outcome in these 
studies, prompts further evaluation.  In AFFIRM, on-treatment analysis showed the presence 
of sinus rhythm was associated with a 47% reduction in mortality, while use of antiarrhythmic 
drugs was associated with increased mortality.123  In the RACE trial in a sub-study of patients 
in NYHA II/III heart failure, the successful maintenance of sinus rhythm in the rhythm 
control arm appeared beneficial at follow up, with a trend towards lower mortality, bleeding, 
heart failure hospitalization, and pacemaker implantation.  Purely by intention-to-treat, more 
cardiovascular deaths, heart failure hospitalization, and bleeding occurred in patients 
randomized to rate control, whilst thromboembolic complications, drug side effects, and 
pacemaker implantation were more frequent under rhythm control.124  Restoration of sinus 
rhythm was associated with improved survival in the DIAMOND trial, which enrolled 
patients with EF <35% in NYHA class III/IV.  Maintenance of sinus rhythm was an 
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independent marker of survival, although use of the rhythm-control drug – dofetilide – did not 
confer the same advantage.35   
A further consideration is that of the cohorts studied, in particular their rhythm status during 
and after therapy.  In AFFIRM 54% of patients were already in sinus rhythm at enrolment, as 
they included paroxysmal and persistent AF.  Of those on rate control, 35% were in sinus 
rhythm at 5 years.  Similarly, in AF-CHF, only two thirds were in AF at trial onset; the 
outcomes are further weakened by a 21% crossover from rhythm to rate control (due to 
‘failure’ of rhythm control) and a 10% crossover in the other direction (mostly for worsening 
heart failure); 58% of rhythm-control patients had documented recurrent AF during the study.  
This highlights two problems: i) rate versus rhythm studies have not generally compared these 
treatment modalities for persistent AF, and ii) pharmacologically based rhythm control is not 
very effective.  Ultimately, this means we cannot conclude that the strategy of rhythm control 
is not warranted, or that restoration of sinus rhythm would not be advantageous.  
There is significant evidence that sinus rhythm is associated with improved symptoms, quality 
of life, hospitalisations and mortality.  If AF is truly an independent risk factor for worsening 
heart failure, then the conclusion has to be there is another reason for apparent lack of benefit 
from rhythm-control strategies. The first may be their relative inefficacy in maintaining sinus 
rhythm, thus potentially weakening the statistical benefit in treatment groups.  However a 
more compelling reason may be the adverse effects, including proarrhythmia, negative 
inotropy, and extra-cardiac complications, of antiarrhythmic drugs used in rhythm-control 
trials to date.123  Thus, the true benefit of maintaining sinus rhythm in heart failure patients 
may be difficult to establish using drug-based rhythm-control strategies.   
  
39 
1.3.4.1 Catheter ablation as an alternative rhythm-control strategy 
Catheter ablation, a therapy which could restore sinus rhythm without the need for long-term 
antiarrhythmic drug therapy, might be the logical solution to determining and achieving the 
potential benefit of maintaining sinus rhythm in heart failure patients.  Radiofrequency 
catheter ablation for AF has developed from two sources: first, the recognition that 
compartmentalisation of the atria by surgical cut-and-sew techniques (such as the Cox Maze), 
could restore and maintain sinus rhythm in patients with even persistent and permanent 
AF;115, 116 secondly, the finding that the triggering, re-initiating, and maintaining foci of AF 
can be electrically isolated and/or destroyed in the region of the pulmonary veins,47 with later 
work additionally showing the importance of ganglionated nervous plexi125, 126 and highly 
fractionated electrical activity.127  The development of catheter and computerised mapping 
technology has allowed refinement of these techniques, so that now AF ablation can be 
offered to symptomatic AF patients who fail antiarrhythmic drug therapy,128, 129 and has been 
shown – largely in patients without significant ventricular dysfunction – to be superior to 
medical therapy in terms of quality of life and morbidity130, 131 and, in a retrospective, non-
randomised trial, mortality.132     
Whereas the greatest experience, and highest rate of success, has been in those with 
structurally normal hearts and paroxysmal AF,128, 129 small non-randomised studies have 
examined the feasibility and role of ablation in treating AF in patients with reduced systolic 
function and symptomatic heart failure. 58 patients with congestive cardiac failure and 58 
matched controls without heart failure underwent ablation for (mostly persistent) AF.133   
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Figure 1-6 Impact of AF ablation on LV function 
Improvement of left ventricular echocardiographic parameters after catheter ablation of 
atrial fibrillation, reproduced with permission from Hsu et al,133 Copyright Massachusetts 
Medical Society. 
 
In the heart failure group, at mean follow up of 12 months, LVEF improved by average 21% 
(Figure 1-6), in line with exercise capacity and symptoms.  Sinus rhythm was achieved in 
approximately 80% of patients at 1year follow up.  In 94 AF patients with impaired LV 
function, ablation resulted in maintenance of sinus rhythm in 73%, improvement in quality of 
life, and a non-significant improvement in LVEF for patients who maintained sinus 
rhythm.134  More recently, PVI in patients with paroxysmal AF was shown to improve left 
ventricular function in an observational study.135   
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The PABA-CHF study was reported in mid-2008, and was a multicentre investigation of 81 
patients with LVEF ≤40%, NYHA class II-III heart failure, and drug-resistant atrial 
fibrillation.  Patients were randomised to undergo PVI or atrioventricular node ablation with 
biventricular pacing and followed up for 6 months, with a composite primary endpoint of 
quality of life score, 6-minute walk distance and echocardiographic left ventricular ejection 
fraction.    The success rate of PVI in maintaining sinus rhythm was 71% off antiarrhythmic 
drugs: all three endpoints improved in the PVI group compared with AV nodal ablation.   
However, the population was a mixed bag of about half paroxysmal and half persistent AF, 
and AV node ablation (with pacing) was applied to patients with a mean QRS duration 
90±10ms – which would not be routine practice unless patients had truly failed medical rate 
control (for which there was no pre-requisite).  In fact, the baseline heart rate in the ‘rate-
control’ arm was 82±11bpm, so these patients had reasonable rate control, a narrow QRS, and 
were often in sinus rhythm!  Thus one could argue that the study was pre-designed to show an 
inevitable superiority of PVI over the alternative strategy of nodal ablation and biventricular 
pacing, which is non-physiological and almost certainly worse than intrinsic His-Purkinje 
activation.  Rate regularisation would only be a benefit in those with persistent AF, and would 
of course be at least equalled by those treated with PVI assuming a reasonable rate of success 
in maintaining sinus rhythm.  Overall, therefore, the PABA-CHF study does not provide 
much additional support for the application of PVI over optimal medical therapy, as it did not 
study or reflect contemporary optimal clinical practice.     
Hence, at the time of commencement of this study in October 2008, catheter ablation for 
persistent AF in patients with heart failure had not been tested in a randomised trial, nor was 
it known whether ablation is superior to optimal medical rate-control management in this 
context. 
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1.4 Interventional Electrophysiology 
1.4.1 Historical Background 
The field of clinical cardiac electrophysiology has developed rapidly in the last few decades.  
The discipline of clinical electrocardiography gave rise to physicians and scientists focussed 
on elucidating the mechanism of clinical arrhythmias.  At the same time there was an 
increasing understanding of cardiac anatomy and the conducting system.  In the 1940s and 
1950s it was discovered that cardiac electrical activity which could not be detected by surface 
ECG could be measured by placement of intracardiac electrode catheters.  Thereafter Durrer 
et al,136 simultaneous with Coumel et al,137 showed that cardiac arrhythmias could be 
induced, studied and terminated by programmed stimulation.  In turn this guided surgical, 
pharmacological, and later catheter-based approaches to treating cardiac arrhythmias.   
1.4.2 Radiofrequency Ablation 
In the late 1960s the first surgical interruption of an accessory pathway was performed at 
Duke University,138 and was later applied to interrupt atrioventricular conduction in patients 
with drug-refractory ventricular rates in AF.  However surgical ablation carried with it a 
significant morbidity and mortality, and there was an impetus to find a less invasive and more 
readily applicable approach.     
In 1982, Scheinman et al139 then Gallagher et al140 published their experience of direct current 
(DC) ablation of the AV node, and the era of interventional cardiac electrophysiology was 
born.  Only 5 years later, Borggrefe et al were the first to use radiofrequency (high frequency 
alternating current) as the ablation energy source when treating an accessory pathway.  
Radiofrequency ablation provides a dose-related tissue response and well-defined controllable 
lesion size with both greater lesion longevity and lesser risk of collateral damage than DC 
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shock.  As it uses frequencies in the range 300-1000Hz, skeletal and cardiac muscle are not 
stimulated and the applications is not usually painful, except in sites of epicardial cardiac 
nerve plexi.     
Radiofrequency catheter ablation became the definitive treatment for a variety of clinical 
arrhythmias during the 1990s, including atrioventricular nodal reentry tachycardia 
(AVnRT),141, 142 accessory pathways,143, 144 atrial flutter,145-147 the atrioventricular node,106 and 
ventricular tachycardias.148, 149  
1.4.3 Development of AF ablation 
Development of strategies to treat these common arrhythmias relied upon a detailed 
understanding of the mechanisms involved in tachycardia initiation and maintenance.  This 
was followed by surgical approaches to treatment in many cases, then direct current and 
latterly radiofrequency ablation.  The challenge in treating atrial fibrillation was that 
mechanisms were not clearly understood, and to a certain extent this remains the greatest 
challenge in treating persistent AF. 
Based upon the multiple wavelet hypothesis, compartmentalisation of the atria should lead to 
a substrate where wavefronts can no longer coexist and meander as they will encounter 
electrical barriers to propagation.  An alternative option is to sequester areas of the atrium 
from activation during a beat originating from the sinus node.  This latter approach was the 
basis for the ‘corridor’ procedure introduced by Giraudon and colleagues in 1985, and applied 
to patients with both chronic and paroxysmal AF.150, 151  However, this inevitably leads to 
complete isolation of the left atrium, and the majority of the right, thus does not allow 
restoration or maintenance of normal haemodynamics as neither atrium contracts prior to 
ventricular systole (they remain in fibrillation).  Its use was primarily for allowing the sinus 
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node to remain as pacemaker and to propagate through the normal conducting system to the 
ventricles, avoiding the need for AV node ablation (Figure 1-7). 
 
 
Figure 1-7 The corridor procedure for atrial fibrillation 
Schematic diagram showing the exclusion of the left and majority of the right atrium to 
allow propagation of the sinus impulse through to the atrioventricular node (AVN).  The 
excluded atria remain in fibrillation: the only potential advantage of the procedure over 
AVN ablation was that ventricular pacing could be avoided compared with the AV nodal 
ablation technique.  However, post-operative impairment of the sinus node could still 
necessitate pacemaker insertion.152, 153 Reproduced with permission.154  
 
James Cox separately developed the ‘maze’ procedure, which in contrast to the ‘corridor’ 
procedure sought to render the patient free of AF and maintain atrial activation, allowing 
restoration of the majority of atrial and atrio-ventricular haemodynamics, as well as 
preventing AF and permitting normal sino-atrial pacemaker function (Figure 1-8).  Over 
many years of follow up this has been shown to be highly effective in treating AF, with 
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success rates around 70-90% at long term follow up, varying according to adherence to the 
full Maze-III lesion set, comorbidities, type of surveillance, and duration of follow up.155 
  
Figure 1-8 The Cox-Maze III procedure 
(a) Schematic showing propagation of the impulse from the sinoatrial node (SAN) 
through the post-Maze atrium to the atrioventricular node (AVN).  Adapted and 
reproduced with permission156  
(b) Cox-Maze III lesion set as seen from a posterior view of the atria.  The right shows 
the original operation, the left the more recent modification to avoid posterior wall 
isolation and potentially allow for greater contractile function of the left atrium.  A cryo-
lesion (black asterisk) is typically added at the epicardial coronary sinus  as it has been 
shown to improve outcomes.  Reproduced with permission157  
a 
b 
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This procedure requires open-heart surgery including cardiopulmonary bypass and their 
associated morbidities; it is highly technically challenging and thus has been confined to 
relatively few centres with the sufficient surgical skill and experience; and approximately 
10% of patients require pacemaker insertion for sinus node dysfunction subsequent to 
surgery.155  Alternative energy sources and techniques have been used, in an attempt to make 
the procedure technically easier, and quicker, but with the trade-off being potential lack of 
transmural lesion formation and reduced overall success; such techniques have included 
radiofrequency, microwave, and cryo-ablation.  Most recently the Cox-Maze IV procedure 
was introduced, replacing the majority of Cox-Maze III surgical incisions with bipolar 
radiofrequency lesions, and in an experienced centre this has been shown to be highly 
effective.158 
A less invasive non-surgical approach was sought, in part inspired by the success of catheter 
ablation procedures for other arrhythmias.  In 1994, Schwartz et al159 and Haïssaguerre et 
al160 attempted percutaneous treatment of AF by placement of linear radiofrequency lesions in 
the LA and RA respectively.  Although the former showed great promise in terms of sinus 
rhythm restoration and maintenance, procedural times were in excess of 10 hours, and 
complications >20%.  Catheter and sheath technology required further development, as did 
the lesion strategy.   
Right-atrial lesions were shown to be effective in highly selected patients with paroxysmal 
and persistent AF, but it became apparent this strategy would not suffice in the majority.161, 162   
During this period of development of catheter-based approaches aimed at reproducing linear 
lesions in the atria, Haïssaguerre, Jais and colleagues provided a new insight into the 
mechanism of AF initiation and in turn ushered in a new era in non-pharmacological 
management of AF.   Up until 1996 the majority of computer modelling, animal experimental, 
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and surgical human mapping data supported the multiple wavelet hypothesis, and a focal 
mechanism was not considered likely.  In a small series of 9 patients with paroxysmal AF, 
focal discharges leading to a surface ECG pattern of AF were demonstrated in both the right 
and left atrium, the latter from the pulmonary veins, and all were successfully treated with 
radiofrequency ablation.163  Following this, a larger series of 45 patients was studied, and 
65/69 (94%) of atrial ectopic beats initiating AF originated from the pulmonary veins.47  
Moreover, after radiofrequency ablation targeted at these sites, 62% of patients had no 
recurrence of AF.   
1.4.4 Pulmonary Vein Isolation 
This revelation led to the development of focal AF ablation,46 and later pulmonary vein 
isolation (PVI) as it was realised that multiple foci could exist within multiple veins.164, 165  A 
complete barrier to electrical activation of the LA from the PV could be created by targeting 
all connecting muscle sleeves with radiofrequency ablation. The location of ablation gradually 
moved from the PV ostium further towards the LA to the so-called PV antrum, in order to 
reduce the risk of PV stenosis with ablation at deeper sites. Although some series suggested 
that complete isolation of the PV antrum was not necessary, merely a significant reduction in 
voltage132, 166 or high-frequency signal within the area,167 it has gradually been accepted that 
complete PV isolation is associated with a superior outcome.168  In the majority of centres, PV 
isolation is assessed by the placement of a multipolar circular or spiral catheter within each 
the pulmonary veins; this may also be used to guide the site of ablation as it has long been 
recognised that complete circumferential ablation is not always necessary to achieve lasting 
isolation.169 
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1.4.5 Linear lesions 
Pulmonary vein isolation alone is highly effective in treating patients with paroxysmal AF, 
but found to be less so in those with persistent or longstanding persistent (previously called 
permanent) AF.164 
Hence interventional electrophysiologists have combined similar techniques to those first 
used by Schwartz, that is to reproduce similar lesions to the surgical maze procedure, in order 
to create not only PVI but also further compartmentalisation of the atrium.    Many operators 
added such linear lesions during the early period of AF ablation in 1998-2003.  The ability to 
create complete transmural lesions was challenging with the available technology,167 the 
major advance in which was the use of constant saline irrigation through the catheter tip.  This 
permitted the delivery of deeper lesions whilst minimising the risk of tissue overheating and 
char/thrombus formation.   
1.4.5.1 Roof line 
One of the bases for the original Cox-Maze III procedure and its later modifications, was that 
a barrier should exist at or near the posterior wall to prevent macroreentrant circuits from 
passing between the pulmonary veins.  These may act as drivers of atrial fibrillation and/or be 
responsible for atrial tachycardia occurring after treatment of AF.  The roof line Figure 1-9 
connects the contralateral encircling pulmonary vein lesions in the superior LA and, when 
complete, prevents conduction at this level between the anterior and posterior LA wall, whilst 
maintaining conduction inferiorly (around the septum and/or mitral annulus).  Hocini et al 
demonstrated that conduction block could be created in 96% of cases, and resulted in 
improved success (arrhythmia free off antiarrhythmic drugs) from 69 to 87% in a cohort of 90 
patients with paroxysmal AF.170  Subsequently the technique has been shown to improve 
success rates for persistent AF ablation.171 The roof line is added after completion of PV 
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isolation, given the compelling evidence for PVI as the cornerstone of all types of AF 
ablation.   
 
Figure 1-9 Roof line 
3D reconstruction of left atrium using NavX system (St Jude Medical, MN, USA).  The 
left atrium is seen from above and behind, with left atrial appendage (LAA) top left.  
Ablation (red dots) has been performed in rings around each pair of pulmonary veins 
(LIPV = left inferior pulmonary vein; RSPV = right superior pulmonary vein).  Following 
this, a line of ablation (arrow) has been created on the roof of the left atrium between 
the left and right isolation lines.  After sinus rhythm restoration, pacing manoeuvres 
between the LAA and high posterior wall permit assessment of conduction block.   
 
 
LIPV 
LAA 
RSPV 
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1.4.5.2 Mitral line 
The Cox-Maze III lesion set included an incision from the lower portion of the PV and 
posterior wall exclusion zone connected to the mitral annulus, with a complementary lesion 
placed at the coronary sinus.172  The primary basis for this was again to prevent the existence 
of macroreentrant circuits that may drive AF and/or lead to post-AF atrial tachycardias, and 
failure to complete this lesion was associated with worse outcome. 
 
Figure 1-10 Mitral line 
The left atrial model from Figure 1-9 has been rotated to show a left lateral view.  The 
mitral annulus is seen cut out from the geometry.  A line of ablation (arrow) has been 
created between the annulus and the left inferior pulmonary vein (LIPV), joining the 
pulmonary vein encirclement.  This lateral ‘mitral valve isthmus’ line can be checked for 
integrity by pacing from the coronary sinus (CS) and left atrial appendage (LAA), which 
approximate each side of the line. Ablation is sometimes required from within the CS, 
which apposes the epicardial surface of this region as shown.  
CS catheter 
LAA 
LIPV 
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Several different lesions may theoretically be able to prevent complete circumnavigation of 
the mitral valve annulus (MVA) and anterior/inferior LA.  In the presence of a baseline PVI 
lesion set, with or without a roof line, the options are to place a linear lesion between the right 
PV and the septal MVA, an anterior line from the roof to the MVA, or a line from the left PV 
(under the LAA) to the MVA.  Of these, the shortest is typically the latter – otherwise known 
as the lateral mitral isthmus (MVI), and the longest is the septal line.  The lateral MVI may 
however be difficult to block due to non-transmural ablation, and some operators used the 
anterior approach.  This, however, has the drawback – whether performed surgically or with 
catheter ablation – of causing a severe intraatrial conduction delay: the lateral LA and LAA 
are activated very late, thus producing ineffective atrial contraction as it would coincide with 
ventricular systole.  Hence most operators performing this line use the lateral approach 
(Figure 1-10).  Jais et al showed that addition of an MVI line to PVI and right flutter line 
increased arrhythmia-free survival from 69 to 87% in 100 patients treated for paroxysmal AF.  
Creation of a transmural lesion and this block is more challenging, even with irrigated tip 
catheters.  This may be due to thickness of the atrial muscle and/or the presence of an 
effective heat sink in the coronary sinus, which reduces conductive heating at the epicardial 
surface.173  In the above study, block could be achieved in 92% patients although two thirds 
required some ablation within the coronary sinus.174  Subsequent reports have highlighted the 
additional benefit of MVI ablation in treating persistent and longstanding persistent AF, with 
typically lower success rates for achieving block (70-90%) and but similar improvements in 
outcome compared with PVI alone.175, 176  Epicardial ablation from within the CS is 
frequently needed;174 radiofrequency power is typically reduced here in order to minimise the 
risk of collateral damage to the CS and circumflex artery, although the clinical risk appears 
small.177  
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1.4.5.3 Combined linear lesions 
Several studies have prospectively compared PVI alone with PVI and combined linear lesions 
(roof and MVI) in treatment of persistent AF.  The majority have shown a significant 
improvement in arrhythmia freedom at follow up with additional linear lesions at the baseline 
procedure.171, 176, 178  The downside of adding these lesions, other than the additional 
procedural time, is that incomplete lesions clearly predispose to atrial tachycardia during 
follow up.167, 171, 179, 180   Thus it is imperative that conduction block is obtained and confirmed 
during the index procedure whenever possible. 
1.4.5.4 Other linear lesions 
Other lines have been used during AF ablation, in both atria.  Although a posterior line, in 
addition to the roof line, can create posterior wall isolation, there is concern regarding the risk 
of collateral damage to the oesophagus due to its proximity to the posterior wall.  Some 
studies have suggested that the LA posterior wall is an important part of the AF substrate, and 
that isolation of this region may improve outcomes from AF surgery181 and catheter 
ablation.182, 183   
Long linear lesions in the right atrium were shown to be largely ineffective in early studies 
into catheter ablation.  However, the addition of right atrial lesions has been shown to 
improve outcomes from AF surgery,184 and more recently in some catheter ablation 
studies.185, 186   
The addition of a right atrial flutter line, at the cavotricuspid isthmus (CTI) between the 
tricuspid valve and inferior caval vein, has been investigated in patients undergoing AF 
ablation.  Initial data showed that elimination of atrial flutter can successfully treat 
paroxysmal AF.187  It remains unclear whether prophylactic CTI ablation should be routinely 
added in patients undergoing elective AF ablation.  Some studies would support this,184 
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particularly if atrial flutter has been seen clinically or within the electrophysiology 
laboratory,188 whilst others showed little or no benefit on arrhythmia freedom.189  
Nevertheless, given the morbidity associated with recurrent atrial flutters and the relative 
simplicity of performing a CTI line during AF ablation, many centres perform this routinely 
during catheter ablation of persistent AF.190, 191  
1.4.6 Complex fractionated electrograms 
The AF substrate is complex and the mechanisms remain incompletely understood.  Given 
that the success rates of AF ablation were still significantly below that of SVT and flutter, 
there was impetus to find new or alternative techniques to achieve termination of AF and 
lasting sinus rhythm. 
Allessie and colleagues noted that fragmented unipolar electrograms could be recorded at 
sites of wavefront pivot points or zones of slow conduction,192 during induced AF in humans.  
Such electrograms display high frequency, low amplitude, multicomponent signals of 
prolonged duration, and have also been recorded in the ventricle after healed myocardial 
infarction,193 and during atrial flutter.194   Given that sites showing complex fractionated 
electrograms (CFE) may represent sites of wavelet reentry, Nademanee et al hypothesised 
that eliminating these area by catheter ablation such areas of slow conduction would stop 
multiple wavelet reentry and therefore AF.  The initial study on 121 patients showed that 3D 
map-guided radiofrequency ablation of CFE site was associated with termination of AF in 
115 (95%), although 32 (28%) required administration of the class III drug ibutilide.  At 1 
year, 87 (72%) patients were free of arrhythmia and off antiarrhythmic drugs after a single 
ablation.127  A large proportion of CFEs were located in the pulmonary venous antrum, thus 
PVI may have also been an effective strategy in some of this cohort.   
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CFEs may be defined as fractionated and composed of ≥2 deflections ± perturbation of the 
baseline with continuous deflections from a prolonged activation complex, or atrial 
electrograms with a very short cycle length (≤120ms) typically with multiple potentials when 
compared with atrial cycle length from other parts of the atria.127  
There remains debate as to the aetiology and relevance of CFE, which may represent slow 
conduction,192, 193, 195, 196 localised reentry, collision of wavelets,50, 192 anisotropy-related 
behaviour,196, 197 or location of epicardial ganglionated plexi.198  Since the initial data from 
Nadamanee et al supporting CFE ablation to eradicate AF, many investigators have targeted 
CFE during AF ablation.  Outcome data is varied.  There is limited data on beneficial effect in 
paroxysmal AF.199  Regarding persistent AF, one study has shown a benefit with CFE 
ablation alone,200 while a number of studies have used CFE ablation in conjunction with 
antral PVI,201 or as part of a stepwise ablation strategy incorporating linear lesions.202, 203  
Such discrepancies might relate to the heterogeneity of CFE mapping.  Observational errors 
can occur with subjective operator-determined conventional CFE mapping, and use of an 
ablation catheter for CFE mapping has potential disadvantages, which include requirement of 
sequential single point map creation, low tip-ring resolution and catheter deformation of the 
atrial surface which may change local activation. Two published studies have used automated 
algorithms for mapping prior to ablation of CFE, with single point-by-point acquisition.201, 204 
Although there are limitations with any automated process, the algorithm used here has been 
shown to have good sensitivity (0.75) and specificity (0.8) for correlation with physician-
identified CFEs.205  The ability to rapidly acquire repeat CFE maps is desirable, given that 
22% of CFE sites may show some degree of temporal change.206  To date the ideal ablation 
strategy for high burden, persistent and chronic AF has not been fully defined.  Equally, the 
exact role of CFE guided ablation and its role particularly for persistent AF ablation is yet to 
be determined. 
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1.4.7 Mapping technologies 
Catheter placement and tracking has traditionally been performed using fluoroscopy.  With 
the development of more complex ablation techniques, including long linear lesions 
encircling the PV or joining atrial substructures, much investment has gone into developing 
technologies to allow non-fluoroscopic navigation and tracking systems in order to improve 
accuracy and efficacy of interventional electrophysiological procedures.  Fluoroscopy 
provides 2-dimensional information, and does not provide visualisation of endocardial 
contours.  In contrast, modern mapping systems have the ability to display catheters within a 
virtual 3-dimensional environment, reconstruct virtual endocardial contours, track catheter 
position, and record a variety of parameters at the endocardial surface including activation 
time, electrogram amplitude, ablation sites.  
The principal technologies now used in AF ablation are CARTO (Biosense-Webster, 
Diamond Bar, CA) and EnSite NavX (St Jude Medical Inc, St Paul, MN).  CARTO utilises a 
low intensity magnetic field, with a complementary sensor built into the mapping and ablation 
catheter, which in combination allow determination of the location and orientation of the tip 
electrode in addition to providing local electrical information.  Hence the term 
electroanatomical mapping was coined.  The latest version, CARTO3, also allows display of 
multiple catheters in order to improve orientation and navigation.  
Ensite NavX is capable of locating and displaying any standard EP catheter within a 3-
dimensional field.  In contrast to CARTO it does not use a magnetic field and does not require 
specific catheters; the system consists of three pairs of patches placed on the body surface in 
orthogonal planes.  A low power 5.7KHz electrical field is generated across each pair of 
patches; the voltage/impedance gradient is used to calculate the position of any electrode 
placed within the field.  Importantly, unlike CARTO the system can record both anatomical 
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and electrical information simultaneously from up to 64 electrodes, and thus has the ability to 
be used to map rapidly with high resolution.  In addition, the system is able to record long 
segments to allow retrospective assessment of the arrhythmia substrate. 
Imaging from CT or MRI can also be integrated with either system to improve accuracy, 
although the latest iterations of mapping systems are now capable of providing accurate 
geometry of complex structures such as the posterior LA without this additional information. 
1.4.8 Complications of AF ablation 
Procedures for AF ablation are increasing, and with increased experience, improved 
technology, better targeting of effective lesions, and shorter procedure times, the high 
complication rates of the early procedures in the mid 1990s are thankfully historical.   
However, significant complications occur in 2-6% of patients207 and include transient 
ischaemic attack or stroke (0.5-1.5%), tamponade (0.5-4%), symptomatic PV stenosis (<1%), 
and right phrenic nerve palsy (0.3%, usually transient). Procedures are long – often 3-6 hours 
for persistent AF, require specialist facilities and expertise, and are modestly more 
challenging in patients with heart failure in part due to concomitant atrial dilatation and an 
increased surface area to which lesions must be applied. 
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1.5 Conclusion and hypothesis 
The co-existence of atrial fibrillation and heart failure carries significant morbidity and is 
associated with worsened mortality.  The optimal management in the era of interventional 
treatments for AF remains unclear.  Pharmacological therapy for AF rhythm-control offers no 
clear advantage over rate control, however compelling observational data exists that sinus 
rhythm is advantageous when it can be achieved without significant collateral morbidity. 
The editorial associated with publication of the main AF-CHF trial outcomes, by Cain and 
Curtis,208 made the following comments:  
“Driven by these circumstances, investigators should next focus on a rhythm-control strategy 
that eliminates the confounding contributions of low efficacy and high toxicity associated with 
antiarrhythmic drug therapy to better determine the desirability of maintaining sinus rhythm 
in patients with atrial fibrillation. Ablation therapy serves this purpose.  … 
Ultimately, studies must also test the superiority of ablation therapy, as compared with rate 
control, since ample data show that rate control is an acceptable strategy and one that is 
almost certainly more cost effective than any other approach.” 
 
On this basis, the logical step would be to assess catheter ablation as a rhythm control 
strategy, in comparison with a rate control approach, in a prospective randomised controlled 
trial.  Catheter ablation may allow not only better maintenance of sinus rhythm, but can in 
theory achieve it without the requirement for antiarrhythmic drugs.  
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1.5.1 Main hypothesis 
 
A strategy of rhythm control by catheter ablation, compared with rate-control, for 
management of persistent atrial fibrillation in patients with heart failure, improves 
cardiovascular performance, symptoms, and neuroendocrine status. 
 
This was investigated by a clinical trial, the design of which is presented in chapter 2. The 
results of the main trial outcomes are presented in chapter 5.  Chapter 6 includes further 
analysis of the measured imaging parameters within the main trial.  Chapter 7 presents the 
biomarker sub-study of the clinical trial.  
1.5.2 Secondary aim and hypothesis 
High-density contact mapping is a feasible method to investigate the human atrial substrate 
in advanced heart disease.  It may have a role in assessing the impact, and facilitate 
optimisation, of catheter ablation procedures in persistent atrial fibrillation in heart failure. 
These investigations are presented in chapters 3 and 4. 
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2 Clinical trial design and methods 
2.1 Introduction 
In order to investigate the hypothesis that catheter ablation-based rhythm control is superior to 
medical rate control, a prospective randomised controlled trial was designed to be conducted 
in a single tertiary cardiac centre (both sites of the Royal Brompton and Harefield NHS 
Foundation Trust), with recruitment from referral centres at district general hospitals, and the 
heart failure and arrhythmia services within the hosting Trust.   
At the point of study commencement in 2008-9, having performed searches via Medline, 
PubMed, Clinicaltrials.gov, and the WHO ICTRP website, it was established that no trial had 
compared these strategies.  Three studies intending to evaluate similar patient populations but 
with different outcome measures were in the recruitment phase. ‘Catheter Ablation Versus 
Standard Conventional Treatment in Heart Failure Patients With Atrial Fibrillation 
(CASTLE-AF)’, NCT00643188, scheduled to complete in 2013, had the primary outcomes of 
mortality and heart failure hospitalisation.  Two smaller scale studies were also in 
recruitment: ‘Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart 
Failure’, NCT00292162, using a primary outcome measure of LVEF, with no designated 
comparator group.* The third was ‘Atrial Fibrillation Management in Congestive Heart 
Failure With Ablation (AMICA)’, NCT00652522: all patients receive device (ICD/CRT) 
implantation, the comparator being ‘best medical treatment’, and a primary outcome of 
change in LVEF. 
                                                
* This study was subsequently published as a comparison of radiofrequency ablation and continued medical 
treatment (rate control), despite this treatment arm allocation not being pre-defined on ClinicalTrials.gov (see 
MacDonald et al in Chapter 8)  
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2.2 Clinical trial design  
A placebo-control/double-blind design would not feasible in view of the ethical issues with 
performing a 'sham' AF ablation procedure under anaesthesia, and indeed such types of study 
has been advised against under international guidelines.128  Thus an ‘open-label’ model was 
used, so that investigators administering therapies would be aware of patient allocation; 
however, assessment of the primary endpoint and imaging endpoints was performed by 
blinded physiologists and cardiologists respectively.   
The study population was defined as patients with persistent atrial fibrillation (minimum 7 
days), congestive heart failure with New York Heart Association (NYHA) functional class II 
– IV; and left ventricular ejection fraction (LVEF) ≤ 35%.  The strategies of rate control and 
catheter ablation were compared in a 1:1 randomised fashion. 
2.2.1 Choosing a study population 
2.2.1.1 Type of atrial fibrillation 
The majority of heart failure patients presenting with AF do so when it is persistent.19 
Moreover, as discussed in the opening chapter, comparison of rate control with rhythm 
control are has some fundamental flaws when examining populations including those with 
paroxysmal AF.  Rate-control is not a logical therapy to apply to a patient in sinus rhythm, 
although this argument can be balanced by the need for the same medication in heart failure 
(e.g. beta-blocker).  In terms of how the investigatory science might alter clinical practice, a 
relatively homogeneous cohort would be required to allow conclusions to be drawn about the 
relative merits of rhythm control and rate control.  Both the AFFIRM and AF-CHF studies 
had mixed populations of paroxysmal and persistent AF.  Hence, unsurprisingly, a substantial 
proportion of patients in the rate-control group were in sinus rhythm: 54% of rate control 
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patients in sinus at baseline in AFFIRM, 35% at 5 years; whilst in AF-CHF the absolute 
difference in rhythm between groups was approximately 40% (where the target for an ideal 
comparison of rate versus rhythm control of AF would be approaching 100%).  This, based 
upon the notion that it is a ‘sinus rhythm is better than AF’ hypothesis that is really being 
tested – would unfairly strengthen the relative outcome for rate control, versus rhythm 
control, in virtually all circumstances.  Furthermore, paroxysmal AF is often poorly tolerated 
in patients with heart failure and catheter ablation would already be clinically justified in heart 
failure patients who cannot tolerate or receive amiodarone.  In order to best examine the 
impact of AF and comparison of its maintenance versus its restoration to sinus rhythm in this 
cohort, only those with persistent (i.e. beyond 7 days continuous) AF were selected. 
2.2.1.2 Degree of left ventricular dysfunction 
Although it is increasingly recognised that there exists a spectrum of left ventricular (LV) 
dysfunction in patients with clinical heart failure, the vast majority of clinical trials in heart 
failure have been performed in those with significantly reduced LV systolic function, 
typically below 35-40% as assessed by radionuclide ventriculography, angiography, or 
echocardiography.  Defining heart failure in those with preserved LV ejection fraction 
(LVEF) is challenging,209, 210 and probably more in the presence of atrial fibrillation,211 
particularly as its presence can be used in defining the condition.210  Hence the present study 
set out to enrol patients with at least moderate LV systolic dysfunction, with a cut off at 
LVEF 35% as assessed by radionuclide ventriculography.    
2.2.1.3 Inclusion criteria 
• Age ≥ 18 years ≤ 80years 
• Impairment of left ventricular systolic function (left ventricular ejection fraction ≤35% 
by radionuclide ventriculography) 
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• NYHA II-IV symptoms, on optimal heart failure therapy* 
• Persistent AF (clinically present for > 7 days)   
Optimal heart failure therapy included cardiac resynchronization therapy where appropriate 
(see exclusion criteria). Patients were all referred from cardiology and/or heart failure 
specialist services, and must have been established on stable heart failure therapy prior to 
enrolment.  Pre-enrolment AF rate-control criteria were not specified.   
2.2.1.4 Exclusion criteria 
• CRT or ICD device implanted in the previous six months 
• AV nodal ablation within previous three months 
• Prior AV nodal ablation or complete heart block with a single chamber pacemaker 
• Contraindication to anticoagulation 
• Persistent thrombus in the left atrium despite anticoagulation 
• Active malignancy 
• Cerebrovascular accident within the previous 6 months 
• Reversible causes of AF including thyroid disorders, acute alcohol intoxication, recent 
major surgical procedures, or trauma 
• Reversible causes of heart failure including acute myocarditis, alcohol 
• Cardiac events including myocardial infarction (MI), percutaneous coronary 
intervention (PCI), valve or coronary bypass surgery within the previous 3 months 
                                                
* Patients with a recent diagnosis of heart failure were only recruited after a minimum of 3 months from initial 
diagnosis, and in the presence of unstable or NYHA class IV symptoms had been stabilised by in- or out-patient 
specialist heart failure nurse or physician-led therapy for a minimum of 1 month.   
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• Prior left atrial catheter ablation with the intention to treat AF 
• Prior surgical interventions for AF such as the surgical MAZE procedure 
• Previous heart transplant, or on urgent heart transplant waiting list 
• Severe neuro-muscular disease  
• Creatinine clearance <30 ml/min 
• Serum bilirubin >50 micromol/L 
• Body mass index >40 kg/m2 
• Contraindication to general anaesthesia 
• Active participation in another research study 
• Unable to understand and comply with protocol or give written informed consent. 
2.2.2 Outcome measures 
Choosing a relevant and measurable endpoint is challenging in trials of heart failure.212  
Despite contemporary optimal medical and/or device therapy, the prognosis of advanced heart 
failure is poor.  For many patients mortality risk is less relevant than symptom burden, quality 
of life, and ability to perform routine tasks.  A very large study cohort would be required to 
establish a mortality benefit of catheter ablation, which was outside the remit of this study, 
which instead sought to examine parameters that may be markers of prognosis, as well as 
symptomatic and functional status. 
Impairment of exercise intolerance is both a hallmark symptom of heart failure and one of the 
most important indicators of long-term survival.  Given that peak oxygen consumption is a 
strong prognostic indicator,213-216 may be a more reliable indicator of long-term survival than 
ejection fraction,217, 218 and correlates with symptomatic status,219 change in peak oxygen 
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consumption (peak VO2) at cardiopulmonary exercise treadmill testing was chosen as the 
primary endpoint in this study.  Peak VO2 has been widely demonstrated to stratify mortality 
risk in chronic heart failure patients, both as a continuous variable,214 and as a threshold 
determinator in deciding on those who are candidates for cardiac transplantation.215  Cardiac 
resynchronisation therapy has been shown to improve peak VO2 in patients with underlying 
dyssynchrony.220  Beta-blockers have not been shown to affect peak VO2, but do favourably 
lower ventilation per unit increase in carbon dioxide production (VE/VCO2 slope).221  Peak 
VO2 is known to be lower in heart failure patients with AF than with sinus rhythm,222  and has 
previously been shown – albeit not specifically in heart failure patients - to increase after 
cardioversion if sinus rhythm is maintained.223-226  
Biomarkers, in particular B-type natriuretic peptide (BNP) have become key elements in the 
diagnosis of heart failure.227, 228  BNP also is one of the best predictor of prognosis available 
to date,229 improves outcomes when used as a guide to heart failure therapy,230, 231 and it is 
now well established that improvements in the heart failure syndrome are associated with a 
reduction in BNP concentrations.231, 232  BNP levels have been shown to fall after catheter 
ablation for paroxysmal and persistent AF, largely in patients without ventricular 
dysfunction.233, 234  The study will prospectively examine the effect on BNP levels of ablation, 
versus rate-control, in this cohort of patients with significant LV dysfunction.  
The left ventricular ejection fraction (LVEF) is frequently used as an endpoint or outcome in 
studies looking at heart failure therapies, including aforementioned studies of AF ablation.  
Multiple-gated acquisition radionuclide ventriculography is regarded as the gold standard for 
quantifying LVEF, and are highly reproducible (test variability <3% in our institution).  As 
cardiac magnetic resonance imaging is contraindicated for patients who have implantable 
devices, and echocardiographic data are susceptible to inter-operator and intra/inter-scan 
variability, radionuclide imaging was the primary modality of choice in assessing left 
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ventricular function.  However, LVEF does not take account of diastolic dysfunction, and is 
regarded insufficient as a global measure of heart failure severity. Clinical trials have shown a 
variable prognostic association of change in ejection fraction.212  Given the superiority of 
peak oxygen consumption as a prognosticating test, change in LVEF was a secondary 
outcome measure in this study. 
2.2.2.1 Primary outcome 
• Peak oxygen consumption (VO2) at cardiopulmonary exercise test* 
2.2.2.2 Secondary outcomes  
• LV ejection fraction as detected by radionuclide ventriculography* 
• Minnesota Living With Heart Failure Questionnaire (LHFQ) score* 
• 6 minute walk distance* 
• B-type natriuretic peptide (BNP)* 
• Freedom from AF; freedom from atrial arrhythmias* 
• LV dimensions and ejection fraction (Biplane Simpson’s method) as measured with 
transthoracic echocardiography; presence and amplitude of A wave on transmitral 
Doppler; left atrial size 
• Combined endpoint of LVEF, 6 minute walk distance, and LHFQ score 
• Composite endpoint of mortality and unplanned hospitalisation for major 
cardiovascular events (including worsening HF, myocardial infarction, unstable 
angina, ventricular arrhythmia, stroke, pulmonary embolism, cardiac transplantation) 
                                                
* Indicates endpoints registered on ClinicalTrials.gov at trial commencement April 2009 
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2.2.3 Ethical approval and registration 
The study was approved by the Hillingdon and Hounslow Research Ethics Committee in 
December 2008 on behalf of the UK National Research Ethics Service, and was approved by 
the institutional review board in April 2009.  The trial, ARC-HF,* was registered prior to 
commencement on ClinicalTrials.gov with identifier NCT00878384. 
2.2.4 Recruitment 
Patients were recruited from the cardiology and/or specialist heart failure services of Royal 
Brompton & Harefield NHS Foundation Trust (RBHT).  Some were referred for assessment 
for eligibility from linked referring hospitals; however, all patients were then investigated and 
enrolled on the RBHT site.  All relevant cardiologists and specialist nurses were informed 
about the trial by email or poster, and the procedure for referral.   At onset of the study, the 
heart failure clinics at RBHT were screened for 1 year for all patients with AF and heart 
failure. 
Patients apparently meeting the inclusion/exclusion criteria were then approached regarding 
possible participation.  After verbal discussion, all patients were sent a detailed information 
sheet (see appendix). Consent forms were signed prior to patients undergoing any baseline 
investigations.  All patients who were formally approached were logged on a candidate list 
form, and their final destiny recorded for purposes of the Consort diagram.     
                                                
* A Randomised Trial to Assess Catheter Ablation versus Rate-Control in the Management of Persistent Atrial 
Fibrillation in Chronic Heart Failure 
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2.3 Baseline Investigations 
All patients underwent clinical examination, 12 lead ECG, routine blood tests, and the 
following investigations prior to randomisation.  Prior to commencing investigation, all 
patients were allocated a sequential study code to permit pseudo-anonymisation of data, 
which was used on the case report form (see appendix).  After the baseline visit, data from the 
CRF were transferred to an electronic CRF in the form of an Excel spreadsheet, and stored on 
local NHS computer servers.  
2.3.1 Radionuclide ventriculography (RNV) 
2.3.1.1 Acquisition Technique 
In vivo red blood cells were labelled with 800 MBq of 99mTc.  A dual-headed gamma camera 
with a high-resolution low-energy collimator was employed.  For ECG gating an R-R window 
width was set at 20%, but widened up to 50% on each side in case of markedly irregular heart 
rate.235 Wider window allows inclusion of beats with variable lengths, which may reduce 
image quality but is a true representation of the cardiac haemodynamics in arrhythmias. This 
avoids an otherwise long acquisition time, which may not be practicable for heart failure 
patients or can lead to patient motion and resultant low quality images. For planar imaging, 
using a single detector, a planar oblique acquisition with the best septal separation angle was 
selected. R-R interval was gated into 16 (Harefield) or 32 (Brompton) frames with matrix size 
of 64×64 pixel size of 0.39 cm. A total of nine million counts was acquired.  
2.3.1.2 Image Analysis 
On planar imaging, a semi-automated region of interest was selected around the left 
ventricular blood pool on both end-systolic and end-diastolic planar images. A further region 
of interest over a background area (usually the mediastinum) was also selected and used to 
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background-correct counts within the blood pool regions of interest. Left ventricular ejection 
fraction was calculated as the difference between corrected end-diastolic and end-systolic 
counts divided by the corrected end-diastolic counts. The planar EF was used for inclusion 
criterion purposes. 
2.3.2 Cardiopulmonary exercise test (MVO2) 
Graded treadmill exercise testing was performed with continuous measurement of ventilation 
(VE), oxygen consumption (VO2), and carbon dioxide production (VCO2) were measured 
continuously with a respiratory mass spectrometer: Medgraphics Ultima CPX (Medical 
Graphics Corporation, St Paul, Minnesota, USA) system at Royal Brompton Hospital and 
Oxycon Pro (Jaeger, Hoechberg, Germany) at Harefield Hospital.  Baseline and follow-up 
investigations were kept at the same hospital site to avoid the introduction of errors due to 
subtle differences between the equipment used.   
All patients were encouraged to exercise to exhaustion on the modified Bruce protocol.  This 
includes a stage 0 during which patients walk at 1 mph on a 5% gradient.   The modified 
Bruce protocol was deemed suitable for patients with heart failure, including the elderly,214 
and was the standard protocol used for this study: however if the patient was not able to keep 
up with the treadmill then the slower-onset Naughton protocol was used after a 5 minute rest 
period.  Data were analyzed offline by cardiac physiologists blinded to the study protocol 
without reanalysis by study investigators.   
Peak VO2 was defined as the mean of the highest 2 consecutive values of 15-second averages 
of VO2. The VE/VCO2 slope was obtained by linear regression analysis of the data acquired 
throughout the entire period of exercise.214, 236, 237  All patients had baseline and follow tests 
performed with the same equipment and protocol.  Continuous 12-lead ECG monitoring was 
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performed alongside respiratory gas analysis.  Additional parameters recorded at each stage 
were respiratory exchange ratio (RER), heart rate, and blood pressure.  The weight-adjusted 
peak VO2 (ml/kg/min) was used as the primary outcome measure for the study.   
2.3.3 Quality of Life score (Minnesota LHFQ) 
The Minnesota LHFQ questionnaire (see appendix) is a 21 question validated quality of life 
assessment tool,238 with each question scoring 0-5, total 105.  Higher scores reflect greater 
symptoms or impairment, and a lower quality of life.  This was given to each patient for 
completion, without additional prompting by the investigator, at the beginning of each visit 
prior to clinical interview and/or examination.  Patients were not allowed to see their score 
from previous attendance to reduce the chance of participant bias. 
2.3.4 Blood tests and biomarkers 
Blood tests were taken at rest, prior to radionuclide ventriculography and exercise testing: full 
blood count, urea and electrolytes, coagulation profile, liver function tests, thyroid function 
tests, C-reactive protein, and plasma for biomarkers (see below). BNP was measured using a 
Triage BNP immunoassay on a Beckman Access 2 analyser.  Blood for other biomarkers was 
collected into 7ml ethylene-diamine-tetra-acetic acid-containing tubes and centrifuged at 
1000G for 5 minutes, within 1 hour of sample acquisition.  Plasma was extracted for freezer-
storage of 1-2ml plasma aliquots at -70 degrees C, for later analysis (see Chapter 7). 
2.3.5 Holter monitoring 
Baseline 24h monitoring was performed (except in patients who had a recent equivalent 
recording and the data were available), with repeat recording at 6 and 12 months (48h for 
patient in the ablation arm).  Data were analysed semi-automatically to produce mean, 
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minimum and maximum 1-minute-averaged heart rates, premature aberrant (ventricular 
ectopic) count, and the Holter was scanned for evidence of pauses (defined as >3 seconds) 
and any ventricular tachyarrhythmia (defined as ≥3 cycles).  If Holter recordings were not 
complete in patients with implantable devices, with appropriate programming of atrial sensing 
and arrhythmia recording, lack of atrial arrhythmia and/or mode switch could be used as a 
surrogate for recording arrhythmia recurrence.  In non-device patients, inadequate Holter 
recorders were repeated to ensure the minimal monitoring requirements were met. 
2.3.6 Six minute walk test 
A 15-metre corridor was used (30 metre lap).  Baseline heart rate was recorded via apical 
auscultation over a period of 30 seconds.  After the observing investigator demonstrated the 
course, the patient was given the following instruction: 
Please walk as far as you can in 6 minutes.  You should not run.  I will inform you when you 
have reached about 3 minutes, and when you have about 1 minute left.  If you need to rest 
please slow down or stop at one of the chairs, and resume walking when you are ready.   
No encouragement was given from the observer.239  Laps were recorded on the CRF, and the 
total distance (including partial laps) calculated at completion.  Apical heart rate was 
reassessed immediately at completion of exercise, over a period of 30 seconds, and recorded 
as the peak heart rate. 
2.3.7 Transthoracic echocardiogram 
A standardized protocol was used to acquire images on Vivid 7 or Vividi echocardiograph 
machines for subsequent analysis on EchoPAC software (GE Healthcare Milwaukee, WI, 
USA).  Standard 2D, colour/pulsed/continuous Doppler was acquired.  LA size and method-
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of-discs LV ejection fraction (average 3 cycles) was calculated by 2 independent observers 
for final results analysis.  At follow up post ablation, presence of atrial contraction was 
assessed by mitral A-wave Doppler, and where possible the A' tissue Doppler component (see 
chapter 6 for detailed discussion). 
2.4 Randomisation Protocol 
After baseline investigations, eligible patients were randomised by the Clinical Trials and 
Evaluation Unit, Royal Brompton Hospital, on a 1:1 basis to either catheter ablation, or a rate-
control strategy.  Randomisation was performed in permuted blocks, by age (≥50, <50) and 
presence/absence of pre-existing complete AV block, in order to minimize group imbalance.  
The study investigators were blinded to block-size. 
2.5 Post randomisation care 
2.5.1 Medical therapy (rate-control) group 
Patients were managed with pharmacologic therapy as required to achieve a mean heart rate 
less than or equal to 80 bpm during rest and 110 bpm on activity (as measured during a 6 
minute walk test).82  The drugs to be used were at the discretion of the treating physician: 
prospectively recommended drugs acceptable for this purpose included (but were not limited 
to) beta-blockers, digoxin, and amiodarone. The follow up period started from the day of 
commencement of the rate control protocol, i.e. the same day as randomisation – as any 
changes were immediately made and appropriate medication prescribed.  
If rate-control criteria were not met at baseline, patients re-attended at 4 weeks for repeat 
resting and ambulatory rate control assessment, recommended to be assessed at 6 minute walk 
whenever possible.  A further visit was scheduled at 8 weeks if rate control was not achieved.  
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Given that catheter ablation of AF, in patients who do not have an indication for pacing, could 
potentially avoid the need for either AV node ablation or pacemaker insertion, the protocol 
did not specifically recommend either pacing or pacing/ablation for those who failed rate 
control.  These strategies were permitted if clinically indicated and the use of these techniques 
would be recorded for purposes of retrospective outcome analysis. 
2.5.2 Catheter ablation group 
Patients who were randomised into the catheter ablation group undergo percutaneous 
radiofrequency catheter ablation as set out in section 2.6.  At randomisation, a provisional 
date was identified found for catheter ablation.  Unless medically indicated, no adjustments to 
medication were made at this point.  Once the date for ablation was confirmed, patients 
without pacemakers were given advice to half rate control medication on the day prior, and to 
omit this on the day of the procedure, to minimise the risk of profound sinus bradycardia on 
restoration of sinus rhythm.   
The follow-up period did not start immediately at randomisation, but on the date of the first 
scheduled ablation procedure.  Previous studies have been variable in reporting and execution 
of follow up after catheter ablation procedures: in some cases follow up has been commenced 
after the ‘last successful’ ablation procedure,240 which would theoretically allow ‘resetting’ of 
the follow up time indefinitely; alternatively a limited ‘treatment phase’ could be set, 
followed by follow up without treatment.241  The former would skew the true follow up times 
between groups in an intervention versus non-intervention study such as ARC-HF, so this 
type of approach was avoided.  The latter could involve effectively withholding therapy for 
recurrent atrial arrhythmias, which may be readily amenable to ablation particularly if atrial 
tachycardia was the presenting rhythm, where it may reflect a positive transition on the 
‘journey’ from AF towards lasting sinus rhythm.242 However it was deemed appropriate to 
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commence follow up once treatment in the ablation arm had begun, and not reset for repeat 
procedures.  
2.6 Catheter ablation protocol 
For a more detailed procedural protocol please see chapter 4. 
Anticoagulation strategy for the procedure followed contemporary local protocol.  Until 
December 2010, all patients undergoing AF ablation stopped oral anticoagulation (e.g. 
warfarin) five days before the procedure, and received subcutaneous injections of low 
molecular weight heparin (1.5mg/kg) until 24 hours prior to ablation.  Bridging therapy was 
resumed after the procedure as below.  From January 2011, all procedures were performed on 
uninterrupted warfarin with an INR in the range 2-3.5.  
The procedure was performed under general anaesthesia in all cases. A trans-oesophageal 
echocardiogram (TOE) was performed to exclude thrombus in the left atrial appendage, 
assess patency of the interatrial septum, and assess pulmonary venous anatomy.  
Thereafter radiofrequency catheter ablation was performed using a 3.5mm irrigated-tip 
ablation catheter guided by a three-dimensional mapping system.  Catheter ablation involved 
the following strategies, in a stepwise fashion243:   
• Circumferential antral electrical isolation of all four pulmonary veins confirmed by a 
circular pulmonary vein mapping catheter. 
• Linear ablation within the left atrium at the roof and mitral isthmus 
• Further ablation guided by mapping of complex fractionated electrograms (CFE) 
within the left atrium 
• DC cardioversion to sinus rhythm 
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• Linear ablation in the cavotricuspid isthmus (CTI) within the right atrium 
In order to assess electrophysiological properties of the atria, prior to and after each stage of 
ablation during AF, the atrial fibrillation cycle length was recorded in both atria at the level of 
the appendages, and a contact map of local electrogram mean cycle length (see chapters 3 and 
4) acquired using a multi-polar mapping catheter.  The map acquired after roof and mitral 
isthmus line was guide ablation of CFE in the left atrium. 
Once sinus rhythm was restored, all linear lesions were assessed for integrity by pacing and 
sensing manoeuvres from the left atrial appendage and posterior wall (for the roof and mitral 
lines) and the coronary sinus (for the CTI line).  This technique is discussed in detail in 
chapter 4. 
The minimal therapeutic goal was isolation of all pulmonary veins. If atrial tachycardia (AT) 
ensued at any point thereafter, the AF ablation protocol was terminated and the AT was 
mapped and ablated as appropriate. All those with persisting AF underwent further ablation in 
a stepwise fashion until completion of the left atrial ablation protocol or until sinus rhythm 
was restored. If sinus rhythm or AT was not achieved by the end of left atrial CFE ablation 
and final mapping, DC cardioversion was performed.  
Peri-procedural fluid management was dealt with on a case-by-case basis: patients were 
generally not pre-hydrated, given the likelihood of a large amount of transcatheter irrigation 
during the procedures.  Loop diuretics were given towards the end of procedure if appropriate, 
although were typically avoided earlier on to avoid hypotension under anaesthesia and the 
need for vasopressors.   
For patients bridged off warfarin, anticoagulation with low-molecular weight heparin and 
warfarin was started 6 hours after the ablation in the absence of active bleeding. Patients were 
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routinely kept for a minimum 1-night stay, and routinely discharged if transthoracic 
echocardiography was satisfactory (without significant pericardial collection) the day after 
ablation. 
A 2-month ‘blanking period’ was chosen when assessing arrhythmia recurrence.  Although 
the contemporary international consensus statement recommended 3 months,128 the choice of 
2 months would at worst underestimate success for catheter ablation, and is consistent with 
other clinical trials of 6-12 months duration,240, 244, 245 aiming to allow repeat intervention 
when necessary in this cohort of patients where rhythm fluctuation could be detrimental.  
During the blanking period, any recurrence of AF or new onset of atrial tachycardia could be 
treated by DC cardioversion. Further atrial tachyarrhythmias which developed after the 
‘blanking’ period led to scheduling of a second ablative procedure.  A maximum of 3 
ablations could be performed during the study period.*   
Antiarrhythmic therapy could be used at the discretion of the physician in the first 2 months.  
At a maximum of 2 months antiarrhythmic drugs, other than non-sotalol beta-blockers, were 
stopped unless there was a separate on-going indication (e.g. ventricular arrhythmias); after 
this time any continuation or initiation was recorded. 
                                                
* Redo ablation procedures, when indicated, followed a similar protocol: i) pulmonary vein isolation was 
confirmed and re-established when necessary; ii) atrial tachycardia was diagnosed and treated in the 
conventional manner (see chapter 4); iii) linear lesions were re-ablated in sinus rhythm if there was reconnection 
until bidirectional block was confirmed with a minimum 15 minute waiting time; iv) CFE ablation was 
performed if AF persisted – within the left or right atrium; v) further lesions could be added in either atrium at 
operator discretion  
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2.7 Follow-up visits 
The onset of the follow-up period was defined in the rate control group at commencement of 
therapy (i.e. upon randomisation), and at the first scheduled ablation procedure in the catheter 
ablation group.  Thereafter, visits were scheduled for assessment and investigation at or near 
3, 6, and 12 months.  Patients underwent the following repeat assessments: 
• Quality of Life Questionnaire (all visits) 
• History and clinical examination (all) 
• 12-lead ECG (all) 
• Blood tests: full blood count, urea and electrolytes, liver function tests, thyroid 
function tests, lipid profile, CRP, BNP, plasma for biomarkers (all) 
• Cardiopulmonary exercise test (baseline, 3, and 12 months) 
• Six minute walk test (all) 
• Radionuclide ventriculography (baseline and12 months) 
• 48 hour Holter monitoring (baseline,6, and 12 months) 
• Transthoracic echocardiogram  (baseline,6, and 12 months) 
 
A flowchart showing the overall trial structure is shown in Chapter 7 (Figure 7-1) 
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2.8 Power calculations and statistical analysis 
2.8.1 Power calculation 
The primary endpoint, peak VO2, is known to be reduced in AF patients and has been shown 
to improve after cardioversion approximately 10-15%.223, 225, 226  It has been shown to be 13% 
lower in heart failure patients with AF compared to sinus rhythm.222   
The study was designed to detect an effect size in VO2, comparing ablation with rate-control, 
of 0.80 times the size of the standard deviation of difference, with two-sided alpha 0.05, 
power 80%. If the standard deviation per group was 12.5% (e.g. 2ml/kg/min for patients with 
VO2 of the order of 16 ml/kg/min) this would mean ability to detect a difference of 1.6 
ml/kg/min (i.e. 10%) which would be deemed clinically relevant based on prior studies.217, 246, 
247  The number of patients required was 25 in each group.    
There was an expectation for some patients to drop out of the protocol during follow up, 
either through declining catheter ablation during the pre-procedural phase after 
randomisation, or for patients in the rate control arm wishing to undergo ablation.  Although a 
recent randomised study of catheter ablation had shown no drop-out,240 that was a study with 
two interventional arms where patients may be motivated to continue. A contemporaneous 
study, from the same investigatory group, comparing catheter ablation with medical therapy 
(in a non-heart failure cohort) showed crossover rate of 9% and 63% interventional (ablation) 
and non-interventional (medical) arms respectively.241    The latter could be seen in the 
context of a multi-centre study where crossover was protocolised.  In contrast, ARC-HF was 
designed as a single centre study to be coordinated by a single investigator, and where 
crossover was both strongly discouraged and not formally protocolised.  Nevertheless, it was 
concluded that the proposed recruitment target should include an adjustment to account for 
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20% dropout, although this could be reviewed according to actual recruitment versus dropout 
rate during the study.  This was reflected in the initial details registered on ClinicalTrials.gov 
in April 2009.  
The Minnesota Living With Heart Failure Questionnaire (LHFQ) quality of life score has 
been shown to improve with heart failure intervention.  In a study of CRT published 2002, 
there was an improvement in score from 78+/-24 to 52+/-23.112  More recently, an 
observational study found CRT in AF patients led to a 25.2 point improvement in score.248  In 
PABA-CHF the improvement was approximately 20 points.240  Based on the above sample 
size, the study would be powered to detect a change of 20 points assuming a group standard 
deviation of 25.  
Left ventricular ejection fraction (LVEF), as assessed by radionuclide ventriculography, 
might be expected to increase of the order 5-20% in those restored to sinus rhythm based on 
previous studies.133, 135  The study was powered (at 80%; alpha 0.05) to detect an absolute 
improvement of 10% in  (SD 20) in LVEF between groups.    
The study was designed to detect event endpoints.  A composite endpoint for cardiovascular 
events and death was pre-specified as above in order to collect relevant data, but power 
calculation was deemed inappropriate. 
2.8.2 Statistical analysis 
Continuous baseline variables are presented as mean ± standard deviation (SD). Categorical 
variables are presented as frequency/percentage(%), and compared with Fisher’s-exact or 
Chi-squared test.  Outcomes were assessed, on an intention-to-treat basis, by independent 
comparison of absolute changes from baseline.  Parametric data were analysed by t-test and 
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represented as mean and 95% confidence interval (CI); non-parametric/ordinal data were 
analysed by Mann-Whitney U-test and represented as median and interquartile range (IQR).   
A composite endpoint (using the Hochberg modification of the Bonferroni procedure249 for 
multiple tests of significance, with 3 parameters similar to recent published studies)240, 250, 251 
was defined, consisting of ejection fraction, 6-minute walk distance (6MWD), and LHFQ 
score. The endpoint would be achieved if all 3 component endpoints have P value <0.05, if 
two have P < 0.025, or if one had an endpoint <0.017. 
The composite (secondary) endpoint for major cardiovascular events was analysed by the 
Kaplan-Meier method and represented as an event-free survival curve.  Arrhythmia-free 
survival was also analysed by Kaplan-Meier method.   
A two-sided level of p < 0.05 was considered statistically significant.  All the above 
calculations and further exploratory or post-hoc analyses were performed with SPSS version 
20 (IBM). 
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3 High density mapping in human atria 
3.1 Abstract 
3.1.1 Introduction 
There is an increasing need for catheter ablation procedures to treat complex atrial 
tachycardias (AT) and atrial fibrillation (AF), often requiring detailed endocardial mapping.  
Sequential point-to-point contact mapping of complex arrhythmias is time consuming and 
may not always be feasible.   This study assessed the utility of a novel spiral duo-decapolar 
high-density (HD) mapping catheter to delineate complex arrhythmia substrates for ablation. 
3.1.2 Methods  
Patients underwent HD mapping using a spiral catheter (AFocusII) and the EnSite NavX 
system, during catheter ablation procedures to treat atrial arrhythmias. 
3.1.3 Results 
In 26 patients, a total of 32 atrial arrhythmias were mapped and ablated, comprising 5 focal 
AT, 8 macroreentrant AT, 11 persistent AF and 8 paroxysmal AF.  The HD catheter was used 
to acquire endocardial surface geometries in all cases, and to map the pulmonary veins in 
patients undergoing AF ablation.  In persistent AF, HD catheter mapping permitted creation 
of highly detailed complex fractionated electrogram (CFE) maps (left atrium 449±128 points 
in 7.2±2.6min, right atrium 411±113 points in 6.7±1.6min).  In AT, activation mapping was 
performed with acquisition of 305±158 timing points in 7.3±2.6 minutes, guiding successful 
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ablation in all cases.  During follow up of 7.0±2.6 months, all AT patients remained free of 
significant arrhythmia.  
3.1.4 Conclusions 
High-density contact mapping with a novel spiral multipolar catheter allows rapid assessment 
of focal and macroreentrant AT, and complex fractionated electrical activity in the atria.  It 
has further multi-functional capabilities as a pulmonary vein mapping catheter, and for 
accurate geometry creation when used with a 3 dimensional mapping system.   
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3.2 Background 
Over the past decade there have been major advances in the mapping and ablation of both 
atrial and ventricular tachycardias. The exponential rise in catheter ablation cases has resulted 
from both an increased incidence of atrial arrhythmias and the expectations of 
electrophysiologists to successfully treat them by catheter ablation.  The recent focus in 
technology has been to generate electro-anatomical maps superimposed upon patient-specific 
geometries derived from CT/MRI/real-time echocardiograms of the cardiac chamber in 
question.  This has been very successful in both delineating arrhythmia mechanisms and the 
identification of suitable targets for ablation.252  However, the creation of electrical-
anatomical maps still requires detailed point-by-point contact data acquisition that is time 
consuming, lacks resolution and may be difficult for irregular or non-sustained atrial 
tachycardias (AT).  Non-contact mapping has the advantage in mapping non-sustained 
arrhythmias but there may be loss of resolution in the unipolar electrogram reconstruction 
process compared with contact bipolar systems253 particularly in scarred atria. Accuracy is 
dependent on distance of the endocardial surface from the mapping array which further limits 
its use in dilated and complex chambers such as the left atrium.254   
There is an increasing recognition that patients with persistent atrial fibrillation (AF) may 
benefit from ablation of complex fractionated electrograms (CFE).127 These electrograms are 
often of low amplitude, beyond the resolution of a non-contact mapping array, and their 
identification by sequential point-to-point mapping is a time consuming process that 
significantly prolongs procedure times.255, 256  The process of sequential data collection could 
be improved by the use of multipolar contact mapping.257, 258  The pre-existing multispline 
catheter may be utilised for this,205, 242 although its distal configuration may not be optimal for 
all endocardial surfaces, for example the pulmonary venous antra where a conventional 
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circular mapping catheter might additionally be required.,  However, the latter catheter is not 
specifically designed for en face mapping of the atrial wall, requiring multiple overlapping 
sites to create a detailed map.    
The followed study assessed the utility of a novel spiral high-density (HD) contact mapping 
catheter used in conjunction with a 3D mapping system to delineate complex arrhythmia 
substrates for ablation.  
3.3 Methods 
3.3.1 Patient population 
Patients referred for electrophysiology study and catheter ablation of atrial arrhythmias 
between February and July 2009 at Royal Brompton Hospital, Harefield Hospital, and The 
Heart Hospital, London, were included in the study.  The study population comprised 
unselected patients with complex arrhythmias in whom the HD mapping catheter was used in 
this time period.  All patients gave written informed consent prior to the procedures. 
3.3.2 Electrophysiology study and ablation procedure 
Procedures were performed under conscious sedation (n=10) or general anaesthesia (n=16) in 
a post-absorptive state.  Transoesophageal echocardiography was performed to exclude 
intracardiac thrombus prior to mapping and ablation.   Femoral venous access was used in all 
cases and either standard single or double transseptal puncture performed to allow a sheath 
and catheter to access the left atrium when necessary, depending on operator preference, 
followed by anticoagulation with Heparin to maintain an activated clotting time of 250-350 
seconds.   
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In all cases, the Ensite NavX 3-dimensional mapping system (St Jude Medical, St Paul, MN) 
was employed to display real-time catheter positions, create 3D chamber geometries, display 
bipolar electrogram information, and to guide catheter navigation for mapping and 
ablation.252, 259 For all procedures, an intracardiac electrode was chosen as a stable geometric 
reference, either within the coronary sinus or using a fixed reference in the right atrium.  No 
image CT/MRI image integration was performed as per local practice. 
3.3.3 High density mapping 
The HD (AFocusII, St Jude Medical) catheter is a 20-pole catheter with a distal spiral 
configuration (7F shaft, 4F spiral ring). This can be used for both geometry creation and high-
density contact electrogram mapping, deployed in the appropriate chamber through a long 
sheath (Preface, Biosense Webster or Mullins/SL1, St Jude Medical).  The HD catheter has a 
primary unidirectional deflectable curve controlled at the handle.  During the study period 2 
versions were available – one having close-paired bipoles with 7-1-7mm spacing, and the 
other with even 4-4-4mm spacing (Figure 3-1).  The latter may therefore be configured to 
record 19 simultaneous bipolar signals (1-2, 2-3 and so forth), although for purposes of this 
study and consistency of point density, 10 bipoles were recorded from each catheter.   No 
comparison was made between the two types of spiral catheter, as the majority of cases used 
the 4-4-4 spaced catheter which has been the only prototype made available commercially.  
The catheter was used to create 3D reconstructions of the atria and pulmonary veins as 
required, and then for endocardial activation and voltage mapping during spontaneous and/or 
induced atrial arrhythmia.  
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Figure 3-1 Spiral high-density mapping catheter.  
Shown is the distal portion of the AFocusII high-density mapping catheter.  The central 
portion is able to ‘telescope’ into smaller ostia or around uneven surfaces such as the 
PV carina, and its electrodes provide even distribution of endocardial coverage (cf. 
standard circular catheter, where the central area is empty) for detailed mapping 
3.3.4 Activation mapping 
ATs were mapped by a combination of entrainment and activation mapping, the latter using 
the Diagnostic Landmark Mapping feature of the system.242  A time window for activation 
was set just below the tachycardia interval usually encompassing at least 90% of tachycardia 
cycle length.  Where a P wave was inscribed, at least 100ms of the window was allocated 
prior to P-wave onset.   
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To study local activation time (LAT), data from all available bipoles were acquired.  Using 
the diagnostic landmark function, electrogram deflections were automatically annotated by a 
QS morphology or max –dV/dt and displayed in a standard colour to time coded isochronal 
sequence map on the reconstructed 3D chamber geometry.   At each collection point, the data 
for up to 10 cycles were stored and analysed for consistency.  Data points were deemed 
inaccurate if poor contact or noise artefact occurred.  These points were manually checked 
and deleted or re-sampled to an appropriate cycle retrospectively for inclusion.   After 
multipoint acquisitions, annotation markers were checked for consistency - defining local 
activation as the first steep deflection from baseline.  Interpolation and surface projection 
settings were set at 10mm.  Thus, points not in contact (<10mm) with the atrial surface were 
rejected automatically and not analysed.  AT mechanism was defined, after analysis of 
isochronal and propagation maps, as macroreentrant (MR) if continuous activation could be 
mapped accounting for >95% of cycle length (CL), and confirmed whenever possible by 
concealed entrainment from within the circuit.  AT was defined as focal (FAT) if mapping 
defined a focally-emanating source with centrifugal activation. 
3.3.5 Complex fractionated electrogram (CFE) mapping 
CFEs were defined as fractionated high frequency potentials exhibiting multiple deflections 
from the isoelectric line and were characterised using the CFE-mean tool within the NavX  
system.  CFE-mean is defined as the mean time between consecutive deflections during a 
predefined recording period, and has been recently described in detail.257  CFEs were defined 
when the CFE-mean was between 30 and 120ms, with colour spectrum set across the range 
80-120ms (30-79ms white, >120ms purple), although this could be altered retrospectively.  
On the basis of published data 5 seconds was chosen as the recording duration at each site.257, 
260  The catheter was maintained in a stable position for at least 5 seconds prior to each 
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acquisition.  Signals were sampled at 1,200Hz, band-pass filtered between 32 and 300Hz and 
annotated using the ‘Diagnostic Landmark’ (St Jude Medical) tool on 1-second update.  
Settings were standardised to: dV/dt detecting width 10ms, refractory period 30ms, sensitivity 
0.04-0.1mV, interpolation and surface projections 10mm based on previous studies.201, 205, 257, 
260  Points >10mm from the geometric surface were considered as non-contact (‘unused’) 
points and not displayed on the CFE map.  In patients undergoing CFE mapping, the 
following parameters were recorded: time for complete mapping of each chamber and net 
points acquired (total minus ‘unused’). 
3.3.6 Radiofrequency ablation 
Radiofrequency ablation (RFA) was then performed in all cases using an open-irrigated 
3.5mm or 4mm tip catheter (Celsius Thermocool, Biosense Webster, Diamond Bar, CA; Cool 
Path Duo, St Jude Medical), flow rate 17-30ml/min, with temperature limited to 480C, power 
limits of 30-35W in the LA, 30W on posterior wall, 25W near venous ostia or within 
coronary sinus, and 45W in the cavotricuspid isthmus.  
3.4 Results 
3.4.1 Group Results 
Patient characteristics, underlying diagnoses, and intra-procedural findings are presented in 
Table 3-1. A total of 26 patients (22 male), 59±11 years old (24-77years), were studied.  3 
patients had complex congenital heart disease, 8 had paroxysmal AF and 11 had persistent 
AF.  4 patients had AT (2 persistent) following prior AF ablation, refractory to anti-
arrhythmic drugs ± attempts at cardioversion.  
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Table 3-1 Patient characteristics and summary of ablation strategy 
Atrial tachycardia cases are shown in bold 
 
PAF=paroxysmal AF, persAF=persistent AF; macro=macroreentrant AT; PVI = antral pulmonary vein 
isolation.  PT=procedure time (total cath lab time including anaesthesia), ST = fluoroscopy screening 
time, RF = total radiofrequency ablation time  
 
A total of 32 atrial arrhythmias were mapped and ablated: 5 were defined as focal AT (3 RA, 
2 LA), 8 as macroreentrant (MR) AT (4RA, 4LA), 11 persistent AF and 8 paroxysmal AF.  A 
close-paired spacing spiral catheter was used in 9 early cases (cases 1-8 and 12), and even-
spaced in the remaining 17.  For the patients with AT, a total of 305±158 HD derived LAT 
points were collected over 7.3±2.6 minutes.  The range of point-acquisition rates was wide at 
24-112 points per minute, explained by the differing anatomies and presence of non-sustained 
tachycardias.   Macroreentrant circuits were found involving the following structures: 
cavotricuspid isthmus (n=1), RA atriotomy (3), mitral isthmus (3), and peri-right PV utilising 
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the septal mitral isthmus (1) all with demonstrable concealed entrainment.  Focal ATs were 
found to emanate from: Crista terminalis (1), Peri-RA atriotomy (2), LA septum (1), and 
posterior LA (1).  In addition, a left upper pulmonary vein tachycardia was seen in patient 22 
during initial PV mapping and terminated during antral PV isolation (PVI).  The study did not 
prospectively define a follow up period or minimal ECG monitoring, as the intention was to 
investigate the acute handling and mapping capabilities of the spiral catheter.  However, 
during 7.0±2.6 months follow up, patient 3 had one documented episode AT on his device 
which was terminated by anti-tachycardia pacing (previously ineffective for AT prior to 
ablation), whilst all other patients remained free of AT, as judged by clinical,12 lead ECG and 
minimum 48 hour Holter  at follow up. 
Examples of the different atrial arrhythmias mapped by the HD catheter are discussed below.   
3.4.2 Macro re-entrant tachycardias 
3.4.2.1 Patient 7 – Fontan atrial tachycardia 
This 24 year old woman with a past history of Fontan surgery for univentricular physiology 
had repeated hospitalisations for AT episodes often with 1:1 AV conduction.  Burst pacing 
induced her clinical AT CL 300ms with 1:1 AV conduction.  HD mapping was used from the 
outset to create a map of the RA with 288 surface points in 5 minutes. 
This showed a macroreentrant circuit around the inferior border of the atriotomy scar.  Linear 
ablation connecting the scarred zone to the IVC terminated tachycardia (Figure 3-2).   A 
further macroreentrant tachycardia was induced, utilising a small mid-atriotomy channel, 
which was mapped (345 points, 7 minutes) and ablated in a similar fashion, rendering all AT 
non-inducible. 
 
  
90 
 
Figure 3-2 Fontan atrial tachycardia.   
Right anterior oblique (left) and left posterior oblique (right) projections of Fontan atrium 
in patient 7.  Yellow dots show mapping points superimposed on acquired geometry 
surface.  Isochronal map during initial tachycardia (CL 300ms), with peri-IVC circuit 
through scar-IVC isthmus (solid arrow); broken arrows show colliding wavefronts at the 
superior border of the anterolateral atriotomy scar.  Lower EGM panel shows highly 
fractionated (asterisks) electrogram in slow conduction zone (arrowed) between 
atriotomy and IVC, where ablation (brown dots) terminated AT (upper panel).  SVC = 
superior vena cava; IVC = inferior vena cava!
 
3.4.2.2 Patient 26 – Left atrial tachycardia post AF ablation 
This 65 year old man with previous lone AF had undergone PVI but had recurrent paroxysmal 
AF, with other ECGs suggestive of atrial tachycardia.  A cavotricuspid isthmus line was 
initially created to prevent typical isthmus dependent flutter identified. Burst atrial pacing 
then induced a stable tachycardia identical to the clinical AT on surface ECG.  The ATCL 
was 220ms, with PPI TCL+8ms from septal mitral valve isthmus.   A rapid activation map 
was acquired (143 points in 5 minutes; Figure 3-3) demonstrating peri-mitral flutter, which 
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slowed and terminated during linear ablation at the lateral mitral isthmus (involving both CS-
epicardial and endocardial approach).   Bidirectional block was confirmed conventionally, 
and no tachycardia was inducible thereafter. 
 
Figure 3-3 Left atrial tachycardia after previous AF ablation.   
Posterior (left) and anterior (right) projections of the left atrium (patient 26), showing 
isochronal mapping data during peri-mitral (solid arrow) left atrial tachycardia.  The 
timing window is set to demonstrate ‘head-meets-tail’ (purple-white-red) in the region of 
the posterolateral mitral valve isthmus, and caudocranial block at the posterior roof 
(broken arrows show colliding wavefronts).  Ablation points are shown as red dots on 
the endocardium between left inferior pulmonary vein and mitral valve annulus, and the 
free floating orange balls show the position of ablation lesions within coronary sinus to 
achieve mitral isthmus block. EGM panel shows mitral isthmus block after ablation: 
while pacing HD catheter from LAA (left atrial appendage) there is proximal to distal 
activation in the coronary sinus recording indication no activation from the isthmus end 
 
3.4.3 Focal AT 
3.4.3.1 Patient 4 – Focal AT in congenital heart disease 
A 63 year old man with congenitally corrected transposition (ventricular inversion), an atrial 
septal defect and moderately impaired systemic RV function presented with recurrent drug-
refractory attacks of AT.  He had not undergone any prior cardiac surgery.  His clinical AT 
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with CL 250ms was induced.  Conventional mapping excluded isthmus dependent flutter.  
The RA activation sequence suggested a high RA or high superior PV origin.  The focally-
emanating AT was rapidly localised by HD mapping (563 points in 5 minutes) to the superior 
part of the crista terminalis (Figure 3-4), and successfully ablated.  
 
 
Figure 3-4 Focal tachycardia in congenitally corrected transposition.   
Modified lateral (left) and postero-inferior (right) views of biatrial geometry and 
superimposed isochronal map in Patient 4.  563 points were acquired in 5 minutes 
allowing rapid identification of a focally emanating source (white) near the Crista 
terminalis, which was successfully ablated (brown dots).  Inset panel shows a highly 
fractionated local bipolar electrogram (arrowed) at the successful ablation site 
 
3.4.4 Non-sustained AT 
3.4.4.1 Patient 3 – non-sustained AT after prior cardiac surgery 
A 72 year old man with a prior Starr-Edwards aortic valve replacement for rheumatic aortic 
valve disease, left ventricular impairment and a CRT-D device presented to pacing clinic with 
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increasing dyspnoea and ankle oedema.  Sustained AT was noted, and pace-terminated via the 
device.  Device interrogation revealed earlier non-sustained ATs.   At the procedure, after 
geometry creation in sinus rhythm, burst pacing induced AT with CL 460ms.  The 
tachycardia terminated early during right atrial mapping. Right atrial geometry and bipolar 
voltage was acquired in sinus rhythm, showing an area of very low voltage on the lateral wall 
consistent with a prior atriotomy. Empiric ablation was performed at the cavotricuspid 
isthmus, achieving bidirectional block.  Attempts at re-induction always produced non-
sustained (5-20 second) runs of AT.  Using live and recorded electrogram data, HD mapping 
was used to assess activation and voltage in the region of interest (peri-atriotomy).   All 
tachycardias (AT2 CL 430-450ms, inferior to mid-scar; AT3 490-510ms, lateral scar border) 
appeared to be focally emanating from the peri-scar region in the lateral RA wall, however on 
further inspection it was apparent the first of these was probably macroreentrant involving a 
discrete channel in the atriotomy scar (Figure 3-5); entrainment manoeuvres were not feasible 
as the tachycardia would not sustain.  Radiofrequency energy was applied to the channel 
during both tachycardia and CS pacing and 2 regions of early activation as identified by prior 
mapping.  No tachycardia was inducible thereafter.   
  
94 
 
Figure 3-5  Non-sustained atrial tachycardia.    
Right and left anterior oblique projection of right atrial activation map in AT1, patient 3.  
The area of low-voltage (bipolar amplitude <0.05mV) from mapping in sinus rhythm is 
outlined in black.  Note incomplete RA map due to non-sustained tachycardia (89 points 
taken in real-time), although rapid mapping of the scar border zone revealed likely 
macroreentry, utilising a channel in the scar.  Ablation at this site (arrowed, with local 
electrogram) rendered AT1 non-inducible.  Two further non-sustained AT were focally 
emanating and ablated inferior and lateral to scar border (brown ablation points). 
TVA=tricuspid valve annulus; CS=coronary sinus 
 
3.5 Atrial fibrillation 
The AF cases were considered as a group. 8 patients with paroxysmal AF, and 11 with 
persistent AF were studied.  In all cases the HD catheter was used to create LA geometries, 
TVA 
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and as a pulmonary vein mapping catheter. The HD catheter was also used to confirm 
conduction block of antral isolating lines by pacing.  A total of 73 PVs were mapped with the 
HD catheter (3 cases of common left pulmonary vein), and subsequent isolation established in 
all cases by confirmation of PV entrance block or dissociated PV potentials.  
In persistent AF cases, CFE maps (Figure 3-6) were acquired in 9 patients (total 9 RA maps, 
23 LA maps).  Acquisition times (mean±SD) for complete endocardial colour coverage (at 
10mm interpolation), number of points acquired (net, after exclusion of unused off-surface 
points), and calculated points /minute (p/min) for each atrium were as follows:  RA 6.7±1.6 
min, 411±113 points, 63±15 p/min;  LA 7.6±2.4min, 449±128 points, 64±24 p/min.  PVI is 
performed as the first step in persistent AF ablation, with linear and/or CFE ablation 
performed at operator discretion.  CFE ablation here was performed using algorithmic map 
data and/or conventional RF-catheter information.   
Persistent AF was converted to atrial flutter with ablation in 2/11 cases.  One was successfully 
ablated, and the other had multiple ATs of changing morphology and cycle length, and sinus 
rhythm was restored by DC cardioversion.   At 5.1±1.6 months follow up, 5/11 (45%) 
persistent AF patients had recurrence of AF, 4 of whom underwent repeat ablation; 3/8 
(37.5%) of paroxysmal patients had recurrence of arrhythmia requiring repeat ablation (all of 
these had PV reconnection; 1 patient had AT from the right PV terminated by re-isolation). 
Geometry acquisition, handling and mapping characteristics were comparable to a standard 
multipolar circular mapping catheter, although this was not quantitatively assessed.  
Reconstruction around venous ostia, at the venous carina, and at the left atrial appendage 
ridge appeared accurate based on fluoroscopic assessment and 3D mapping, as long as the 
usual reassignment to multiple geometries is made to avoid false interpolation. No geometries 
required ‘touch-up’ from the mapping/ablation catheter.  There was no significant learning 
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curve observed with the catheter, although we noted some unique handling characteristics 
which differ from standard circular catheters: i) the shaft is central relative to the spiral head, 
rather than eccentric as is necessitated by the design of circular catheters, which allows 
‘telescoping’ of the central portion (poles 15-20) relative to the outer ring, which in turn 
permits mapping around irregular structures, smaller diameter pulmonary vein ostia, and 
permits minimal ‘tenting’ of the LA walls to create a surface which may be closely tracked by 
the subsequent mapping/ablation catheter; ii) the spiral head may become deformed and 
flattened relative to the shaft (default is perpendicular axis), however withdrawal into the 
sheath usually solves the problem – rarely the catheter had to be removed and restored to its 
perpendicular confirmation; iii) in 2 cases the pull-wire flexion mechanism failed, although in 
both it was during a long AF case with multiple catheter manipulations, and appeared to be 
where the whole of the flexible portion was not outside the transseptal sheath.  Flexing only 
with the catheter fully advanced may avoid this complication. 
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Figure 3-6 Complex fractionated electrogram maps in persistent AF. 
Posterior (left) and antero-superior (right) projection of left atrial complex fractionated 
electrogram (CFE) maps acquired by the HD catheter at baseline (upper panel), and 
after ablation (red dots - antral pulmonary venous isolation and roof line; lower panel). 
LAA= left atrial appendage.  Colour settings: white <80ms, red-blue 80-120ms, >120ms 
purple.  Sample contact bipolar electrograms (1 second snapshot) are shown, this 
example demonstrating a significant organisational effect of PVI and linear ablation with 
marked prolongation of local mean cycle lengths (CFE mean) 
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3.6 Discussion 
This study describes the initial experience with a novel spiral multipolar catheter with high-
density mapping capabilities used for a variety of atrial arrhythmias.  
The principal advantage of this catheter is its ability to simultaneously acquire contact 
electrograms from multiple bipoles over a 3cm2 area allowing rapid, high-resolution data 
collection with minimal chamber distortion.  Spiral conformation of the distal catheter 
obviates the need for multiple overlapping acquisitions as required with a standard circular 
catheter, and qualitatively appears to improve contact in complex areas such as around the PV 
anatomy compared with a multispline catheter.  When combined with the 3D mapping 
system, extensive numbers of activation points can be collected in a relatively short time 
(mean 305 points in 7.3 minutes), allowing focal and macroreentrant ATs to be characterized 
quickly.  It can be particularly useful for non-sustained tachycardias where rapidity of 
mapping is paramount: mapping with conventional techniques may either require repeated 
tachycardia inductions (if possible) or use of non-contact mapping.   
As with existing multipolar catheter mapping,242 there are some caveats in the use of the HD 
catheter.  When mapping circuits causing AT, not all electrodes may be in contact with the 
chamber wall at any one time and caution must be exercised in accepting all points during 
data collection.  Those points out of timing with the general activation map should be checked 
for annotation accuracy to avoid misinterpretation.  However, the mapping system can be 
programmed to display points in order of timing or acquisition, so one can readily identify 
incorrect annotations and/or unusual patterns of activation.  Once these simple rules were 
followed, in conjunction with the NavX isochronal and propagation map functions, the 
differentiation of the 5 focal and 8 macro re-entrant AT was straightforward, including 
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patients with complex atrial substrates and multiple tachycardias (range 1-3).  All of the 13 
mapped AT were successfully identified and ablated.  
3.6.1 Benefits over existing technologies 
3.6.1.1 Atrial tachycardia 
Increased rapidity and/or coverage of mapping should confer benefit in cases of relative 
haemodynamic instability, and in cases of non-sustained arrhythmia.  As demonstrated in 
cases 2 and 26, complete maps with high-density point acquisition throughout are not 
necessary in most cases.  However, higher density mapping can be rapidly performed in 
regions of interest, including at scar boundaries or near critical isthmuses.  Furthermore, the 
case of patient 3 highlights potential capabilities of this system for mapping non-sustained 
arrhythmia, something that may otherwise require non-contact mapping.  Our results compare 
favourably with mapping using a multi-spline catheter: Patel and colleagues mapped post-AF 
AT circuits, acquiring mean 365±108 points in 8±3 minutes; as commented in their study, this 
is faster than can be typically achieved with conventional point-to-point mapping.242  
Although not specifically examined in this study, this form of mapping would be expected to 
reduce the time for scar-isthmus mapping in complex atrial substrates, and therefore may be 
superior to conventional point-to-point mapping.261 
3.6.1.2 Atrial Fibrillation 
The flexible spiral design, in particular the telescoping property of the central portion of the 
spiral, allows the HD catheter to also be used for pulmonary vein ostial mapping, and 
subjectively facilitates accurate geometric reconstruction of complex structures such as the 
venous carina and appendage ridge.  The pulmonary veins were mapped with the HD catheter 
alone in this series, to guide ablation and isolation. No PVs required additional mapping with 
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another catheter.  In patients with persistent or chronic AF, high density mapping of CFEs 
was also performed to create local cycle length or ‘fibrillation interval’ maps, using the NavX 
system to guide ablation.  
Similar high density mapping has been previously described by using a multi-spline 
catheter,262 but the shape of the spline catheter is less well adapted for PV mapping. Since the 
initial data supporting CFE ablation to eradicate AF,127 many investigators have targeted CFE 
during AF ablation, although outcome data is varied.200-203 A recent clinical trial reported that 
CFE-map guided CFE ablation combined with PVI improves success in patients with high AF 
burden (STAR-AF),263 however a recent randomised study showed that up to 2 hours of 
conventional CFE mapping and ablation after PVI provided no additional clinical benefit.256  
Such discrepancies might relate to the heterogeneity of CFE as a substrate for ablation or the 
mapping techniques used.  Observational errors can occur with subjective operator-
determined conventional CFE mapping, and use of an ablation catheter for CFE mapping has 
potential disadvantages, which include requirement of sequential single point map creation, 
low tip-ring resolution and catheter deformation of the atrial surface which may change local 
activation.  Two published studies have used automated algorithms for CFE-mapping, with 
single point-by-point acquisition resulting in mapping density only around 25% of the HD-
acquired maps.204, 264  The algorithm used here has been shown to have good sensitivity (0.75) 
and specificity (0.8) for correlation with physician-identified CFEs.205  The ability to rapidly 
acquire repeat CFE maps is desirable, given that 22% of CFE sites may show some degree of 
temporal change.206  This study has shown that the HD catheter could be an ideal tool for 
rapid high density mapping of CFE in the atria, if they are to be targeted during catheter 
ablation of AF. 
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3.6.2 Emerging technologies 
High-density mapping is also possible with the recently available Mesh catheters (Bard, MA), 
giving a high spatial resolution of bipolar electrograms, shown to be a feasible and effective 
technique for mapping PV ostia.265, 266  The more recent innovation of the high-density mesh 
ablator (HDMA, Bard, MA) facilitates a single catheter approach to mapping and ablation of 
AF in situations where PVI is all that is required.  However the success rates for acute PV 
isolation and medium-late freedom from AF are significantly lower than for conventional 
irrigated-tip catheter ablation.267, 268 The success of PV isolation alone for treatment of 
persistent AF has been shown to be disappointing.  Furthermore, these non-steerable 
expandable catheter technologies are not appropriately designed for mapping of the atrial 
walls, unlike the steerable multi-spline, circular or spiral catheters. If PV isolation alone is the 
goal, perhaps newer versions of these catheters will be appropriate for single-catheter 
solutions to AF.  In the setting of persistent AF and/or post-AF atrial tachycardia, there is 
likely to be advantages of multi-polar mapping with suitably adapted catheters.  Currently, 
this is only possible with the RF-impedance-based system used in this report, however novel 
catheter technology is being developed for magnetic-based mapping systems which will allow 
similar rapid geometry creation and activation mapping.269  
3.6.3 Complications and safety 
There were no unexpected difficulties encountered in manipulating the catheter around the 
atria and no complications encountered in any of the cases, including mitral valve 
entanglement or perforations.  However, there should be vigilance for potential valve 
apparatus entanglement and appropriate knowledge of correct untangling manoeuvres 
(clockwise rotation of the shaft with withdrawal back into a long sheath to free the catheter).   
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3.6.4 Limitations 
This was a dual-centre pilot assessment of the handling characteristics, safety, and utility of 
the spiral HD mapping catheter.  The study did not set out to assess follow-up outcomes, thus 
the follow up period is relatively short and it is not possible to draw conclusions about long 
term arrhythmia freedom using this technique. No comparison was made with a conventional 
point-point 4mm-tip ablation catheter for tachycardia mapping, or with a circular catheter for 
PV mapping or geometry collection.  Although the improved resolution of HD mapping may 
allow more accurate representation of scar boundaries and reduce wavefront misinterpretation 
due to low-density interpolation, investigation of this would require a comparative study with 
conventional point-point mapping.  A higher density of points may be recorded with the even-
spaced catheter if 19 sequential bipoles are acquired, and may allow less map interpolation 
and improved accuracy – particularly for CFE mapping, although only 10 were acquired 
during this study for consistency with the earlier close-spaced device.  Larger randomised 
studies are required to assess the full clinical utility of the catheter on procedure/fluoroscopy 
time, and clinical outcomes from ablation.  
3.7 Conclusion 
A novel, multielectrode, mapping catheter with spiral distal conformation has been shown 
capable of multiple roles during catheter procedures for atrial arrhythmias.  It permits 
pulmonary vein mapping, rapid coverage of the atria for activation (and voltage) mapping of 
focal and macro-reentrant AT, and rapid high-density mapping of complex fractionation 
during persistent AF.  When used with a 3D mapping system capable of simultaneous multi-
electrode sampling it may have a role in reducing the duration of complex ablation 
procedures, particularly those where CFE are targeted.  The catheter also facilitates three-
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dimensional geometry creation and may be used for conventional assessment of conduction 
block at the pulmonary veins or across linear lesions. 
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4 The impact of catheter ablation upon the AF substrate in 
heart failure   
4.1 Abstract 
4.1.1 Introduction 
Ablation of persistent atrial fibrillation (AF) can be challenging, often involving not only 
pulmonary vein isolation (PVI) but also additional linear lesions and ablation of complex 
fractionated electrograms (CFE). This study examined the impact of stepwise ablation on a 
human model of advanced atrial substrate: persistent AF in heart failure.  
4.1.2 Methods 
Patients with persistent AF and left ventricular ejection fraction ≤35% were enrolled, 
including all patients randomised to the ablation arm of the ARC-HF study, and those who 
underwent ablation using the same protocol at the end of the study follow up period having 
been in the rate-control arm.  High-density CFE maps were recorded bi-atrially at baseline, in 
the left atrium (LA) after PVI and linear lesions (roof and mitral isthmus), and bi-atrially after 
LA CFE ablation.  The surface area of CFE (≤120ms) remote to PVI and linear lesions was 
defined as CFE-area.  
4.1.3 Results 
In 30 patients, a total of 168 CFE maps were recorded.  CFE-area was reduced after PVI 
(18.3±12.03cm2 to 10.2±7.1cm2, p<0.001), and again after linear lesions (7.7±6.5cm2, 
p=0.001).  Complete mitral isthmus block predicted greater CFE reduction (p=0.02).  Right 
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atrial CFE-area was reduced by LA ablation, from 25.9±14.1 to 12.9±11.8cm2 (p<0.001).  AF 
terminated in 6 pts.  Estimated 1-year arrhythmia-free survival was 72% after a single 
procedure.  Incomplete linear lesion block was an independent predictor of any arrhythmia 
recurrence (HR 4.69, 95% CI 1.05-21.06, p=0.04). 
4.1.4 Conclusions 
Remote LA CFE-area was reduced following PVI and linear lesions.  Furthermore, LA 
ablation reduced remote right atrial CFE-area.  CFE reduction was greater in the presence of 
complete mitral block.  Block of all lines was associated with a successful clinical outcome.   
The reduction of CFE-area by ablation at remote sites would suggest many of these 
phenomena do not represent sites of source activity driving fibrillation elsewhere. Robust 
linear ablation, following PVI, in an advanced persistent AF substrate, diminishes the target 
area for CFE ablation and also resulted in a favourable clinical outcome in this cohort. 
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4.2 Background  
Catheter ablation of paroxysmal atrial fibrillation (AF) via pulmonary vein isolation (PVI) is 
highly effective.164, 271  In contrast, in the majority of those with persistent AF, particularly if 
long-lasting or associated with structural heart disease, PVI is crucial but alone is often 
insufficient for long-term maintenance of sinus rhythm.272  Ablation of complex fractionated 
electrograms (CFE), which may contribute towards – or reflect severity of – the atrial 
substrate,127 has shown variable benefit in randomized studies.244, 256  Linear lesions at the left 
atrial roof and lateral mitral isthmus can also improve outcomes.171, 176, 178  Combining these 
approaches appears beneficial,273 although the optimal ablation strategies and order of their 
application remain uncertain. 
In patients with structurally normal hearts, PVI reduces remote left atrial CFE.274, 275 
Experimental and clinical models suggest that, unlike the reversible electrical remodelling 
associated with atrial tachymyopathy or ‘lone’ AF, where remote CFE reduction might be 
explained by acute electrical remodelling, a more advanced atrial substrate is seen in heart 
failure with evidence of structural remodelling including dilatation and fibrosis, which are not 
acutely reversible.28, 58, 59, 65  In the latter population, the effect of PVI and linear lesions on 
CFE remote from ablation sites is not known.   
This study sought to investigate the biatrial impact of stepwise ablation on CFE in patients 
with the advanced atrial substrate of persistent AF and HF, using the high-density mapping 
protocol developed in chapter 3, and to assess factors influencing procedural outcome.   
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4.3 Methods 
4.3.1 Patient population 
A total of 30 patients were recruited from the Ablation versus Rate Control for persistent 
atrial fibrillation in Heart Failure (ARC-HF) trial (ClinicalTrials.gov, NCT00878384).  The 
population included all patients randomised to the ablation arm (n=24), and those in the rate 
control who underwent ablation using the same protocol at the end of their follow-up period 
(n=6).  All had symptomatic persistent AF, without prior ablation, and left ventricular ejection 
fraction ≤35%.   
Table 4-1 Baseline patient characteristics 
 n=30.  AF = atrial fibrillation, BNP = B-type natriuretic peptide, BMI = Body Mass Index, 
LA = left atrial, LV = left ventricular 
 Mean±SD or N (%) Median IQR 
Age (years) 63±10 62 56-71 
Gender (male/female) 25/5   
History of AF (months) 50±38 44 20.5-72 
Current AF episode (months) 24±21 16.5 6.25-36 
History of heart failure (months) 63±58 54 21-75 
LA diameter (mm) 50±7 49 46-51.75 
LV ejection fraction (radionuclide,%) 24±9 26.5 16.5-30 
BNP (pg/ml) 406±334 286 183-566 
BMI (kg/m2) 29±5 29 25-32 
Coronary artery disease 12 (40%)   
Diabetes mellitus 7 (23%)   
Medications    
Beta-blockers 28 (93%)   
Angiotensin/aldosterone blockade 30 (100%)   
Amiodarone 3 (10%)   
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4.3.2 Electrophysiology Procedure 
Procedures were performed on continuous oral anticoagulation (except prior to January 2011 
patients received bridging low molecular weight heparin).  After induction of general 
anaesthesia, transoesophageal echocardiography was performed to rule out intracardiac 
thrombus, assess atrial/PV anatomy, and subsequently to guide transseptal puncture for access 
to the left atrium.  After transseptal puncture and placement of two long sheaths (Preface 
Biosense Webster, Diamond Bar, CA, USA) within the left atrium, all patients were 
additionally heparinised to achieve target activated clotting time (ACT) >300 seconds: the 
initial bolus dose was 7000-10000 I.U. in those not on warfarin, and 5000-8000 I.U. in those 
with a therapeutic INR, judged according to prevailing INR and patient body mass.  ACT was 
measured after 5minutes, and 10 minutes after any repeat bolus doses of heparin (1000-4000 
I.U.) if given for ACT<300 seconds, and thereafter at 30-minute intervals throughout the 
procedure.  Additionally, whenever possible, the transseptal sheaths were left on continuous 
side-arm flush with heparinised saline at 25-50ml per hour. 
Catheters were inserted via the femoral veins: (i) a steerable decapole (CR Bard, Lowell, MA, 
USA) was positioned distally in the coronary sinus (CS), in order to act as a stable geometric 
reference for the duration of the long ablation procedure; (ii) a second roving decapole was 
placed initially in the right atrial appendage (RAA) to allow assessment of RAA cycle length 
(CL), and later in the CS proximal to the reference catheter, in order to permit pacing and 
sensing manoeuvres to assess linear block within the mitral and cavotricuspid isthmus 
towards the end of the procedure; (iii) a 20-pole high-density mapping catheter (AFocusII, St 
Jude Medical, St Paul, MN, USA) was inserted via a long sheath (Preface, Biosense Webster, 
Diamond Bar, CA, USA) to the right atrium (RA) and left atrium (LA) sequentially; (iv) a 
3.5mm irrigated-tip F-curve catheter (Thermocool, Biosense Webster) was used for ablation, 
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with power limit of 35W in the anterior LA, 30W on posterior wall, 25W within CS, and 40W 
in the cavotricuspid isthmus (CTI).  When necessary for navigation within a markedly dilated 
left atrium, a steerable transseptal sheath was utilised (Agilis, St Jude Medical). 
The NavX system (version 8, St Jude Medical) was used with the AFocusII catheter to create 
separate left and right atrial geometries, within each using segmental geometries for venous 
structures to improve accuracy.  Sequential atrial CFE maps were performed using the 
methods detailed below and in Figure 4-1: i) at baseline (RA and LA), ii) after PVI (LA 
only), iii) after both roof and mitral lines (LA only), and iv) after LA CFE ablation (RA and 
LA).  RAA and left atrial appendage (LAA) cycle length (CL) was recorded at each stage by 
averaging the recording from a bipolar signal over 10 cycles. 
4.3.3 Complex fractionated electrogram (CFE) mapping 
To systematically identify CFE, high-frequency potentials exhibiting multiple deflections 
from the isoelectric line were characterised using the CFE-mean tool within the Diagnostic 
Landmark mapping feature of NavX.  CFE-mean is defined as the mean time between 
consecutive deflections during a predefined recording period.257  The system monitors 
electrical deflections from the isoelectric line and annotates all deflections meeting the pre-
specified criteria as set-out below.  Annotations are shown by yellow tick-marks as shown in 
Figure 4-5. 
 
  
110 
Figure 4-1 Summary of ablation and CFE mapping protocol  
Mapping shown in dark grey boxes, ablation/therapy shown in white boxes, AF 
termination in light grey boxes.  
RA = right atrium, LA = left atrium, PVI = pulmonary vein isolation,  
CFE = complex fractionated electrograms, LL = linear lesions, CTI= cavotricuspid 
isthmus  
 
  
111 
CFE were defined as sites with CFE mean ≤120ms, using a 5-second recording duration on 
the basis of published data.257, 260 Signals were recorded from all bipoles, producing 19 
simultaneous electrograms at each time point.  Signals were sampled at 1,200Hz and band-
pass filtered between 32 and 300Hz.  Settings were: dV/dt detection on 1-sec update; 
electrogram width 10ms (to remove far-field signals), refractory period 30ms (values below 
this being regarded as non-physiologic for local re-activation), interpolation and surface 
projection 10mm based on previous studies;201, 257, 260 points >10mm from the surface were 
deleted.  Voltage detection threshold was adjusted to exclude background noise, and fixed for 
subsequent maps.  Scar was defined as  <0.05mV.  Acquisitions were made until the whole 
endocardial surface was covered.  Points displaying electrical interference or inappropriate 
detection were deleted. The mitral and tricuspid annuli were defined by typical atrial and 
ventricular electrograms and the contained area excluded.   
For purposes of graphical display during procedures, the CFE-mean colour maps were set to 
show CFE between 30 and 120ms, with a colour spectrum between 80 and 120ms.  Thus, all 
areas with CFE-mean >120ms were coloured purple, those below 80ms (and above 30ms) as 
white, and the range 80-120ms within the colour spectrum (Figure 4-4). 
4.3.4 Catheter ablation protocol 
See also Figure 4-1 
Radiofrequency ablation was commenced in the left atrium after baseline biatrial CFE maps 
were complete, with the map turned off.  Antral pulmonary vein isolation was performed 
typically as ipsilateral pairs, although on some occasions intervenous/carina ablation was 
necessary to achieve the immediate endpoint of PV entrance block (Figure 4-2).   Once block 
was confirmed, a repeat CFE map was recorded in the LA.   Note that pulmonary vein 
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isolation was rechecked at every stage of the procedure, and if recurrent conduction was 
detected, then repeat ablation was performed at conducting gaps until complete isolation was 
achieved.  CFE maps were only recorded at each subsequent stage only after adequate 
pulmonary vein isolation had been sufficiently (re)established.  
Linear ablation was then performed at the LA roof between the ipsilateral venous isolation 
lines, and then at the lateral mitral isthmus between the anterior isolation line at the left 
inferior pulmonary vein and the mitral valve annulus (MVI), with the immediate endpoint of 
local electrogram attenuation by >50% and a maximum of 30 seconds ablation at a single site.  
Following completion of both lines to this standard (endocardially only), a further LA CFE 
map was performed.  
The LA CFE map after the linear ablation stage was used to guide ablation of CFE, with an 
endpoint of abolition or organisation of local electrograms at all annotated CFE sites except at 
the LAA (note that under this protocol, ablation within the LAA was electively avoided to 
minimise the risk of perforation, and ablation at the anterior aspect of the LAA ostium 
similarly avoided but in order to obviate the risk of inadvertent electrical isolation of the 
appendage which might increase the subsequent risk of thromboembolism).   
Finally, if AF persisted, CFE mapping was again performed in both atria, following which 
DC cardioversion was used to restore sinus rhythm.  A minimal biphasic energy of 150J was 
used, and 200-360J when required.       
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Figure 4-2 Pulmonary vein isolation during atrial fibrillation 
 After antral circumferential ablation ring has been created, there is residual conduction 
to the right upper pulmonary vein, with earliest activation at electrode 5,6 of the spiral 
catheter (labelled Lasso).  Entrance block is created during ablation at this site (note 
electrical artefact at ablation onset and at the spiral bipole).  The last activation of the 
pulmonary vein is arrowed.  Atrial fibrillation continues (see coronary sinus recording in 
blue)   
 
If atrial tachycardia ensued at any point, the mapping and AF ablation protocol (after a 
minimum of complete pulmonary vein isolation) was terminated and the tachycardia mapped 
and ablated using conventional methods.  In brief, the intracardiac recordings were assessed 
for stability of activation sequence and regularity, and if possible a P wave identified on the 
surface ECG.  A suitable timing reference was used in the coronary sinus or left atrial 
appendage.  Following this, direction of activation was evaluated at the anterior, posterior and 
inferior LA to establish the likelihood of a macroreentrant tachycardia.  If a focal arrhythmia 
was suggested, then 3-dimensional local activation mapping was performed with either the 
AFocusII or mapping/ablation catheter.  If macroreentry was suggested, the mechanism was 
confirmed by pacing manoeuvres to prove concealed entrainment within or near a critical 
isthmus, and ablation applied as appropriate in order to achieve termination to sinus rhythm.  
Such macroreentry was confined to the site of the left atrial roof, mitral isthmus, or the 
cavotricuspid isthmus.   
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Figure 4-3 Confirmation of linear lesion block 
 In this example from a patient (S59) immediately after restoration of sinus rhythm, the 
left panel shows pacing from the AFocusII catheter (labelled Lasso) positioned in the 
left atrial appendage.  Two decapole catheters are placed within the coronary sinus, 
distally (blue) and more proximally (red).  The mapping (ABLd) signal from the roof is 
shown. The upper orange arrow highlights the conduction time from the stimulus until 
the latest potential detected in the coronary sinus catheter.  Note that the CS catheter 
(blue) is positioned distally enough to ‘straddle’ the mitral isthmus line at CS 5,6, with 
the distal (CSd and CS3,4) part recording a signal on the LAA side of the line.  
Primary mitral isthmus block is therefore present.  Below, the ablation catheter records 
a signal on the posterior aspect of the roof line, which is not blocked.  
The right panel shows achievement of roof block after further ablation then achieves 
roof block, depicted in the right panel, where there has been a split of potentials 
between early and late, showing that the ablation catheter is sitting exactly at the roof 
line, block of which means the impulse now takes 140ms to reach the other side of the 
roof line from the left atrial appendage. 
  
In sinus rhythm, pulmonary vein isolation was reassessed using the AFocusII catheter and 
multisite pacing to show the endpoint of entrance (PVI endpoint) and exit block.  Exit block 
was proven when possible during pacing from the pulmonary vein when ipsilateral pulmonary 
vein capture was demonstrated without atrial capture, however in general was presumed in the 
presence of high-output pacing and no atrial capture.  Entrance block was further clarified, 
when necessary, by assessment of differential pacing and sensing in the right atrium (for right 
PV) and left atrial appendage or CS (for left PV).   
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Similarly, bidirectional mitral and roof-line integrity was assessed by differential pacing and 
sensing from the LAA, CS and posterior wall.  The presence of a blocked line immediately 
after cardioversion was defined as primary block for purposes of subsequent analysis; further 
ablation was performed at incomplete lines (Figure 4-3).  For the mitral isthmus, this could 
include ablation within the coronary sinus opposite the endocardial lesions.  
A linear lesion was then performed at the cavotricuspid isthmus during proximal coronary 
sinus pacing, using the same principles as above ensure bidirectional linear block.  
4.3.5 Data analysis 
Complete study data was recorded on to optical disc (recordable DVD media) and stored 
under the patient’s study code.  For analysis each study was loaded on to an Ensite Laptop 
Review Station (St Jude Medical).     
Prior to formal analysis, the CFE mapping data for each map was manually reviewed and 
cleaned up.  This process involved the following steps, following which each map was re-
saved: 
i. Display of all acquisitions in order of CFE-mean 
ii. Removal of acquisitions with high frequency electrical or mechanical artefact, or 
adjustment within the beat buffer if sufficient retrospective 5-second recording 
available 
iii. Adjustment of peak-peak voltage/amplitude threshold for CFE detection in order to 
account for unavoidable background noise, which varied by patient and atrium.  For 
standardisation of measurement, this threshold was then fixed for subsequent maps 
within the same atrium during the same study 
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4.3.5.1 CFE area assessment 
In the left atrium, in order to assess the remote effect of i) pulmonary vein isolation and ii) 
linear lesions on left atrial CFE, areas excluded by or involved in these lesions were excluded 
from subsequent area analysis.  Thus the saved geometry, with its associated ablation points, 
that was recorded immediately after ablation of the roof and mitral lines was used as the basis 
for calculation of the left atrial ‘denominator’ area, and all CFE map data, stored separately 
from the geometry, was loaded (superimposed) on to this.   
Using the standardised projection and interpolation settings as defined above, and with the 
NavX field-scaling algorithm applied, the NavX surface marker tool (Figure 4-4) was then 
used to demarcate areas as follows: 
i. The area of left atrium remaining after excluding to within 5mm of the PVI encircling 
lesions and linear lesions, and excluding the mitral valve annulus 
ii. The excluded area of pulmonary vein and linear lesions on each side. Thus i+ii 
equalled total baseline LA surface area to drawn around the whole remaining LA.   
iii. All regions with CFE-mean ≤120ms, i.e. all areas within (i) displayed with white-blue 
colour annotation, the sum of which was defined as left atrial CFE-area  
 
This method was designed to permit assessment of remote impact of PVI then linear lesions 
on the remote parts of the left atrium, here defined as all left atrium >5mm from the annotated 
ablation lesions.  Note that the fourth left atrial CFE map, performed after map-guided 
ablation of CFE from the third (post-linear lesion) map, served 2 separate purposes i) 
validation of the impact of direct ablation of CFE sites, also permitting investigation of 
whether new or temporally unstable sites of CFE arose despite targeting the residual CFE 
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after linear ablation, and ii) to provide the denominator map for final right atrial CFE 
assessment (see next paragraph).  
Figure 4-4 Surface marker annotation of CFE    
Anterior (left) and modified posterior (right) view of the left atrium: the geometry and 
CFE map, taken after linear lesions, is displayed. The surface marker tool of NavX has 
been used to annotate CFE areas from baseline (red), post-PVI (amber), and post-
linear lesions (green), which have been left projected on the map surface.  A degree of 
temporal stability of the anterior CFE region is noted, but the posterior and peri-right PV 
regions have disappeared after (remote) ablation. Note: only areas not enclosed or 
affected by PVI and linear lesions have been counted towards CFE-area. 
 
Any example of sequential left atrial CFE maps, projected on to the lesion-set/ geometry 
recorded immediately after linear ablation, is shown in Figure 4-5.  
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Figure 4-5  Sequential LA CFE maps 
High-density CFE-mean maps are shown at baseline and after stepwise ablation.  
Example electrograms and their sites are arrowed: yellow marks show annotation of 
electrograms contributing to the CFE-mean over 5 seconds.    
 
In the right atrium, the same principles were applied but adapted for the difference in 
anatomy, location, and relationship to ablation sites.  In order to assess the remote effect of all 
left atrial ablation (PVI, linear lesions, and CFE ablation) on the right atrium, the saved 
geometry, with its associated ablation points, that was recorded immediately after final (left 
atrial) CFE ablation was used as the basis for calculation of the right atrial ‘denominator’ 
area.  Any left atrial (septal) lesions within 10mm of the right atrial geometry were projected 
on to its surface, to allow exclusion of these areas – which might otherwise confound the true 
remote impact of LA lesions.  After field scaling, the following were performed: 
  
119 
i. The area of right atrium remaining after excluding (to within 5mm) any projected left 
atrial (septal) lesions, and excluding the tricuspid valve annulus, and the ostia of the 
coronary sinus and superior and inferior caval veins  
ii. All regions with CFE-mean ≤120ms, i.e. all areas within (i) displayed with white-blue 
colour annotation, the sum of which was defined as right atrial CFE-area  
An example of right atrial CFE mapping at baseline and after all LA ablation, projected on to 
the final RA lesion-set/geometry (including projected lesions from the LA) taken prior to DC 
cardioversion, is shown in Figure 4-6.  
 
Figure 4-6 Sequential RA CFE maps 
High-density CFE maps are shown in the RA at baseline and after all LA ablation.  LA 
ablation lesions projecting within 10mm of the RA surface have been displayed and the 
area excluded from analysis (black outline top right). Electrograms are shown from the 
lateral wall pre and post ablation, displaying marked organisation of a prior CFE site. 
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4.3.5.2 Atrial segmentation 
In order to categorise CFE distribution, the LA was divided into 3 segments as previously 
described,276 namely anterior, posterior, and appendage (Figure 4-7).  The RA was similarly 
segmented into lateral, septal, and appendage (Figure 4-8).    
 
 
Figure 4-7 Left atrial segmentation 
The anterior and posterior walls were defined superiorly by the roof line between the left 
superior pulmonary vein (LSPV) and right superior pulmonary vein (RSPV), and laterally 
by the mitral valve isthmus (MVI) line in AP and PA views respectively.  The appendage 
was defined by protrusion from the LA geometry as above.  The method of 
segmentation is based on that of Singh et al276  
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Figure 4-8 Right atrial segmentation  
In order to assess differential impact of ablation on CFE-area in regions of the right 
atrium, it was segmented into 3 zones: lateral, septal and appendage.  The tricuspid 
valve annulus (TVA) served as the anterior border for both lateral and septal, with 
division between the two at its midline in en-face projection.  The right atrial appendage 
(RAA) was defined by protrusion from the RA anatomy in a typical anatomical location 
superior to the tricuspid annulus.  On the left, right anterior oblique projection shows the 
lateral RA, and on the right, a left posterior oblique view shows the septal RA.  SVC = 
superior vena cava; IVC = inferior vena cava 
 
4.3.6 Statistical analysis 
Continuous data are presented as mean ± standard deviation, and categorical data as 
frequency/percentage. Change in CFE-area was analysed by absolute and percentage 
coverage of atrial surface area, and compared by paired t-tests. Linear regression was 
additionally performed to assess factors associated with baseline CFE areas (age, gender, 
baseline appendage CL, HF aetiology, amiodarone, LA diameter, AF duration, and LVEF), 
reduction of remote RA CFE area (adding RF duration), reduction of remote LA CFE area by 
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PVI and linear lesions (adding primary linear block).  Arrhythmia-free survival was assessed 
by Kaplan-Meier technique, and Cox regression used to assess influencing factors. Analysis 
was performed within SPSS for Mac.  P-values of <0.05 were regarded as significant.   
4.3.7 Follow-up 
All antiarrhythmic drugs except non-sotalol beta-blockers were discontinued post-ablation, 
unless indicated for ventricular arrhythmia.  Patients were followed up at 3, 6, and 12 months, 
and routinely 6 monthly thereafter, with additional review for symptomatic recurrence.  48h 
Holter recording or equivalent device interrogation was performed at 6 and 12 months, and 
ECG at subsequent follow-ups.  Arrhythmia recurrence was defined as AF or atrial 
tachycardia lasting more than 30 seconds after a 2-month blanking period.    
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4.4 Results 
4.4.1 Catheter ablation procedure 
Total procedural duration was 331±55 min, fluoroscopy time 79±18 min, and total 
radiofrequency ablation time 82±19min (PVI 46±17 min; roof line 3.3±1.7 min, mitral 
isthmus line 4.0±2.3 min, CFE 12.1±7.7 min).  After cardioversion, primary roof block was 
present in 26/30 patients, the remaining 4 being blocked after further ablation (2.3±1.4 min).  
There was primary mitral block in 11/30 patients, and further ablation (6.6±3.5 min) in the 
remainder (including epicardially via the coronary sinus in 15) achieved block in 28/30 (93%) 
patients.  CTI ablation was performed in 28/30 patients (in 2 cases not performed due to long 
procedural duration), achieving bidirectional block in 27/28 (96%).  
4.4.2 Mapping procedure 
A total of 168 CFE maps were acquired (Figure 4-1), constituting 114 LA maps (479±99 
points per map) and 54 RA maps (373 ± 96 points per map).  The total number of points per 
map did not differ significantly between the baseline and subsequent LA (ANOVA p=0.22) 
and RA (p=0.89) maps.  The total surface area included for sequential CFE-area analysis was 
117±24cm2 in the LA (after exclusion of 96±25 cm2 area from PV isolation and linear 
lesions) and 136±33cm2 in the RA.  
4.4.2.1 Impact of catheter ablation on CFE-area 
At baseline LA CFE-area was 18.3±12.0cm2 (16.2±10.6% of LA surface) comprising 
7.9±6.0cm2 (6.8±5.1%) anteriorly, 6.6±5.8cm2 (5.9±5.3%) posteriorly, and 3.8±4.1cm2 
(3.5±3.8%) in the LAA.  After PVI there was a reduction in CFE-area to 10.2±7.1cm2 
(9.0±6.6%, p<0.001 versus baseline), comprising 4.5±4.0cm2 (3.8±3.2%) anteriorly 
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(p<0.001), 2.8±3.2cm2 (2.6±3.0%, p<0.001) posteriorly, and 2.8±2.5cm2 (2.5±2.3%, p=0.11) 
in the LAA.  After addition of linear lesions and compared with post-PVI analysis, total LA 
CFE-area had further reduced to 7.7±6.5cm2  (6.9±5.9%, p=0.002), comprising 4.2±4.2cm2 
(3.7±3.7%, p=0.96) anteriorly, 1.7±2.8cm2 (1.6±2.6%, p=0.008) posteriorly, and 1.7±1.8cm2 
(1.6±1.7%, p=0.01) in the LAA (Figure 4-9).  As expected, direct CFE ablation significantly 
reduced final LA CFE-area, compared with post-linear lesion analysis, to 3.1±3.5 cm2 
(2.8±3.0%, p<0.001), comprising 1.4±2.0cm2 (1.1±1.6%, p<0.001) anteriorly, 0.2±0.9cm2 
(0.2±0.8%, p=0.004) posteriorly, and 1.6±2.1cm2 (1.5±2.1%, p=0.92) in the LAA. 
 
Figure 4-9 Impact of stepwise ablation on left atrial CFE-area  
The percentage (mean±SD) of atrial surface (excluding PVI and linear lesion sites) 
covered by CFE is shown, segmented as per Figure 4-7, at baseline and following 
stepwise PVI, then linear lesions (LL) and finally CFE ablation.  Note that the region of 
the left atrial appendage was not targeted with ablation (see text) during CFE ablation.  
P values are shown for comparisons between steps of ablation, and denoted * <0.05, ** 
<0.01, and *** <0.001 
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Figure 4-10 Impact of stepwise ablation on right atrial CFE-area  
 The percentage (mean±SD) of atrial surface (excluding sites with projected LA lesions) 
covered by CFE is shown, segmented as per Figure 4-8, showing baseline (pre) and 
after all LA ablation (post). 
 P values are denoted * <0.05, ** <0.01, *** <0.001 
 
At baseline, RA CFE-area was 25.9±14.1cm2 (19.2±10.3% of the total RA surface), 
comprising 9.6±6.8cm2 (7.2±4.9%) laterally, 10.1±7.2cm2 (7.7±5.9%) septally, and 
6.2±5.8cm2 (4.3±3.8%) in RAA.  Final RA CFE-area after LA ablation was reduced to 
12.9±11.8 cm2 (9.9±7.8%, p<0.001), comprising 7.0±7.1 cm2 (5.6±5.3%, p=0.03) laterally, 
2.5±2.8cm2 (2.0±2.1%, p<0.001) septally, and 3.6±3.9 cm2 (2.5±2.6%, p=0.01) in the RAA 
(Figure 4-10). 
4.4.2.2 Impact of catheter ablation on AF cycle length 
LAA CL at baseline was 161±28ms, prolonging to 170±37ms after PVI (p=0.003). LAA CL 
after linear ablation was 174±34ms (compared with post-PVI p=0.15), and 180±42ms 
(p=0.01, versus post-linear) after LA CFE ablation.  RAA baseline CL was 167±33ms, and 
175±33ms after PVI (p=0.006).  It was 174±30ms (p=0.29) after linear ablation, prolonging to 
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179±41ms (p=0.01, versus post-linear) after completion of LA ablation.  Hence in both atria 
CL prolonged significantly after PVI and CFE ablation, but was not impacted independently 
by linear ablation.  Change in CL did not significantly correlate with change in CFE-area 
(R=0.21 in RA, p=0.35, for sequential LA maps R =0.08-0.29, p=0.12-0.91).  
4.4.2.3 Predictors of baseline CFE-area 
Non-ischaemic HF aetiology, shorter RAA baseline CL, female gender, and lower LA 
diameter were associated with greater baseline RA CFE-area (as percentage of total surface 
area).  In multivariate analysis only non-ischaemic aetiology remained a significant factor 
(p=0.002, 11.2cm2, 95% CI 4.5 to 17.9).  LA CFE percentage coverage was associated with 
non-ischaemic HF aetiology and shorter baseline LAA CL, although only LAA CL was 
significant in multivariate analysis, with a small effect (p=0.03, coefficient -0.084, 95% CI -
0.161 to -0.008). 
4.4.2.4 Predictors of CFE-area reduction after PVI and linear lesions 
Non-ischaemic HF aetiology, longer baseline LAA CL, and higher EF were associated with 
greater reduction in CFE by PVI alone, although after correction for baseline remote CFE-
area, the reduction in CFE by PVI was independent of any identifiable independent variable.  
However, the reduction of CFE-area after linear lesions was significantly greater in those with 
primary mitral block (p=0.009, -3.43cm2, 95% CI -5.91 to -0.94), but not primary roof block.  
This factor persisted after adjustment for pre-linear lesion remote CFE-area (p=0.02, 
coefficient -2.90cm2, 95% CI -5.30 to -0.49).  
4.4.2.5 Atrial Fibrillation Termination 
Termination of AF was observed in 6 cases.  In 2 patients this occurred just prior to CFE 
ablation (after post-linear lesion mapping), and in both a roof-dependent atrial tachycardia 
was mapped and ablated to sinus rhythm.  In the other 4, termination of AF occurred during 
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CFE ablation, 2 via sustained atrial tachycardia (peri-mitral and focal – both successfully 
ablated), and in 2 cases via transient organisation then sinus rhythm.   Hence 24/30 patients 
had sequential RA maps for comparison, whereas all patients had sequential post-PVI and 
linear lesion LA maps for the above analysis (Figure 4-1).  Considering baseline CL, overall 
AFCL prolongation, CFE-area, LA size, primary linear lesion block, RF time, age, and AF 
duration, there were no statistically significant predictors of AF termination. 
4.4.3 Clinical outcome 
After a single ablation procedure, at 494±223 days follow-up, 19/30 patients (63%) were free 
of atrial arrhythmias. Of the 11 patients with arrhythmia recurrence, 3 had AF and 8 atrial 
tachycardia.  Kaplan-Meier arrhythmia-free survival estimation (Figure 4-11) was 71.8% at 1 
year, off antiarrhythmic drugs, after a single ablation procedure.  Three patients died of 
progressive HF during follow up at 1, 11 and 14 months: none had documented recurrent 
atrial arrhythmia, including two confirmed via device interrogation.   
4.4.3.1 Repeat ablation procedures 
Those with recurrent arrhythmia presented at a median of 206 (range 67-705) days.  Repeat 
ablation procedures were performed in 9 patients (7 for atrial tachycardia and 2 for AF) of 
whom 8 required re-isolation of ≥1 pulmonary vein.  In 2 cases atrial tachycardia was focally 
emanating with presumed microreentrant mechanism, all previous lines remaining blocked.  
Of the remaining 7 cases, linear lesion sites were involved in macroreentrant tachycardia 
circuits in 5 patients (including 3 roof-dependent and 4 peri-mitral tachycardias), of whom 3 
additionally had separate focally-emanating tachycardias near prior CFE ablation sites.   Two 
patients underwent a third ablation procedure, 1 for focally-emanating atrial tachycardias near 
prior CFE ablation sites, and 1 for recurrent AF.  Overall, at last follow-up, 28/30 patients 
(93%) remained in sinus rhythm after 1.4±0.6 procedures.         
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4.4.3.2 Factors influencing arrhythmia-free survival after one procedure 
Age, gender, LA size, heart failure aetiology, ejection fraction, AF duration, baseline CFE-
areas, baseline CL, total change in CL, total change in LA CFE, procedural AF termination, 
radiofrequency duration (total and CFE), and incompleteness of linear lesions at the index 
procedure were analysed as possible risk factors for recurrence: the presence of unblocked 
linear lesions was the only predictor of arrhythmia recurrence in multivariate analysis (Table 
4-2).  Survival curves comparing complete linear block in all lines (roof, mitral, 
cavotricuspid) with presence of any unblocked lines are shown in Figure 4-12 (Log Rank test 
p=0.002).  No patient with procedural AF termination had recurrence within the follow up 
period (Log Rank test p=0.058, Figure 4-13). 
 
Figure 4-11 Atrial arrhythmia-free survival 
 Kaplan-Meier estimation of arrhythmia-free survival after a single ablation procedure.  
Vertical tick marks show the points at which patients were censored (last follow-up) and 
vertical steps show events  
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Table 4-2 Cox regression analysis model  
Cox regression for atrial arrhythmia-free survival after a single ablation 
procedure  
N=30. Multivariate analysis in italics. 
 
HR = Hazard Ratio, CI = confidence interval, p = p value 
AF = atrial fibrillation, CFE = complex fractionated electrogram, CL = cycle length, HF= 
heart failure, LA = left atrial, LL = linear lesion, LV = left ventricular, RA = right atrial, 
RF= radiofrequency ablation  
 
Variable HR 95% CI p HR 95% CI p 
Age 0.99 0.93-1.06 0.77    
Female gender 0.60 0.16-2.31 0.46    
LA size 1.12 1.02-1.24 0.022 1.11 0.99-1.24 0.09 
Ischaemic HF 2.02 0.61-6.69 0.25    
LV ejection fraction 0.98 0.91-1.05 0.56    
AF duration 1.01 0.98-1.04 0.41    
Baseline LA CFE-area 1.01 0.96-1.07 0.62    
Baseline RA CFE-area 1.00 0.96-1.05 0.85    
Change in LAA CL 1.02 0.98-1.07 0.28    
Change in LA CFE 0.92 0.09-9.80 0.95    
AF termination 0.03 0.00-11.44 0.25    
RF duration 1.00 1.00-1.00 0.91    
Unblocked LL 7.49 1.74-32.16 0.007 4.69 1.05-21.06 0.04 
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Figure 4-12 Unblocked linear lesions: impact on success 
Kaplan-Meier survival estimation for atrial arrhythmia-free survival after a single ablation 
procedure, comparing those with and without complete linear lesion block at the index 
procedure  
  
Figure 4-13 AF termination: impact on success 
Kaplan-Meier survival estimation for atrial arrhythmia-free survival after a single ablation 
procedure, comparing those with and without AF termination at the index procedure 
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4.5 Discussion 
The main finding of this study are that in this human model of advanced atrial substrate, 
persistent AF and heart failure, CFE-area is reduced at remote sites following PVI and linear 
ablation.  Within the LA, CFE-area was reduced sequentially following PVI and linear 
lesions. Furthermore, CFE-area in the RA was also reduced after ablation only within the LA.  
Primary block of the mitral isthmus line produced greater reduction of CFE-area compared 
with an unblocked mitral isthmus line.  Additionally, the stepwise ablation approach 
employed resulted in a high freedom from atrial arrhythmia following a single procedure, 
with atrial tachycardia (both macroreentrant and ‘focal’) the usual mode of recurrence, and 
the presence of unblocked linear lesions at the end of the index procedure was the only 
independent predictor of arrhythmia recurrence. 
4.5.1 Ablation of complex fractionated electrograms 
Since the initial data supporting CFE ablation to eradicate AF,127 investigators have targeted 
CFE alone,200 in conjunction with PVI,201, 204 or within a stepwise strategy incorporating 
linear lesions.202, 203  However, studies randomising persistent AF patients to CFE ablation 
have produced sharply differing results.244, 256, 277 A recent clinical trial reported that 
algorithm-guided CFE ablation combined with PVI significantly improved procedural 
success.277  In contrast, another study showed that up to 2 hours of conventional CFE 
mapping and ablation after PVI provided no additional clinical benefit.256  Such discrepancies 
might relate to the heterogeneity of CFE mapping, including use of operator-identification 
versus semi-automated algorithms, and variable mapping density (point-to-point mapping 
pragmatically achieving a resolution approximately 25% of multipolar mapping).204  
However, CFEs also have incompletely understood and heterogeneous aetiologies.  They may 
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be a consequence of slow conduction192, 193, 196 or anisotropy-related behaviour,196, 197 or 
represent endo-epicardial breakthrough,278 localised reentry, wavelet collision,192 or 
wavebreak adjacent to high-frequency drivers,279 or could relate to acetylcholine release at 
locations of epicardial ganglionated plexi.198  Notably, some of these mechanisms suggest 
source activity responsible for maintaining fibrillation, while others suggest passive bystander 
activation: a crucial distinction when judging their relevance as targets for catheter ablation. 
Other investigators have shown that PVI reduces fractionation at non-PV sites.274, 275 More 
recently Matsuo et al showed that, in patients with mostly lone AF, linear lesions combined 
with PVI also reduced CFE at remote sites.280  However, in contrast to the current study, these 
studies examined patients without significant structural heart disease and minimal atrial 
dilatation (mean 40-45mm).  Our study examined a model of more advanced atrial disease 
(LA dilatation and LV dysfunction) and uniquely also examined the impact of left atrial 
lesion sets on CFE in the RA, finding a significant reduction of CFE-area not only in the LA 
but also in the RA.   
If CFE represent sites of reentrant activity responsible for maintaining AF elsewhere - rather 
than simply bystander wavefront collision - then while reduction of remote CFEs by ablation 
in a lone-AF model might be explained by acute electrophysiological remodelling, it is 
perhaps surprising that biatrial CFE can be reduced by remote ablation in an advanced atrial 
substrate associated with chronic stretch and fibrosis.28, 58, 59, 65  However, it is possible, as 
described above, that the mechanisms underlying CFE are heterogenous and, thus, the CFE 
which are abolished by remote ablation are only those which are caused by bystander 
activation. 
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4.5.2 Linear lesions  
Although placement of complete linear lesions can be challenging and incompleteness is 
proarrhythmic,167 they can help achieve long-term freedom from atrial arrhythmias.171, 176, 178  
In addition to preventing macroreentrant tachycardia, compartmentalisation by linear lesions 
may reduce both initiation and maintenance of AF.281  Allessie et al have recently performed 
high-density epicardial mapping of persistent AF in humans282 showing that, rather than 
rotors or foci maintaining AF, the substrate was based on lines of block within the atrial 
musculature, with longitudinal dissociation facilitating multiple wavefronts.  Our observed 
reduction in CFE-area with linear ablation, particularly the greater reduction seen with 
complete lines (primary block), would fit a hypothesis that ‘iatrogenic’ creation of lines could 
alter the propagating route for AF wavefronts and hence affect fractionation observed at 
remote sites, particularly when it is due to incident activation.  Additionally, if some CFE 
represent sites of endo-epicardial breakthrough,278 placement of linear lesions in the vicinity 
of such sites might reduce non-uniform anisotropy and the probability of slow epicardial-
breakthrough.     
Our data additionally shows that a stepwise strategy incorporating linear lesions is associated 
with favourable clinical outcome in this cohort, and reaffirms the importance of robust linear 
ablation, given that unblocked lesions predicted arrhythmia recurrence and participated in the 
offending arrhythmia mechanism in approximately 50% of atrial tachycardia recurrences.  
However, AF recurrence was low, and in those having repeat procedures all atrial 
tachycardias were successfully ablated. 
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4.5.3 Sequence of ablation in a stepwise approach  
The ideal ablation strategy for persistent AF remains uncertain.  Stepwise ablation, including 
PVI, targeting of CFE, and linear lesions, can lead to favourable outcomes.202  Some CFE 
may facilitate ongoing AF,127 and indeed in our study ablation of residual CFE after linear 
ablation both prolonged AF cycle length283 and terminated AF in a handful of cases.  
Although several investigators have attempted to categorise and stratify potential CFE 
ablation sites,203, 284 identification of active versus bystander CFE sites remains challenging.  
One potentially important clinical implication of our data stems from the finding that many 
CFE sites can be rendered ‘normal’ by remote PVI and linear ablation, and thus would be 
themselves unsuitable targets for ablation as they may result from bystander activation.  If one 
intends to pursue CFE ablation, but suspects heterogeneity of CFE mechanisms, then our data 
would support a strategy involving initial application of PVI, then linear lesions – which are 
potentially needed anyway for long term arrhythmia-free success in longstanding persistent 
AF171 – in order to minimise unnecessary subsequent ablation of CFE, which may itself be 
proarrhythmic.285  This is in keeping with the conclusions of prior studies into remote impact 
of ablation on CFE in lone AF,274, 275, 280 and our data would suggest this also applies in the 
case of non-lone AF.  In addition, our finding of significant remote CFE reduction in the RA 
– also suggesting passive bystander activation – may in part explain the previously reported 
lack of benefit of adding routine right atrial CFE ablation to a left sided procedure.286  
Our relatively high single-procedure success mirrors that reported with a similarly extensive 
ablation strategy by other centres,255, 273 Interestingly, a smaller proportion of our patients had 
AF termination.  Although AF termination showed a trend towards predicting improved 
outcome in our cohort, termination was not necessary for long-term success in the majority, 
and this would suggest that ablating to an endpoint of termination may involve unnecessary 
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destruction of atrial tissue.  Notably, we did not use ‘facilitation’ with antiarrhythmic drugs 
peri-procedure, and only a small number of patients were on these agents, which may explain 
a lower termination rate than other series.  The long procedure times inherent to our mapping 
and ablation protocol effectively provided a long ‘waiting time’ after PVI and linear lesions, 
with additional ablation when necessary, a factor that possibly contributed to the improved 
outcome.287    
4.5.4 Limitations 
The present study has several limitations. Firstly, as it did not randomise to different 
treatment strategies, the relative contributions of different lesions towards outcome are 
uncertain.  We elected to apply all contemporary ablation strategies in this clinical trial cohort 
to minimise arrhythmia recurrence.202  Secondly, incomplete linear block as a predictor of 
recurrence could have arguably been confounded by a more difficult or lengthy procedure: 
however, in regression analysis, procedure and radiofrequency duration were not significant 
risk factors.  Finally, to minimise procedural duration in this cohort of patients with heart 
failure, we did not acquire RA CFE maps at every stage of the procedure, hence we cannot 
comment on the component effects of stepwise ablation on the RA CFE-area.  
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4.6 Conclusion 
In patients with persistent AF associated with LV systolic dysfunction, high-density contact 
mapping revealed that both PVI and subsequent linear lesions each had a significant effect in 
reducing LA fractionation at sites remote from ablation.  LA ablation also led to a reduction 
in RA fractionation.  A significant proportion of the CFE seen in the untreated atrium in this 
model of advanced atrial substrate were thus abolished by ablation at remote sites, which 
could suggest the CFE are functional or that the substrate is acutely amenable to modification 
by ablation. Completeness of linear lesions was associated with both greater CFE reduction 
and improved medium-term procedural outcome.  Our study would suggest that targeting 
CFE after PVI and linear lesions could minimise unnecessary collateral damage to atrial 
myocardium, and that such a strategy is associated with a high level of sinus rhythm 
maintenance at follow up. 
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5 The ARC-HF trial results 
5.1 Abstract 
5.1.1 Background  
The optimal therapy for atrial fibrillation (AF) associated with heart failure (HF) is unclear. 
Drug-based rhythm-control has not proved clinically beneficial. Catheter ablation improves 
cardiac function in patients with HF, but impact on physiological performance has not been 
formally evaluated in a randomized trial.   
5.1.2 Methods  
Adults with symptomatic HF, radionuclide left ventricular ejection fraction (EF) 35% or less, 
and persistent AF were randomly assigned to undergo catheter ablation or rate-control.  
Primary outcome was 12-month change in peak oxygen consumption (VO2).  Secondary 
endpoints were quality-of-life, BNP, 6-minute walk distance (6MWd) and EF.  Results were 
analysed by intention-to-treat. 
5.1.3 Results 
52 patients (63±9years, EF 24±8%, median 36 months AF) were randomized, 26 each to 
ablation and rate-control.  At 12 months, 88% of ablation patients maintained sinus rhythm 
(single-procedure success 68%).  In the rate-control group, rate criteria were achieved in 96%.  
The primary endpoint, peak VO2 significantly increased in the ablation arm compared with 
rate-control (difference +3.07ml/kg/min, 95% CI 0.56-5.59, p=0.018).  The change was not 
evident at 3 months (+0.79ml/kg/min, 95% CI -1.01 to 2.60, p=0.38).  Ablation improved 
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Minnesota score (p=0.019) and BNP (p=0.045), but showed only non-significant trends 
toward improved 6MWd (p=0.095) and EF (p=0.055). 
5.1.4 Conclusions 
This first randomized controlled trial of ablation versus rate-control to focus on objective 
exercise performance in AF in HF shows significant benefit from ablation, a strategy which 
also improves symptoms and neurohormonal status.  The effects are not instant but develop 
over 12 months, consistent with progressive amelioration of the heart failure syndrome. 
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5.2 Background 
See Chapter 1 
5.3 Methods 
See Chapter 2 
5.4 Results 
A total of 101 patients were referred for participation, and 75 attended for baseline 
assessment.  52 patients were randomised, 26 patients to each arm (Figure 5-1).  
Baseline characteristics are summarized in Table 5-1  
One patient in the ablation arm withdrew consent for ablation and continued existing therapy.  
One patient in the rate-control arm requested and underwent ablation after 4 months.  Both 
patients attended for all follow-up investigations and were analysed by intention-to-treat.   
One patient in the ablation arm died 11 months post-ablation, due to progressive cardio-renal 
failure. He had chronic lung disease, dilated cardiomyopathy, and a biventricular pacemaker-
defibrillator in-situ for 2 years.  Device interrogation showed no AF recurrence. 
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Figure 5-1 CONSORT diagram for ARC-HF 
AF = atrial fibrillation; GA = general anaesthesia; ITT = intention-to-treat; LVEF = left 
ventricular ejection fraction.  
*no 6 or 12-month data for 1 patient who died before final review 
101#pa&ents#assessed#for#eligibility#
75#baseline#assessment#
52#randomised#
26#rate#control# 26#catheter#abla.on#
26#excluded#pre,assessment#13#declined#participation;#4#LVEF#too#high;#4#not#persistent#AF;#1#death;#1#pending#valve#surgery;#1#AF#ablation##already##performed;#2#other#causes#
23#excluded#post#assessment#16#LVEF>35%;#3#not#persistent#AF;#2#declined#participation;#2#unDit#for#GA#
Analysed#ITT#=#26# Analysed#ITT#=#26*#
1#had#catheter#ablation#after#
4#months#
1#withdrew#consent#for#ablation##
1#death#11#months#after#ablation*#
!
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Table 5-1 Baseline characteristics 
ACE = angiotensin converting enzyme inhibitor, AF = atrial fibrillation, ARB = angiotensin receptor 
blocker, BNP= B-type natriuretic peptide, CRT = cardiac resynchronization therapy, HF = heart failure, 
HR = heart rate, ICD = implantable cardioverter defibrillator, LA = left atrial, LHFQ = Minnesota Living 
with Heart Failure Questionnaire, LVEF = left ventricular ejection fraction, NYHA = New York Heart 
Association,  6MW = 6-minute walk.   
 Rate-control (n=26) 
N (%) / mean±SD 
Catheter Ablation (n=26) 
N (%) / mean±SD 
P-value 
Age 62±9 64±10   0.38 
Male  24 (92) 21 (81) 0.22 
HF aetiology   Ischaemic 
                        Non-ischaemic 
7 (27) 
19  (73) 
10 (38)        
16 (62) 
 
0.38 
Time since HF diagnosis (months) 48±57 68±62 0.22 
Time since AF diagnosis (months) 51±76 51±39       0.98 
Duration of continuous AF (months) 24±29 23±22 0.95 
NYHA class 
       NYHA II 
       NYHA III 
2.50±0.51 
13 (50) 
13 (50) 
2.46±0.51 
14 (54) 
12 (46) 
0.79 
Recent HF hospitalisation (<1year) 7 (27) 10 (38) 0.38 
Minnesota LHFQ score (/105) 49±21 42±23       0.23 
Peak VO2 (ml/kg/min) 18.2±4.8 16.3±5.3   0.19 
Radionuclide LVEF (%) 25±7 22±8       0.13 
LA diameter (M-mode, mm) 46±7 50±6        0.07 
BNP (pg/ml) 283±285  412±324 0.13 
Creatinine 102±28 96±24       0.42 
6MWD (m) 411±109 416±78   0.84 
Resting HR (bpm) 81±12 77±9        0.18 
Exercise HR (bpm) 109±18 108±15    0.88 
Rate-controlled at baseline (≤80/≤110 at 6MW) 14 (54) 17 (65)  0.40 
QRS duration (ms) non-paced only 113±21 119±19    0.37 
Pre-existing ICD; of which CRT 4 (15); 3 (12) 10 (38);  8 (31) 0.06; 0.09 
Ventricular pacing dependent 1 (4) 1 (4) 1.0 
Beta blocker 24 (92) 24 (92) 1.0 
ACE or ARB 26 (100) 25 (96) 0.31 
Aldosterone antagonist 6 (23) 13 (50)    0.04 
Amiodarone 3 (12) 3 (12) 1.0 
Digoxin 12 (46) 16 (62) 0.27 
≥1 prior class I/ III antiarrhythmic  9 (36) 9 (36) 1.0 
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5.4.1 Primary end-point 
At 12 months peak VO2 had increased by 2.13 (-0.10 to +4.36) ml/kg/min in the ablation arm, 
compared with a decrease (-0.94, -2.21 to +0.32 ml/kg/min) in the rate-control arm.  The 
mean difference between the groups (primary endpoint) was +3.07 ml/kg/min (95% CI 0.56 
to 5.59, p=0.018; Figure 5-2).   At 3 months there had been a non-significant increase of VO2 
in the ablation arm (mean difference +0.79ml/kg/min, -1.01 to +2.60, p=0.38).   
 
Figure 5-2 Change in peak oxygen consumption (primary endpoint) 
 By intention-to-treat, change (Δ) in peak VO2 (mean±95%CI) from baseline, comparing 
ablation (shown as solid dot/line) versus rate-control (shown as open dot/dashed line) at 
3 (p=0.38) and 12 month (p=0.018) follow-up. Statistical significance shown between 
groups at each time point: * if p<0.05. 
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Individual responses of VO2 are shown in the graphs below.  Note that the patient who died 
A20 had missing data at 12 months.  Imputation was not performed for calculation of the 
primary endpoint, although sensitivity analyses are discussed in the limitations section. 
 
Figure 5-3 Individual patient responses in peak VO2 – rate control group 
 Line graphs showing absolute peak VO2 (ml/kg/min) recorded at each time point for 
each patient randomised to the rate control group 
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Figure 5-4 Individual patient responses in peak VO2 – ablation group 
 Line graphs showing absolute peak VO2 (ml/kg/min) recorded at each time point for 
each patient randomised to the rate control group 
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5.4.2 Secondary endpoints 
Minnesota LHFQ score (Figure 5-5) improved (reduced) in the ablation arm, non-
significantly at 3 months (p=0.196) but significantly at 6 (p=0.015) and 12 months: median -
15.5 (IQR -26.75 to -7.25) compared with -5 (-16 to +9) under rate-control (p=0.019).  The 
change in score was normally distributed and was additionally analysed by (parametric) t-test.  
The mean reduction in LHFQ score with ablation was -19.6 (95% CI -29.0 to -10.0) 
compared with -5.4 (95% CI -11.7 to + 1.0) for rate control, which corresponded to mean 
treatment effect (difference) of -14.2 points (95% CI -25.1 to -3.3, p=0.012).    
Figure 5-5 Change in Minnesota LHFQ score (secondary endpoint) 
By intention-to-treat, change (Δ) from baseline, displayed as median and interquartile 
range, for Minnesota Living with Heart Failure Questionnaire (LHFQ) score.  Ablation 
shown as solid dots/lines, rate-control as open dots/dashed lines. Statistical 
significance* shown between at 6 months (p=0.015) and 12 months (0.019) by Mann 
Whitney U-test. 
 
* 
Follow up (months)
 
LF
H
Q 
sc
or
e
25
20
15
10
5
0
5

 

0 3 6 12
* 
  
146 
Figure 5-6 Change in plasma BNP (secondary endpoint) 
By intention-to-treat, change (Δ) from baseline, displayed as median and interquartile 
range, for plasma B-type natriuretic peptide (BNP) levels.  Ablation shown as solid 
dots/lines, rate-control as open dots/dashed lines. Statistical significance* shown 
between at 6 months (p=0.038) and 12 months (0.045) by Mann Whitney U-test. 
 
 
BNP similarly showed non-significant decrease at 3 months (p=0.132) but significant 
reduction at 6 (p=0.038) and 12 months (p=0.045) in the ablation arm: median -124(-284 to 0) 
pg/ml, compared with -18(-86 to +31) pg/ml for rate-control (Figure 5-6).  
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Six-minute walk distance (Figure 5-7) tended to increase in both groups towards 6 months.  At 
12 months, ablation produced a non-significant increase (p=0.095) (median +21metres, -51 to 
+89) compared with a decrease under rate-control (median -10metres, -73 to +15).  Left 
ventricular EF, as measured by radionuclide ventriculography, showed a non-significant trend 
towards improvement in the ablation arm (mean difference +5.6%, CI -0.1 to +11.3, p=0.055) 
– see chapter 6 for further information. 
  
Figure 5-7 Change in 6-minute walk distance (6MWd, secondary endpoint) 
By intention-to-treat, change (Δ) from baseline in 6MWd, median and interquartile 
range.  Ablation shown as solid dots and lines, rate-control as open dots and dashed 
lines. Non-significant trend^ shown for difference at 12 months (p=0.095).   
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5.4.3 Other parameters 
Exercise time mirrored peak VO2 with non-significant change at 3 months in the ablation arm 
(mean difference +54s, -31 to 139, p=0.205) with significant improvement at 12 months 
(mean difference +133s, 19 to 246, p=0.023).  
VE/VCO2 slope showed a non-significant reduction from ablation at 3 months (mean 
difference -3.45, -7.33 to 0.44, p=0.081) and 12 months (mean difference -1.68, -6.50 to 3.14, 
=0.49).  The proportion of ablation patients with VE/VCO2 >34 was 19/26 (73%) at baseline 
and 13/25 (52%) at 12 months, compared with 14/26 (54%) and 11/25 (44%) in the rate 
control arm.  These findings would suggest a trend towards improvement in alveolar gas 
exchange but with no statistically significant difference between groups.  
The proportion of patients achieving satisfactory ventilator anaerobic threshold was analysed 
as a method to compare effort between groups at follow-up.  Using a respiratory exchange 
ratio (RER) of 1.05 as a cut off, this was 17/26 ablation vs. 16/26 rate control at baseline 
(p=0.77) and 16/25 vs. 15/26 at 12 months (p=0.77).  Additionally, the change in RER was 
calculated for each patient. In the rate control arm, change in peak RER was +0.03±0.07 at 3 
months and +0.3±0.12 at 12 months.  By comparison, in the catheter ablation arm the change 
was +0.01±0.12 at 3 months (p=0.39) and 0.01±0.14 at 12 months (p=0.50).  Overall there 
was no evidence of increased motivation in the ablation arm to explain the difference in peak 
VO2 observed in analysis of the primary endpoint. 
NYHA class was assigned by the investigators thus was unblended as was not included as one 
of the pre-specified secondary endpoints, however it collected at every time-point and was 
included in post-hoc analysis given its relevance to clinical practice.  At 12 months, there was 
median reduction of 1 NYHA class in the ablation arm, compared with no change in the rate 
control arm (Mann-Whitney U test p=0.004):  more meaningful in this context is perhaps the 
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mean change of -0.8 (95% CI -1.2 to -0.4) in the ablation arm compared with -0.2 (95% CI -
0.5 to +0.1) for rate control, representing a difference of -0.57 (95% CI -1.01 to -0.12, 
p=0.013).   To put this in perspective, NYHA class changed from 2.5±0.5 to 1.6±0.7 in the 
ablation arm, and 2.5±0.5 to 2.3±0.6 over 12 months in the rate control arm; 13 patients in the 
ablation arm were classified as NYHA I (including 1 patient in sustained but rate-controlled 
atrial flutter), compared with only 1 in the rate control arm.  
Figure 5-8 Change in left atrial (LA) size  
By intention-to-treat, change (Δ) from baseline in LA size as assessed by 2-dimensional 
LA area in the echocardiographic apical 4 chamber view. Ablation shown as solid dots 
and lines, rate-control as open dots and dashed lines.  Statistical significance** shown 
between at 6 months (p=0.001) and 12 months (0.001) by t-test. 
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LA area markedly decreased in the ablation arm at both 6 months (mean difference -4.96 
cm2, -7.23 to -2.68, p=0.001) and 12 months (mean difference -6.22 cm2, -9.17 to -3.27, 
p=0.001; Figure 5-8).  RA area showed similar decrease at 6 months (-5.44 cm2, -8.33 to -
2.61, p<0.001) but not at 12 months (-2.62 cm2, -5.99 to 0.74, p=0.124).  For further 
information see chapter 6. 
The pre-specified combined endpoint, analysed by individual t-tests of components, for 
change in LVEF, 6 minute walk, and LHFQ was rendered positive by the change in LHFQ 
score (p=0.012).* 
5.4.4 Rate-control 
At baseline, rate-control criteria – as defined by 6-minute walk and clinical heart rate 
assessment – were met in 14/26 (54%) patients.  Rate-control drugs were changed in 12: 2 
were started on beta-blockers, 9 had beta-blockers increased, 4 were commenced on digoxin, 
and 1 had digoxin increased.  By 3 months, 23/26 (88%) were rate-controlled.  At 12 months, 
2 were in sinus rhythm (1 after defibrillation at 9 months; 1 after undergoing ablation); of the 
remainder 23/24 (96%) were rate-controlled.  
An increase in beta-blockade did not itself have an impact on (e.g. reduced) VO2 either at 3m 
(p=0.65) or 12m (p=0.66).  The presence of rate control at baseline also did not significantly 
influence change in VO2 (p=0.41 at 12 months) across the entire cohort). 
Holter mean heart rate was 83±14 bpm in the rate control arm at baseline versus 84±9 in the 
ablation arm, 78±11 vs. 74±11 at 6 months (p=0.16) and 78±16 vs. 71±8 at 12 months 
(p=0.07).  Maximum heart rate (1 minute average) was 128±22 vs. 126±23 at baseline 
(p=0.8), 124±25 vs. 101±23 at 6 months (p=0.003) and 116±35 vs. 100±21 at 12 months 
                                                
* i.e. single p-value <0.017 – see Chapter 2 for discussion of Bonferroni principle. 
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(p=0.08).  Minimum heart rate (1 minute average) was 65±13 vs. 68±23 at baseline (p=0.59), 
60±15 vs. 67±24 (p=0.24) at 6 months, and 61±22 vs. 62±14 at 12 months (p=0.97).  
Therefore there was an expected trend towards reduction in range of heart rate with ablation 
(mostly sinus rhythm) versus rate control (mostly AF).  There was no significant difference in 
the level of ventricular ectopic burden compared between time points or groups at baseline or 
during follow up (e.g. at 12 months 54±80 vs. 67±71 ectopics per hour, p=0.58). 
5.4.5 Catheter Ablation 
Of 26 patients randomized, 25 underwent catheter ablation after 1 withdrew consent (patient 
A1).  Procedure duration was 333±61 minutes, fluoroscopy 80±19 minutes, and ablation 
82±20 minutes.  Ablation comprised 47±17 minutes for pulmonary vein isolation, 187±75 
seconds of ablation at the roof ablation (and additional 140±84 seconds in the 4 patients 
requiring additional roof ablation after cardioversion to achieve block), 240±150 seconds 
ablation at the mitral isthmus (plus 364±209 seconds in the 14 patients requiring additional 
ablation), and 719±474 seconds (12±8 minutes) ablation of CFE in the 23/25 patients who 
remained in AF after linear lesions.  All patients had conduction block of the pulmonary veins 
and roof; 24/25 (96%) had mitral isthmus block; 22/25 (88%) had cavotricuspid isthmus 
block (not attempted in 2 due to concern regarding prolonged anaesthetic).  
AF terminated during the ablation procedure in 5 patients, in all cases via some form of atrial 
tachycardia.  This occurred after linear lesions and prior to CFE ablation in 2 patients (A16 
and A21), in both cases being roof-dependent macroreentrant atrial tachycardia.  In 3 others 
transformation occurred during CFE ablation: subsequent atrial tachycardia terminated to 
sinus rhythm spontaneously in 1 patient (A25), and after ablation of ‘focal’ (microreentrant) 
atrial tachycardia in 2 patients (A6 and A26). 
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DC cardioversion was required during the blanking period in 8 patients (5 for AF, 3 for atrial 
tachycardia), 3 of whom remained arrhythmia-free (2 AF and 1 atrial tachycardia).  
During follow-up 5 patients had additional ablation procedures for recurrent arrhythmia: 4 for 
atrial tachycardia, and 1 for AF (followed by a 3rd procedure for atrial tachycardia).  One 
patient had asymptomatic flutter at final follow-up after a single procedure, having been in 
sinus rhythm at previous follow-ups (A3). Another reverted to AF by 6 months, but declined 
further ablation given prior complications (A7).  Mean time to first atrial arrhythmia 
recurrence (including patient A1 – no ablation – blanked to 2 months and without 
cardioversion) was 168 (CI 62-248) days (median 158.5, IQR 87.75 to 221.75 days).  For the 
randomised patients that underwent ablation (excluding A1), this was mean 183 days (95% CI 
62 to 248) and median 206 days (IQR 101.5 to 234.5). 
By intention-to-treat, Kaplan-Meier 1-year arrhythmia-free survival was 69% after a single 
ablation, off antiarrhythmic drugs (Figure 5-9).  Mean arrhythmia-free survival time was 304 
(CI 264-345) days.   Following all procedures, 22/25 (88%) were in sinus rhythm without 
further atrial arrhythmias, 1 of whom was on sotalol and amiodarone for ventricular 
arrhythmias. Excluding the patient who declined ablation, single-procedure success was 72%, 
and multi-procedural success 92%. 
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Figure 5-9 Single-procedure arrhythmia-free survival at 1 year  
Intention-to-treat Kaplan-Meier atrial arrhythmia-free survival estimation, after a single 
ablation procedure.  The blanking period was set at 2 months, after which occurrence of 
documented atrial tachyarrhythmia constituted procedural failure. 
 
5.4.5.1 Complications 
There was one serious procedural complication: a steam-pop caused tamponade during 
cavotricuspid-isthmus ablation, requiring emergency pericardiocentesis and sternotomy to 
repair a perforation at the atrioventricular groove.  This patient (A7) required a prolonged 
period of treatment on the intensive care unit, requiring cardiorespiratory and renal support, 
followed by rehabilitation for a ‘critical-care’ peripheral neuro-myopathy.  He was unable to 
undergo formal follow up investigations at 3 and 6 months but attended at 12 months and was 
able to complete cardiopulmonary exercise testing despite still requiring a tri-frame for 
support – his results were included in the primary analysis.  He was found to be in AF during 
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device follow up at 7 months post-ablation: a repeat catheter ablation procedure was not 
deemed appropriate in view of the previous complication and protracted physical recovery.  
Other complications, delaying discharge from hospital or requiring readmission, were: one 
groin haematoma, one chest infection 2 weeks post-ablation, and one patient with post-
procedural pulmonary oedema which resolved within 24 hours.  All these patients made a full 
recovery and completed follow-up. 
For all patients, the median stay in hospital was 2 days (IQR 2-3, full range 2 to 100 – the 
latter being the patient who had tamponade). 
5.4.6 Composite Endpoint for Major Adverse Clinical Events 
The composite endpoint for event-free survival is shown in Figure 5-10.   
The events in the ablation arm were:  
• lower respiratory tract infection in patient A11 (intensive care admission) within the 
first month after ablation, thought to be related to post-anaesthesia atelectasis 
• unplanned heart failure admissions in 3 patients 
o 25 days after ablation, due to occurrence of atrial tachycardia which required 
cardioversion (within blanking period); this patient (A19) had post-blanking 
recurrence of atrial tachycardia at 206 days post-ablation, which was 
successfully ablated  
o 78 days after ablation, with gastroparesis in the context of worsening right-
sided heart failure.  This patient (A20) had heart failure medication optimised 
but despite optimal care was deemed end-stage and entered a palliative 
management strategy 4 months after entry into the study, and died at 11 
months 
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o 339 days after ablation, with worsening dyspnoea despite maximal medical 
therapy.  A biventricular pacemaker-defibrillator (CRT-D) was inserted (A13)  
o  
Figure 5-10 MACE-free survival by treatment group 
 Kaplan-Meier Major Adverse Clinical Event (MACE)-free survival according to treatment 
group: ablation (solid) versus rate-control (dashed), Log-Rank p=0.76. 
 
The events in the rate-control arm were: 
• cerebrovascular transient ischaemic attack 28 days after enrolment, in the context of a 
subtherapeutic INR, with full recovery (patient RC8) 
• non-ST elevation myocardial infarction, ventricular fibrillatory cardiac arrest, and 
biventricular defibrillator insertion 315 days after enrolment (patient RC21).  
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Defibrillation restored sinus rhythm which was still present at the final follow-up 2 
months later 
• unplanned heart failure admissions in 3 patients 
o 174 days (patient RC2) and 261 days (patient RC3) after enrolment – admitted 
from clinic due to progressive fluid overload and dyspnoea, for additional 
diuresis 
o 182 days after enrolment (RC9) having withdrawn from the rate-control arm 
and undergone catheter ablation: he presented with rapid atrial tachycardia 
necessitating cardioversion and then repeat ablation on 2 occasions (for atrial 
tachycardias not AF).  Sinus rhythm was maintained at final follow up. 
 
 
5.5 Discussion 
See Chapter 8 for discussion of the ARC-HF trial results 
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6 Imaging in atrial fibrillation and heart failure 
6.1 Abstract 
This chapter examines the impact of the strategies of rate control and catheter ablation upon cardiac 
function as assessed by the imaging modalities of echocardiography and radionuclide 
ventriculography.  
6.2 Background  
Assessment of cardiac function includes not only clinical and physiological assessment, but also 
relies upon the use of imaging techniques.  The various modalities employed in this process can 
assess cardiac chamber size, volumes, contractile or ‘systolic’ function, relaxation or ‘diastolic 
function’, and valve structure and function.  Imaging parameters of left ventricular function, in 
particular, have significant diagnostic and prognostic utility in patients with heart disease.289-293  
Indeed, this has led to left ventricular ejection fraction (LVEF) being used as a marker of disease 
severity and an inclusion criterion for heart failure studies, such as those examining 
pharmacological interventions,23, 90 and more recently for cardiac implantable electronic devices 
such as automatic implantable cardioverter-defibrillators (ICDs)294 or cardiac resynchronisation 
therapy (CRT)250, 295 and thus these measurements are pivotal to patient selection in the clinical 
application of these therapies.  The change in LVEF over time has also been shown to be a powerful 
prognostic marker, as demonstrated in the V-HeFT studies.291   
Imaging ventricular function is however challenging in patients with atrial fibrillation (AF), due to 
the beat-to-beat variability impacting upon both diastolic filling and to a lesser extent systolic 
contraction.  Indeed, averaging of several cardiac cycles can be required to give reproducible 
results,296, 297 and still it remains challenging to know the true accuracy of any individual 
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measurement of LVEF given the effective lack of a gold standard for what is a variable 
measurement.235, 298, 299  However this does not mean that LVEF measurement does not have utility 
in patients with atrial fibrillation.  On the contrary, many clinical trials and investigations of AF and 
its therapeutic intervention have utilised ejection fraction measurement by echocardiographic, 
radionuclide, or magnetic resonance techniques,22, 122, 133, 300 and improvements in LVEF has been 
shown to parallel improvement in a broad range of outcomes.106  Also, most large-scale clinical 
trials into optimal heart failure management have included patients with atrial fibrillation, which 
may be present in 10-50% of patients with heart failure, depending upon severity.13   Importantly, 
adequate assessment of left ventricular function is vital to allow appropriate thromboembolic risk 
stratification.10  
Cardiac imaging can also investigate chamber size and valve function.  Left atrial enlargement is 
present in many patients with AF, and may predispose to45, 301, 302 or be a consequence of the 
condition.303 Its severity correlates with the chance of successfully restoring sinus rhythm with 
cardioversion.301, 304  Left atrial dilatation has also been demonstrated as an independent prognostic 
marker in patients with ventricular dysfunction.305, 306    Mitral regurgitation is present to varying 
degrees in patients with AF and is a recognised aetiologic factor.307  It has also recently been shown 
it may be a consequence of persistent AF.308  
Hence, although imaging parameters cardiac function may not in isolation be robust as a surrogate 
primary endpoint for investigation of therapies targeted at atrial fibrillation, they provide additional 
information regarding the impact of different therapies, which can help guide clinical decision-
making.  Radionuclide ventriculography and echocardiography were therefore performed as part of 
the baseline and follow-up assessment of patients undergoing treatment with rate-control or catheter 
ablation within the ARC-HF study, constituting a sub-section of the secondary endpoints.  
Radionuclide ventriculography was chosen as the principle measure of ejection fraction for both 
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inclusion criteria and for secondary endpoint analysis within the clinical trial as registered on 
ClinicalTrials.gov (NCT00878384).    
6.3 Methods 
Subjects were patients enrolled within the ARC-HF study, comprising 52 patients with 26 randomly 
allocated each to catheter ablation and rate control.   Patients underwent baseline radionuclide 
ventriculography and echocardiography prior to enrolment, with a follow up scan at 1 year.  
Additionally, subjects underwent additional an echocardiogram at 6 months. 
6.3.1 Radionuclide ventriculography (RNV) 
6.3.1.1 Acquisition Technique 
In vivo red blood cells were labelled with 800 MBq of 99mTc.  A dual-headed gamma camera with a 
high-resolution low-energy collimator was employed.  For ECG gating an R-R window width was 
set at 20%, but widened up to 50% on each side in case of markedly irregular heart rate.235, 299 
Wider window allows inclusion of beats with variable lengths, which may reduce image quality but 
is a better representation of the cardiac haemodynamics in arrhythmias. This avoids an otherwise 
long acquisition time, which may not be practicable for HF patients or can lead to patient motion 
and resultant low quality images. For planar imaging, using a single detector, a planar oblique 
acquisition with the best septal separation angle was selected. R-R interval was gated into 16-32 
frames with matrix size of 64×64 pixel size of 0.39 cm.  A total of nine million counts was 
acquired.  
Where available (25/52 patients), 3-dimensional single-photon emission computed tomography 
(SPECT) imaging was acquired.  180° acquisition was performed from right-anterior oblique 450 to 
left posterior oblique 450 in noncircular orbit with heads at 90° by step and shoot method. 32 steps 
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(16steps/head) of 30 seconds each were acquired in a 64×64 matrix with pixel size of 0.59 cm. Each 
cardiac cycle was gated into 16 frames. Follow up scans were performed with the same equipment 
and imaging sequence.  
6.3.1.2 Image Analysis 
Image analysis was performed in a blinded manner by nuclear medicine technicians and all results 
reviewed and confirmed by nuclear medicine physicians.  On planar imaging, a semi-automated 
region of interest was selected around the left ventricular blood pool on both end-systolic and end-
diastolic planar images. A further region of interest over a background area (usually the 
mediastinum) was also selected and used to background-correct counts within the blood pool 
regions of interest. Left ventricular ejection fraction was calculated as the difference between 
corrected end-diastolic and end-systolic counts divided by the corrected end-diastolic counts. The 
planar EF was used for inclusion criterion purposes.  
6.3.2 Transthoracic echocardiography 
A standardized protocol was used to acquire images on Vivid 7 or Vividi echocardiograph 
machines for subsequent analysis on EchoPAC software (GE Healthcare Milwaukee, WI, USA).  
Standard 2D images and colour/pulsed/continuous Doppler were acquired.  Atrial size and method-
of-discs LV volumes and ejection fraction (average 3 cycles) was calculated by 2 observers for final 
results analysis, both of whom were blinded to the prior randomisation.  At follow up scans in sinus 
rhythm, presence of atrial contraction was assessed by mitral A-wave Doppler, and where possible 
the A! tissue Doppler component.  Other parameters measured were LV wall thickness, LA 
diameter, LV and right ventricular (RV) pre-ejection period, mitral E/A, lateral mitral annular E! 
(tissue Doppler), mitral regurgitation severity,* left ventricular outflow tract (LVOT) velocity time 
                                                
* Mitral regurgitation graded absent/trivial, mild, moderate, severe: for mild and above, the MR was graded using 
standard colour Doppler and proximal isovelocity surface area (PISA) – effective regurgitant orifice (ERO)   
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integral (VTI), estimated cardiac output*, tricuspid annular plane systolic excursion (TAPSE) and 
tricuspid regurgitation pressure gradient as an estimate of pulmonary artery pressure. 
6.3.3 Statistical analysis   
 
See chapter 2 (Methods) for further information.  Assessment of normality, parametric and non-
parametric testing, and correlation measurements were performed in SPSS Statistics for Mac 
version 20.  Bland-Altman plots were created within Excel for Mac.  All results were analysed on 
an intention-to-treat basis, i.e. by allocation to undergo rate control or catheter ablation.  Follow-up 
results were analysed as absolute change from baseline, and then compared between groups.  Other 
than for pre-specified secondary endpoints (LVEF and LA size), further analyses were exploratory 
with no adjustment made for multiple comparisons (e.g. Bonferroni).  
6.4 Results 
For patient characteristics see Chapter 5, Table 5-1. 
6.4.1 Radionuclide ventriculography 
Planar RNV data was available for all 52 patients at baseline, and 50 patients at follow up (1 death; 
1 image quality insufficient and patient unable to tolerate a repeat scan due to back discomfort).  3D 
SPECT data was available in 25 patients, with follow-up data available in 24 (1 death).  Baseline 
planar LVEF was 23±8 (median 23, IQR 18 to 29.25). In the subgroup of patients with 3D SPECT, 
baseline LVEF was 29±11 (median 29; IQR 19 to 38). 
The impact of the treatment strategies is shown in Table 6-1.  
                                                
*  = heart rate x stroke volume [= π(LVOTdiameter/2)2`x VTILVOT] 
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Table 6-1 Radionuclide ventriculography data 
EDV= end-diastolic volume, ESV = end-systolic volume, EF = left ventricular ejection 
fraction, SPECT = single-photon emission computed tomography. * death of 1 patient 
prior final follow up, and insufficient scan quality in 1 patient, therefore change-data 
refers to n=24 (n=12 for SPECT) 
 
 
Rate control (RC) 
(n=26 planar, n=13 SPECT) 
Catheter ablation (CA) 
(n=26 planar, n=12 SPECT*) 
RC versus CA  
p values 
Base 12m change p Base 12m change p Base 12m change 
Planar EF % 24.9 (7.2) +5.4 (8.5) 0.003 21.5 (8.3) +11.0 (11.5) <0.001 0.13 0.055 
SPECT EF % 31.5 (11.5) +5.1 (8.4) 0.047 26.7 (9.1) +6.3 (10.5) 0.08 0.26 0.78 
SPECT EDV ml 200.5 (68.6) -6.2 (39.8) 0.58 208.6 (60.8) +28.5 (44.1)  0.06 0.76 0.055 
SPECT ESV ml 140.1 (65.3) -11.7 (36.1) 0.27 156.5 (59.3) +4.36 (46.9) 0.76 0.52 0.35 
 
Planar EF significantly increased from baseline in both arms.  In the rate control arm, this was from 
24.9±7.2 to 30.2±9.4 (p=0.003), an increase of 5.4±8.5%.  In the catheter ablation arm, EF 
increased from 21.5±8.3 to 32.8±14.3 (p<0.001), an increase of 11.0±11.5%.  However, when 
comparing the change from baseline between groups (defined as the secondary endpoint), there was 
only a non-significant/borderline trend towards a greater improvement in the ablation arm (mean 
increase over rate control: +5.6%, CI -0.1 to +11.3, p=0.055).  The differential impact on 3D 
SPECT was even less marked, increasing by 6.3±10.5% under ablation versus 5.1±8.4% with rate 
control, p=0.78.  There was an apparent trend towards increase in end-diastolic volume (EDV) and 
decrease in end-systolic volume (ESV) in both groups although this did not approach statistical 
significance. 
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Planar EF increased in 19/26 (73%) rate control (p=0.003 compared with baseline) and 19/24 (79%) 
catheter ablation (p<0.001) patients, whereas SPECT EF increased in 9/13 (69%, p=0.047 
compared with baseline) and 8/11 (73%, p=0.08) respectively. 10/24 (42%) of catheter ablation 
patients showed >10% improvement in planar EF, compared with 6/26 under rate control (23%) 
(Fisher exact p=0.13).  
Figure 6-3 Left ventricular ejection fraction: impact of ablation vs. rate control 
 Change in left ventricular ejection fraction (LVEF) from baseline, as assessed by planar 
radionuclide ventriculography (left) and echocardiography by biplane method-of-discs (right).  
The intention-to-treat data are presented showing the ablation group as solid dots/lines and 
rate-control group as open dots/dashed lines.  2-sided p-values for intergroup comparison 
(independent t-test) are shown at follow-up.  
6.4.2 Echocardiography 
Echocardiographic data is presented in Table 6-2.  Echocardiographic LVEF was shown to be 
different between the groups at baseline, being significantly lower in the catheter ablation arm 
despite randomisation.  When examining change, there was an overall increase in EF in both 
groups, although this was less marked than for RNV (Figure 6-3).  In the catheter ablation arm, 
LVEF was 26.2±8.8% at baseline, increasing to 33.2±11.1% at 6 months (p=0.004) reflecting a 
change of +6.5±10.3%, and 33.5±9.4% at 12 months (p<0.001 compared with baseline), reflecting a 
total change of +6.8±8.9%.  By comparison, the change in the rate control arm, although 
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positive, was of lower magnitude: baseline EF was 33.7±12.2%, increasing to 34.6±9.4 at 6 months 
(p=0.65), reflecting a change of +1.0±10.8%, and 35.4±10.2% at 12 months (p=0.49 compared with 
baseline), a change of +1.7±12.6%.   
When comparing the change between groups, as pre-specified for secondary endpoint analysis, the 
increase in the ablation arm was shown to be a statistical trend rather than reaching significance.  At 
6 months, the increase in the catheter ablation arm was 5.6% greater than the rate control arm (95% 
CI -0.4 to +11.5%, p=0.066) and at 12 months was 5.1% greater (95% CI -1.1 to 11.2%, p=0.104). 
Of the other parameters, the most striking change was in left atrial (LA) size, a pre-specified 
secondary endpoint parameter.  LA diameter was shown to have a marginal increase in the rate-
control arm at 6 (+0.1±3.4mm, p=0.87) and 12 months (+0.5±5.2mm, p=0.63), but a significant 
decrease in the catheter ablation arm at 6 months (-4.8±4.6mm, p<0.001) and 12 months (-
5.7±5.3mm, p<0.001) reflecting a change from 49.9±6.4mm to 44.0±8.3mm. 
Figure 6-4 Atrial size: impact of ablation vs. rate control  
 Change from baseline in left atrial area (left) and right atrial area (right), as measured in apical 
4-chamber view.  Ablation group shown as solid dots/lines, rate-control as open dots/dashed 
lines. 
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Table 6-2 Echocardiographic data 
 
Est. CO = estimated cardiac output (from LVOT VTI – see text), E(E!) = mitral (tissue) Doppler E wave, EDD/V = end-diastolic diameter/volume, EF = ejection fraction, 
ESV = end-systolic diameter/volume,  IVSd = interventricular septum diastole, LA = left atrium, LV = left ventricle, LVOT = LV outflow tract, PWd = posterior wall 
diastole, RV= right ventricle, TAPSE = tricuspid annular plane systolic excursion.  *no follow-up data available for patient who died, therefore n=25 for change data 
 
Rate control 
n=26 
Catheter ablation 
n=26* 
Rate Control vs. 
Catheter Ablation (p) 
Base 6m change p 12m change p Base 6m change p 12m change p Base Δ6m Δ12m 
IVSd mm 11.2 (1.9) -0.3 (2.5) 0.59 -0.4 (1.6) 0.18 9.9 (1.9) +0.6 (2.3) 0.22 +0.9 (1.8) 0.02 0.53 0.21 0.008 
PWd mm 10.5 (1.8) -0.3 (2.1) 0.40 -0.4 (2.0) 0.33 10.5 (1.9) -0.4 (2.2) 0.33 -1.0 (2.9) 0.11 1.0 0.88 0.41 
LVEDD mm 61.4 (8.5) -0.9 (5.2) 0.39 -1.0 (4.9) 0.31 61.4 (7.4) -0.4 (4.6) 0.64 -0.1 (2.9) 0.93 1.0 0.75 0.47 
LVESD mm 53.4 (9.6) -2.3 (5.4) 0.04 -1.8 (5.6) 0.12 55.0 (8.4 -4.0 (5.8) 0.002 -3.2 (6.5) 0.02 0.66 0.28 0.39 
LVEDV ml 141 (53) -4 (30) 0.56 0 (34) 0.99 149 (64) +4 (34) 0.60 1 (30) 0.86 0.62 0.43 0.92 
LVESV ml 96 (45) -3 (25) 0.49 -2 (28) 0.70 113 (61) -6 (30) 0.33 -8 (28) 0.18 0.27 0.75 0.48 
LVEF % 33.7 (12.2) +1.0 (10.8) 0.65 +1.7 (12.6) 0.49 26.2 (8.8) +6.5 (10.3) 0.004 +6.8 (8.9) <0.001 0.02 0.07 0.10 
LA diameter mm 46.4 (7.2) +0.1 (3.4) 0.87 +0.5 (5.2) 0.63 49.9 (6.4) -4.8 (4.6) <0.001 -5.7 (5.3) <0.001 0.07 <0.001 <0.001 
LA area cm2 27.2 (6.9) +1.5 (6.2) 0.40 +2.0 (7.0) 0.16 29.5 (5.8) -4.9 (6.5) <0.001 -4.7 (7.1) 0.003 0.207 0.001 0.001 
RA area cm2 21.3 (4.5) +1.9 (4.9) 0.16 +2.7 (4.8) 0.01 22.6 (4.7) -3.6 (5.0) 0.001 0 (7) 0.92 0.32 <0.001 0.12 
TAPSE mm 17.2 (3.9) +1.0 (4.3) 0.27 +1.6 (4.5) 0.08 16.3 (4.1) +3.1 (5.9) 0.02 +2.8 (5.2) 0.01 0.44 0.14 0.38 
LVPEP ms 111 (28) +1 (24) 0.82 +2 (20) 0.70 128 (39) -5 (30) 0.37 -3 (29) 0.62 0.07 0.40 0.85 
RVPEP ms 94 (23) +7 (22) 0.13 +11 (23) 0.02 103 (28) +7 (30) 0.31 +3 (25) 0.63 0.23 0.97 0.23 
Mitral E ms-1 0.94 (0.19) +0.06 (0.14) 0.03 +0.08 (0.18) 0.03 0.99 (0.21) -0.12 (0.16) 0.001 -0.07 (0.17) 0.04 0.37 <0.001 0.003 
E!  ms-1 0.11 (0.03) +0.01 (0.03) 0.25 +0.01 (0.03) 0.36 0.11 (0.06) -0.03 (0.05) 0.03 0.00 (0.10) 0.91 0.76 0.01 0.69 
E/E!  ratio 8.9 (3.9) 0.0 (3.1) 0.95 +1.5 (5.7) 0.19 10.5 (4.5) +2.3 (9.4) 0.23 +0.7 (6.3) 0.56 0.20 0.24 0.64 
LVOT VTI cm 12.9 (3.5) +2.3 (3.2) 0.003 +2.1 (2.6) 0.001 11.2 (3.3) +2.9 (4.6) 0.03 +3.8 (5.4) 0.005 0.09 0.65 0.18 
Est. CO l/min 3.3 (0.7) +0.2 (0.9) 0.35 +0.3 (0.8) 0.09 2.8 (0.9) +0.2 (0.9) 0.53 +0.3 (1.1) 0.17 0.07 0.90 0.95 
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2-dimensional LA area, which is a more robust measure than M-mode diameter,309 was shown to 
have a similar profile (Figure 6-4): under catheter ablation, there was a change from 29.5±5.8cm2 at 
baseline to 24.7±6.5cm2 at 6 months (change -4.9±6.5, p<0.001) with a area of 25.0±8.1cm2 at 12 
months (change from baseline -4.7±7.1, p=0.003); with rate control LA area was 27.2±6.9cm2 at 
baseline, 28.3±8.6cm2 at 6 months(+1.5±6.2, p=0.40), and 29.2±8.2cm2 at 12 months (+2±7, 
p=0.16).  Comparing change between groups, at 6 months LA area was 6.4cm2 lower in the catheter 
ablation arm (95% CI -10.0 to -2.8, p=0.001), and at 12 months 6.7cm2 lower (95% CI -10.7 to -2.7, 
p=0.001).  Right atrial area showed similar magnitude change at 6 months (-5.4cm2, 95% CI -8.3 to 
-2.6, p<0.001), although at 12 months the difference between groups was non-significant (-2.6cm2, 
95% CI -6.0 to +0.7, p=0.12).  
All patients who underwent catheter ablation and had sinus rhythm at follow up had a recordable 
mitral Doppler A wave and lateral mitral tissue Doppler atrial component (A!).  At 6 months 22/25 
(88%) patients at 6 months were in sinus rhythm and had A wave amplitude 0.46±0.14ms-1, and A!  
amplitude 0.05±0.02ms-1.  At 12 months, the same proportion were in sinus rhythm, with A 
0.44±0.13ms-1and A!  0.05±0.02ms-1.* Unsurprisingly, this recovery of mechanical left atrial 
systolic function was reflected in the mitral E waveforms, which may be due to the change in 
proportion of ventricular filling occurring passively during early ventricular diastole: whilst 
amplitude of the E wave had increased in the rate-control arm at 6 and 12 months, there had been a 
significant decrease in the catheter ablation arm at follow-up.  The difference between the groups 
was highly significant at both 6 (p<0.001) and 12 months (0.003).  However, there was no 
significant change in the E/E! ratio.   
                                                
* Not included are the two patients in the rate-control arm: the patient (RC9) who underwent catheter ablation at 4 
months, with subsequent repeat procedures for atrial tachycardia, had a recorded A amplitude of 0.35ms-1 and A!  of 
0.04ms-1 at 12 months; the patient (RC21) who was defibrillated at 10 months had A amplitude 0.4ms-1 and A! 0.03ms-1 
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Although there was an increase in LVOT VTI in the catheter ablation arm, this was not reflected in 
overall cardiac output estimation.  This appears to be at least partly explained by the difference in 
heart rate seen in the two groups: at baseline heart rate (at the time of echocardiography, average 
over 30 seconds) was 81.4±14.1bpm in the rate control arm, and 83.9±13.5bpm in the ablation arm 
(p=0.53); at 6 months, heart rate was 77.6±16.0bpm and 69.2±13.8bpm (p=0.051) respectively, and 
77±18.6bpm and 67.5±10.7 bpm (p=0.03).   Therefore, there was a small but statistically significant 
reduction in heart rate with catheter ablation (and predominantly sinus rhythm) compared with rate 
control (where patients were predominantly in atrial fibrillation), which would offset – and may 
indeed have been responsible for – the increase in LVOT VTI. 
TAPSE increased in the ablation arm at 6 (p=0.02) and 12 (p=0.01) months, with no significant 
change in the rate control arm, suggesting an improvement in right ventricular systolic function. 
However, when comparing the change at follow-up this was not significant (12 month difference 
+1.21mm, 95% CI -1.5 to +4.0, p=0.38).  Mitral regurgitation (defined as >trivial and quantifiable 
by PISA-ERO) was present in 15/26 ablation arm patients, and 11/26 (p=0.27) rate-control patients 
at baseline, the majority mild or mild-moderate, with PISA-ERO 0.06±0.07cm2 and 0.06±0.05 
respectively (p=0.97).  At follow up, there was a trend towards a small reduction in the ablation arm 
(-0.05±0.08) compared with the rate control arm at 6 months (+0.03±0.10, p=0.15) which reached 
significance at 12 months (mean difference in ablation arm -0.15cm2, 95% CI -2.7 to -.03); the 
number of patients with quantifiable MR was 8/26 and 5/26 respectively (p=0.26).  
6.4.3 Reliability and co-relation of estimates of LV function 
In order to assess reliability and comparability of the three modalities (planar, SPECT, echo) used 
to assess LVEF, correlation estimations (Pearson unless otherwise stated) and Bland-Altman 
plots310 were created to compare values at baseline (Figure 6-5) and follow-up (Figure 6-6). 
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Figure 6-5 Reliability and correlation of LV parameters – baseline data 
Left: Bland-Altman plots for echo and radionuclide ventriculographic (RNV) measurements, at 
baseline.  The solid line represents the mean difference, and dashed lines 2 standard 
deviations either side.  Right: Scatter-plots with regression lines and square of the Pearson 
correlation coefficient (R2) displayed for each.  
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Figure 6-6 Reliability and correlation of LV parameters – 12-month follow-up data 
 Left: Bland-Altman plots for echocardiographic and radionuclide ventriculographic (RNV) 
measurements, at 12 month follow-up.  The solid line represents the mean difference, and 
dashed lines 2 standard deviations either side.  Right: Scatter-plots with regression lines and 
square of the Pearson correlation coefficient (R2) displayed for each. See text for discussion.
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Figure 6-7 Scatter plots and correlation: atrial fibrillation and sinus rhythm 
 Scatter plots for 12-month follow up echocardiographic and radionuclide ejection 
fraction measurements, with lines of best fit and square of the Pearson correlation 
coefficient (R2). 
 
Additionally, LVEF measurements at follow-up were compared between sinus rhythm and 
atrial fibrillation/tachycardia (Figure 6-7). 
Echocardiographic and SPECT LVEF was generally higher than planar radionuclide LVEF.  
Echo LVEF % was 6.8±8.9 higher than radionuclide at baseline, with modest correlation 
(p<0.001, R2=0.37).  SPECT LVEF % was 5.1±6.2 higher than planar RNV, with better 
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correlation (p<0.001, R2= 0.67).  Echo end-diastolic volume (EDV) was generally lower than 
SPECT EDV, by 63.3±34.7ml (correlation p<0.001, R2=0.73), and similarly for end-systolic 
volume (ESV) by 50.3±35ml (correlation p<0.001, R2=0.72).  There was a clear proportional 
difference in the volume assessments, with greater difference at higher volumes.  
At 12-month follow-up, similar relationships were present.  Echo gave LVEF % values that 
were 3.0±8.1 higher than planar RNV (correlation p<0.001, R2=0.55), and SPECT was 
3.8±8.0 higher than planar (correlation p<0.001, R2=0.49).  Echo EDV was 70.3±37.4ml 
lower than SPECT EDV (correlation p<0.001, R2=0.75) and echo ESV was 44.6±33.3ml 
lower than SPECT ESV (correlation p<0.001, R2=0.78).  
At follow-up, there appeared to be a marginally closer relationship between 
echocardiographic and planar RNV values in those patients in sinus rhythm (correlation 
p<0.001, R2=0.69), compared with those in AF (correlation p<0.001, R2=0.47).  In sinus 
rhythm, echo LVEF % was 2.0±8.6 higher than planar RNV LVEF, and SPECT LVEF % was 
3.9±9.1 higher than RNV.  In atrial fibrillation, echo LVEF % was 4.0±7.6 higher than RNV, 
and SPECT LVEF % was 3.7±7.5 higher than RNV. 
Change in LVEF from baseline to 12 months correlated between echo and planar LVEF 
(p=0.002, R2=0.19), whereas change in LVEF did not significantly correlate between SPECT 
and planar EF (p=0.105, R2=0.15) or echo LVEF (p=0.18, R2=0.08).    
6.4.4 Correlation with physiological outcomes/biomarkers 
The change in LVEF by different modalities was compared with the change in the ARC-HF 
study endpoints, namely change in peak VO2 by Pearson correlation, and change in 
Minnesota Living with Heart Failure Questionnaire (LHFQ) score and plasma B-type 
natriuretic peptide (BNP) by Spearman rank correlation (Table 6-3)  
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Planar radionuclide ventriculography correlated best with all three endpoints.  SPECT 
correlated poorly, although the smaller sample size may have impacted upon this. 
 
Table 6-3 Correlation of LVEF measurements with other ARC-HF endpoints 
 For each modality of LVEF assessment, correlation estimations were performed using 
Pearson (comparing change in VO2) and Spearman Rank correlations (comparing 
change in LHFQ score and BNP) against change (Δ) in LVEF, from baseline to 12 
months follow-up.  Correlation coefficient values (R) are shown with corresponding 2-
sided p-values 
 
BNP = B-type natriuretic peptide, LHFQ = Minnesota Living with Heart Failure 
Questionnaire score, LVEF = left ventricular ejection fraction, VO2 = peak oxygen 
consumption at treadmill exercise testing  
 
 
ΔPlanar LVEF 
n=50 
p 
ΔEcho  LVEF 
n=51 
p 
ΔSPECT LVEF 
n=25 
p 
ΔVO2 0.54 <0.001 0.35 0.01 -0.31 0.15 
ΔLHFQ score -0.41 0.003 -0.22 0.13 -0.32 0.13 
ΔBNP -0.52 <0.001 -0.28 0.05 -0.23 0.28 
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6.5 Discussion 
In this clinical trial, the strategies of catheter ablation-based rhythm control and robust 
protocol-guided rate control were compared by assessment of cardiopulmonary exercise 
capacity, symptomatic status, neurohormonal activation, and imaging parameters of cardiac 
function.  The modalities of radionuclide ventriculography and 2-dimensional 
echocardiography were used to assess the latter. 
The principal measure of left ventricular function in this study was planar radionuclide LVEF, 
which increased significantly in both arms (Figure 6-3), although with greater magnitude in 
those randomised to undergo catheter ablation.  Although this increase, when compared 
between treatment groups, showed a statistical trend (p=0.055) rather than significance, 
change in planar RNV LVEF positively correlated well with the positive endpoint of peak 
oxygen consumption, and also with quality-of-life score and plasma BNP where a reduction 
(improvement) in these values was associated with increased LVEF (negative correlation).  
Echocardiographic LVEF increased significantly in the catheter ablation arm, with only slight 
(non-significant) change in the rate-control arm, although inter-group comparison showed 
again only a weak trend towards greater increase in LVEF at follow-up.  Echo LVEF 
correlated less well than RNV with the other positive endpoint outcomes.  Interestingly, 
although the magnitude and vector of change was different between  RNV and LVEF, the 
relative improvement in the ablation arm was remarkably similar at 12 months (5.6 vs. 5.1% 
for RNV and Echo respectively; Figure 6-3).  SPECT LVEF was evaluated only in a subset of 
patients, and thus was likely to be underpowered for endpoint analysis and comparison.  
However, this relatively novel technique, performed at the same sitting as standard planar 
ventriculography, was shown to record left ventricular volumes with some correlation to 
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echocardiographic measures, albeit with evidence of a proportional difference producing 
larger differential error at higher LV systolic and diastolic volumes. 
Consistent with prior studies, the data showed a relative overestimation of LVEF using 
SPECT compared with planar RNV,311 and of echo (biplane Simpson’s) versus planar 
RNV.312    The modalities used showed a moderate of correlation in LVEF, although with 
marked variability in agreement when assessed by Bland-Altman method, as previously 
reported.313  Cardiovascular magnetic resonance imaging has been reported as a more 
accurate and reliable technique than echo and radionuclide ventriculography, and has been 
proposed as the preferred modality in heart failure patients.312  However, in the modern era, a 
significant proportion of patients with heart failure are managed with implanted devices such 
as CRT and ICDs, which render MRI contra-indicated – although compatible devices are on 
the horizon.  Hence, in designing ARC-HF, cardiovascular magnetic resonance was not 
chosen as an imaging modality: inclusion would have meant either its use only in a small sub-
group, or recruiting for a heart failure study from a population of patients which would not 
reflect a realistic clinical cohort.  Indeed, in ARC-HF, 27% of patients had implanted devices 
at study enrolment.  
Planar radionuclide ventriculography is known to be highly reproducible,314, 315 and RNV 
LVEF is thus often used as an inclusion criterion and/or endpoint in heart failure clinical 
trials, and was chosen as the principal measure of LVEF in the ARC-HF study given its 
ability to cope with arrhythmias without the user-dependency of echocardiography.   
However, as with any measure of ejection fraction there is a degree of variability in results 
that is increased by the presence of atrial fibrillation.  The lack of clear positivity in the 
endpoint of LVEF from either planar RNV or echo may relate to this high variability in 
measurement of EF.  Additionally, there was a small but significant improvement observed in 
LVEF in the rate-control arm, reducing the differential change when comparing treatment 
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arms.  Both of these effects would reduce the effect size, the first by increasing the standard 
deviation of the group means, and the second by reducing the treatment effect (mean 
difference), leaving the current study marginally underpowered to detect a statistical 
difference in the endpoint of LVEF.    
Previous non-randomised observational studies examining the impact of heart failure found 
significant increases in LVEF after catheter ablation.  The Bordeaux group reported a 
significant increase of 21±13% in LVEF and a reduction in systolic and diastolic diameters by 
8±7 and 6±6mm respectively,133 compared with a non-significant increase of 5% (7.2±3% in 
‘responders’) as reported by the Cleveland group.134  The profound increase in the former 
should be seen in the context of a non-randomised cohort of patients undergoing catheter 
ablation in its first few years of application for AF, and as such may have been a highly-
selected group.  Additionally, the duration of heart failure was not specified, and it is possible 
that some of these patients had a form of tachycardia or other reversible cause of 
cardiomyopathy: in the case of the former, subgroup analysis showed a greater improvement 
in those without rate control at baseline.133  Indeed in our study, there was a trend for those 
with adequate rate control at enrolment to have a less marked increase in planar RNV LVEF 
than those with inadequate control (-5.2%, 95% CI -11.0 to 0.66 %, p=0.08).  Also, the 
patients in our study had a median duration of heart failure 48months (IQR 12-81) compared 
with AF duration 36 months (IQR 12-63) reflecting a cohort that, on the whole, had well-
established chronic heart failure and persistent AF.   Finally, the use of echocardiographic 
LVEF in the above non-blinded studies would open up the possibility of bias, which could 
influence the baseline LVEF during AF by choice of shorter cycle lengths (faster heart rate) 
with near-inevitable reduction of ejection fraction, and the potential for error in biplane 
estimation of LVEF during follow-up regardless of rhythm.  Radionuclide ventriculography 
LVEF estimation is less open to bias by its semi-automatic calculation, and in ARC-HF 
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investigators reporting both this and echocardiographic LVEF were blinded to the treatment 
allocation group. 
There was evidence of return of left atrial mechanical function in patients who underwent 
catheter ablation.  Although this has been reported previously in patients after AF ablation 
without significant structural heart disease,233 this has not previously been reported in the 
context of severe LV dysfunction and longstanding AF.    Despite a prolonged history of AF 
and extensive left atrial ablation in many cases, contractile function is able to return, which 
may contribute towards improved haemodynamics through atrial primer pump function and 
atrioventricular synchrony.   Furthermore, a marked reduction in biatrial size was seen by 6 
months, with a maintained significant reduction of LA size in the ablation arm compared with 
an increase in the rate control arm at 12 months.  The had been a reduction in RA size in the 
ablation arm by 6 months but by 12 months this effect appeared to have reversed, with the 
implication that the longer lasting impact of ablation, which itself was mostly confined to the 
left atrium, was mainly on that side.  A reduction in left atrial size has previously been 
reported in patients with lone AF,316-319 but a recent randomised study of patients with heart 
failure showed no impact on left atrial end-diastolic area.300  However, regression of atrial 
dilatation has been demonstrated in the setting of structural heart disease, for instance after 
mitral valve surgery,320 and in patients with diastolic dysfunction administered an 
angiotensin-converting enzyme inhibitor.321  The data from the present study would suggest 
that catheter ablation, if associated with a high rate of sinus rhythm maintenance, can lead to a 
regression in atrial dilatation.  Whether this, itself, could be beneficially protective against 
recurrent atrial arrhythmias remains uncertain, given that prior studies – in patients without 
significant structural heart disease – have provided conflicting data.316, 322  In the present 
study, change in LA size was predictive of recurrence of (any) atrial arrhythmia in those 
randomised to and who underwent ablation (excluding patient A1), with Cox regression 
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statistically significant at  6 months (Hazard ratio 1.19 /cm2, 95% CI 1.01-1.40, p=0.037) and 
showed a trend at 12 months (Hazard ratio 1.10 /cm2, 95% CI 0.99-1.22, p=0.07).   
Although there were some statistically significant changes in TAPSE, suggesting an 
improvement in right ventricular function, and quantitative mitral regurgitation, these results 
– although potentially interesting and consistent with the overall group data – should be 
interpreted with caution as these were not prospectively designated endpoints, the subgroup 
size was small and thus open to random effects, and correction for multiple tests of 
significance was not incorporated into the study design.    
6.6 Conclusion 
Imaging of ventricular function in patients with AF is challenging and methods all have 
pitfalls – including test reproducibility and variability, which can be exaggerated further in the 
presence of irregular and rapid arrhythmia.  In the context of a clinical trial examining the 
relative impact of two strategies to treat AF in heart failure, namely catheter ablation and 
medical rate control, the outcome of change in LVEF from baseline showed overall 
improvements in both treatment arms, with a trend towards a greater increase in LVEF under 
assignment to catheter ablation.  A study with a larger sample size might be expected to show 
a significant difference in this outcome.  Change in planar radionuclide LVEF correlated well 
with changes in cardiopulmonary exercise performance, quality of life score, and B-type 
natriuretic peptide levels.  There is evidence of a regression in left atrial dysfunction after 
catheter ablation and restoration of sinus rhythm, despite often-longstanding persistent atrial 
fibrillation and heart failure, which may contribute towards maintenance of sinus rhythm and 
favourable haemodynamics. 
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7 Biomarkers in atrial fibrillation and heart failure 
7.1 Abstract 
The optimal therapy for AF in heart failure remains unclear: drug-based 'rhythm-control’ has 
been shown to have no clear advantage over drug-based ‘rate-control’.122  The newer therapy 
of radiofrequency catheter ablation has been shown to be feasible in achieving sinus rhythm 
in patients with heart failure and to confer clinical benefits, 133, 134  Outcomes from long-term, 
large scale clinical trials are awaited to assess whether this newer therapy confers an 
advantage to patients, however trials based around event endpoints can be limited by low 
event rates and the need for prolonged follow-up.  Biomarkers may act as surrogate 
markers323 of prognosis and allow earlier assessment of prognostic impact in this patient 
population. 
This chapter examines the impact of rate control and catheter ablation upon neurohormonal 
status in patients with atrial fibrillation and heart failure.  Using a per-protocol analysis, the 
impact of each therapy upon novel and established cardiac biomarkers is presented.   
7.2 Background 
Biomarkers, in particular B-type natriuretic peptide (BNP), have become key elements in the 
diagnosis of heart failure.227, 228  BNP is secreted primarily from the left ventricle in response 
to changes in left-ventricular wall stretch,324 thus levels may be influenced by a number of 
factors including heart rate/rhythm, blood pressure/afterload, fluid status, and co-existing 
conditions like left ventricular hypertrophy or coronary artery disease. BNP is the best 
predictor of prognosis we have to date,229 improves outcomes when used as a guide to heart 
failure therapy,230, 231 and it is now well established that improvements in the heart failure 
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syndrome are associated with a reduction in BNP concentrations.231, 232  BNP levels have been 
shown to fall after catheter ablation for paroxysmal and persistent AF in patients without 
ventricular dysfunction.233, 234  It has been shown that BNP and N-terminal pro-BNP levels 
are not independently affected by AF in advanced heart failure,325, 326 thus BNP is well placed 
for assessing serial change in cardiac function, in parallel with imaging modalities, in 
comparison of rate and rhythm-control. 
The novel peptide apelin is an endogenous peptide ligand for the angiotensin-like 1 (APJ) 
receptor,327 and is known to have potent inotropic effects – alongside reduction in preload and 
afterload – in animal models.328, 329  Plasma concentrations of apelin have been shown to be 
decreased in patients with chronic heart failure when compared with controls330 and its 
concentration shown to be increased after CRT.331 However, data are contrasting, with 
evidence that plasma concentrations are significantly increased in mild-moderate heart failure, 
and decrease back towards control levels in severe heart failure.332  It is uncertain whether the 
changes in plasma apelin are due to increased myocardial apelin production or enhanced 
production from the peripheries as a consequence of improved haemodynamics.333  Tissue 
concentrations are increased after ventricular off-loading by left ventricular assist device 
(LVAD) therapy.332  Thus apelin seems have potential as a novel biomarker for reverse 
remodelling in heart failure.  However, the effect of sinus rhythm restoration on plasma apelin 
levels, in the context of persistent atrial fibrillation, is presently unknown.  
Atrial natriuretic peptide (ANP) is secreted by atrial myocytes under conditions of atrial 
stretch. Several hormones and neurotransmitters, such as endothelin, vasopressin, and 
catecholamines, directly stimulate its secretion.334  It has diuretic, vasodilating, and 
renin/angiotensin inhibitory effects. Plasma levels of ANP are known to be increased in 
patients with heart failure and sinus rhythm,335 and are known to be further increased in 
patients with atrial fibrillation,336 a finding which has been shown to be independent of LV 
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dysfunction.325  Studies have shown that longer duration of AF is associated with lower ANP 
levels, perhaps reflecting some form of ‘atrial insufficiency’ and there may be subsequent 
interplay between two competing mechanisms: the haemodynamic burden of heart failure 
(increasing ANP) and progression atrial degeneration (decreasing ANP).337, 338 Both DC 
cardioversion and AF ablation are known to decrease ANP levels by restoration of sinus 
rhythm in those without structural heart disease.234, 339  In heart failure, ANP proved to be 
inferior to BNP in terms of its diagnostic and prognostic potential, largely due to lack of 
reproducibility. However, recently an assay of the midregional segment of the more stable 
precursor pro-ANP - mid regional pro-ANP (MR-proANP) – has been shown to have 
similar accuracy to BNP as a diagnostic test,340 and may be a stronger prognostic marker.341  
It may also give more direct information about atrial remodelling than other biomarkers 
which relate to ventricular remodelling.  
Interleukin-6 (IL-6) an inflammatory cytokine, has multiple endocrine and metabolic actions 
including haematologic, immune, and hepatic effects. It is secreted during stress and is 
positively controlled by catecholamines.342 IL-6 is known to be increased in patients with AF, 
and may contribute to the pro-thrombotic state in this condition.343 In patients with coronary 
artery disease, raised IL-6 levels were independently associated with AF.344  Furthermore, 
raised levels of IL-6 and C-reactive protein have recently been associated with increased 
likelihood of AF recurrence in patients after radiofrequency catheter ablation.345  There also 
appears to be a link between IL-6 gene polymorphisms, level of IL-6 expression, and the 
propensity to AF after cardiac surgery.346, 347  IL-6 is well known to be raised in patients with 
chronic heart failure,348 particularly in those requiring left-ventricular assist devices.349  
In this study we explored, for the first time, the effects of AF ablation on plasma apelin and 
MR-ANP in a population of patients with heart failure.  Changes in these novel biomarkers 
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were assessed alongside those in the established biomarkers BNP and IL-6, and the compared 
with the effect of rate control over the same time period. 
7.3 Methods 
7.3.1 Study population 
Blood samples were acquired from patients enrolled in a randomized clinical trial (see 
chapters 2, 5, and 6) which was seeking to test the hypothesis that ablation-based rhythm-
control improves outcomes compared to a conventional rate-control strategy, using exercise, 
questionnaire and image-based assessment of cardiovascular function as outcomes. The trial 
population consisted of patients with persistent (documented AF >7 days in duration) or 
permanent (persistent AF >1 year) atrial fibrillation and chronic heart failure NYHA class ≥II; 
LVEF ≤ 35 %.  The strategies of rate control and catheter ablation were compared in a 1:1 
randomised fashion, with primary endpoint of peak oxygen consumption at exercise testing, 
and secondary endpoints including ejection fraction, 6 minute walk, and Minnesota quality of 
life score.  
7.3.2 Sample acquisition 
Prior to exercise testing (and radionuclide ventriculography when applicable), peripheral 
venous blood was collected from patients in the resting state (prior to exercise testing), into 
tubes containing 7ml ethylene-diamine-tetra-acetic acid.  Centrifugation was performed at 
1000G for 5 minutes, within 1 hour of sample acquisition, and plasma was extracted via 
manual pipette into cryo-tubes for freezer storage of 2ml plasma aliquots at -70 degrees C.  
Samples were acquired at enrolment into the trial, and at subsequent follow-up visits at 3, 6 
and 12 months, after randomisation to either rate or rhythm control.   
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7.3.3 Laboratory assays 
Laboratory analyses were performed blinded to the randomisation group, using coded pseudo-
anonymised labelling of samples.   
BNP was measured by immunoassay on the Beckman Access 2 Immunoassay analyser 
(Beckman Coulter, High Wycombe, UK) using the Alere Triage BNP reagents. (analytical 
range 25-5000ng/L). 
Apelin was measured by ELISA (Phoenix Europe GmbH, Karlsruhe, Germany); an 
extraction-free protocol was followed. The antibody used in this apelin assay cross-reacts 
100% with Apelin-12, 13 and 36.  The assay therefore includes all of the above peptides if 
present in the plasma (analytical range 0.01-100 ng/ml). 
MR-pro-ANP was measured by immunofluorescent assay on the Brahms Kryptor analyser 
(Thermo scientific, BRAHMS GmbH, Henningsdorf, Berlin, Germany; analytical range 2.1-
10000 pmol/L). 
IL-6 was measured by immunoassay on the Beckman Access 2 Immunoassay analyser 
(Beckman Coulter, High Wycombe, UK; analytical range 2.5-1500 pg/ml) 
CRP was measured by an immunoturbidimetric method on the Beckman DxC600 
autoanalyser (Beckman Coulter, High Wycombe, UK; analytical range 1.0 - 500mg/L). 
7.3.4 Statistical analysis 
Although the main clinical trial outcomes (including BNP) were analysed on an intention-to-
treat basis, the biomarker sub-study of ARC-HF was designed to examine to impact of 
undergoing ablation thus a per-protocol analysis was used, with censorship of results after 
any breach of protocol.  
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The sample size was calculated for the primary endpoint of the pre-existing clinical trial, 
requiring 25 patients in each group to detect a 10% (SD12.5%) change in peak oxygen 
consumption at exercise testing (see chapter 5).  The magnitude of possible effect on Apelin 
and MR-ANP was unknown, however previous observational studies have examined changes 
in BNP after ablation in similar size populations.233, 234 If similar variability is assumed (SD 
25pmol/L), our study population would be sufficient to detect a 20pmol/L reduction in BNP 
at 80% power, alpha 0.05, for a two-sample t-test method.  
Baseline values are expressed as mean+/-SD or frequency/percentage.  The primary endpoint 
was change in biomarker plasma level at 12 months, and secondary endpoints were change at 
3 and 6 months.  Change was assessed by independent group comparison of individual 
absolute differences from baseline.  Data were assessed for normality by histogram, 
skewness, and Kruskal-Wallis test within SPSS for Mac version 20 (IBM). Based upon this, 
normally distributed data were analysed by independent (two-sample) t-test (adjusted for 
presence/absence of equal variances by Levene’s test) and presented as mean±SD, whilst non-
parametric data were analysed by Mann Whitney U (Wilcoxon rank-sum) test and 
summarised as median and interquartile range (IQR = 25th to 75th percentiles).  Paired t or 
Wilcoxon tests were used to analyse individual responses.  Correlation analyses were 
performed using Pearson (parametric) or Spearman Rank (non-parametric) methods.  P values 
of less than 0.05 were regarded as statistically significant, and a p-value less than 0.1 was 
used as an indication of a non-significant trend.  
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7.4 Results 
A total of 52 patients were investigated. Plasma samples for biomarkers were acquired at all 
available time points. One patient withdrew consent for ablation and continued on normal 
medical therapy, and was excluded from the per-protocol analysis.  Two patients had baseline 
and 3 month assays only: one entered palliative care for end stage heart failure post 3 month 
follow up, was unable to attend 6 month follow-up and died prior to the final 12 month follow 
up; another patient requested catheter ablation at 4 months and results were censored after 3 
month follow up. 
Baseline characteristics are shown in (Table 7-1).  All randomised patients are included, 26 in 
each group.    The groups were well-matched for age, gender, heart failure aetiology and 
clinical characteristics.  The only significant difference was in frequency of aldosterone 
usage, however this would be an acceptable finding in a randomised population (26 
parameters subjected to statistical testing).  
A flow-chart illustrating the study protocol and reasons for patient/result censoring is shown 
in Figure 7-1. 
Results are presented for each biomarker by section below.  Based upon normality testing as 
above, results (change) showed non-parametric distribution in at least one arm in at least 2/3 
of all time points for all assessed biomarkers.  Hence all outcomes are shown as median (IQR) 
change and the groups were compared with Mann Whitney U test.  
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Table 7-1 Baseline characteristics 
 Rate control n=26 
N (%) / mean±SD 
Catheter Ablation n=26 
N (%) / mean±SD 
p value 
 
Age 62±9 64±10 0.38 
Male 24 (92) 21 (81) 0.22 
HF aetiology 
Ischaemic 
Non-ischaemic 
 
7 (27) 
19  (73) 
 
10 (38) 
16 (62) 
 
0.38 
 
Time since HF diagnosis (months) 48±57 68±62 0.22 
Time since AF diagnosis (months) 51±76 51±39 0.98 
Duration of continuous AF (months) 24±29 23±22 0.95 
NYHA class 
NYHA II 
NYHA III 
2.50±0.51 
13 (50) 
13 (50) 
2.46±0.51 
14 (54) 
12 (46) 
0.79 
Recent HF hospitalisation (<1year) 7 (27) 10 (38) 0.38 
Minnesota LHFQ score (/105) 49±21 42±23 0.23 
Creatinine 102±28 96±24 0.42 
Peak VO2 (ml/kg/min) 18.2±4.8 16.3±5.3 0.19 
QRS duration (ms) non-paced only 113±21 119±19 0.37 
Radionuclide LVEF (%) 25±7 22±8 0.13 
LA diameter (M-mode, mm) 46±7 50±6 0.07 
Apelin (pg/ml) 881±423 794±288 0.39 
BNP (pg/ml) 283±285 412±324 0.13 
CRP (mg/L) 3.3±3.2 10.0±16.5 0.052 
IL-6 (pg/ml) 4.4±3.0 5.7±6.8 0.39 
MR-proANP (pmol/L) 353±196 372±142 0.70 
6MWD (m) 411±109 416±78 0.84 
Resting HR (bpm) 81±12 77±9 0.18 
Exercise HR (bpm) 109±18 108±15 0.88 
Proportion rate-controlled at baseline (≤80 rest, 
≤110 at 6MW) 
14 (54) 17 (65) 0.40 
 
Beta blocker 24 (92) 24 (92) 1.0 
ACE or ARB 26 (100) 25 (96) 0.31 
Aldosterone antagonist 6 (23) 13 (50) 0.04 
Amiodarone 3 (12) 3 (12) 1.0 
Digoxin 12 (46) 16 (62) 0.27 
Preexisting ICD; of which CRT 4 (15); 3 (12) 10 (38);  8 (31) 0.06 ; 0.09 
Ventricular pacing dependent 1 (4) 1 (4) 1.0 
ACE = angiotensin converting enzyme inhibitor, AF = atrial fibrillation, ARB = angiotensin receptor 
blocker, BNP= B-type natriuretic peptide, CRP = C-reactive protein, CRT = cardiac resynchronization 
therapy, HF = heart failure, HR = heart rate, ICD = implantable cardioverter defibrillator, IL-6 = 
Interleukin-6, LA = left atrial, LHFQ = Minnesota Living with Heart Failure Questionnaire, LVEF = left 
ventricular ejection fraction, MR-proANP = Mid-Regional proAtrial Natriuretic Peptide, NYHA = New 
York Heart Association,  6MWD = 6-minute walk distance.   
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Figure 7-1 ARCHF biomarker sub-study flowchart.   
Number of patients included for per-protocol analysis shown at each time point  
Patient meets entry criteria 
Age 18-80, NYHA ≥II, LVEF ≤35%, Persistent AF 
Consent 
Baseline Investigations  
Medical therapy 
(rate control) 
n=26 
Catheter Ablation 
(rhythm control) 
n=26  
Randomisation 
(1:1) 
If rate-control not present (target ≤80bpm at rest, 
≤110bpm on exertion) visit at 4±8 weeks to 
optimise 
Recurrent AT/AF? 
Catheter ablation procedure 
(maximum 3 procedures) 
2 month ‘blanking’ 
period 
3 month visit (n=25) 
 
6 month visit (n=24) 
1 patient withdrew 
(requested ablation) 
3 month visit (n=26) 
 
6 month visit (n=25) 
12 month visit (n=24) 12 month visit (n=25) 
1 patient entered 
palliative care 
1 patient withdrew 
consent for ablation 
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7.4.1 Mid-regional atrial natriuretic peptide (MR-proANP) 
Sequential results for change in baseline of MR-proANP are shown graphically in Figure 7-2. 
In the ablation arm, there was a median change of -79.6 pmol/L (IQR -186.2 to -12.7) at 3 
months, -123.1 pmol/L (-231.1 to -13.6) at 6 months, and -106.0 (-228.2 to -60.6) at 12 
months.   In the rate-control arm, there was median change of -39.6 pmol/L (IQR -77.4 to -
0.6) at 3 months, -31.1 (-112.9 to +0.3) at 6 months, and -28.7 (-69 to +9.5) at 12 months.  By 
Mann Whitney U test, reductions in the ablation arm were non-significant at 3 months (0.277) 
and 6 months (0.119) but reached statistical significance by 12 months (p=0.028).   
 
Figure 7-2 Mid-Regional proAtrial Natriuretic Peptide (MR-proANP) 
Change (Δ) in mid-regional proANP (MR-proANP) from baseline at follow-up, 
represented as median with error bars showing 25th and 75h percentiIes (IQR): catheter 
ablation (solid line) vs. rate control (dashed line). Statistical significance* is shown at 12 
months between groups (p=0.028) 
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7.4.2 Apelin 
The sequential changes in plasma apelin are displayed graphically in Figure 7-3.   
In the ablation arm, median change was -27 pg/ml (IQR -250.25 to +161.5) at 3 months, -89.5 
pg/ml (-238.5 to +52.5) at 6 months, and +9.5 pg/ml (-153.5 to +139.75) at 12 months. By 
comparison, in the rate control arm, median change was +74.5 (IQR -65 to 205.25) at 3 
months, +133 pg/ml (-40 to +240) at 6 months, and +120 pg/ml (-9 to +294) at 12 months.  
  
Figure 7-3 Apelin  
Change (Δ) in Apelin from baseline at follow-up time points, represented as median with 
error bars showing IQR: catheter ablation (solid line) vs. rate control (dashed line).  ** 
indicates p=0.002 at 6 months, whereas the difference between groups was not 
statistically significant at 12 months 
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The difference in groups was non-significant at 3 months (p=0.22), although there was further 
change reaching significance at 6 months (p=0.002).  However, due to an overall increase in 
Apelin level in the final 6 months, comparison at 1 year was non-significant (p=0.134).   
7.4.3 B-type natriuretic peptide (BNP) 
Figure 7-4 B-type Natriuretic Peptide (BNP) 
Change (Δ) in BNP from baseline at follow-up time points, represented as median with 
error bars showing IQR: catheter ablation (solid line) vs. rate control (dashed line). The 
change at 6 (p=0.052) and 12 months (0.051) was borderline, showing a statistical 
trend^ rather than meeting significance criteria. 
 
The sequential change for plasma BNP is presented in Figure 7-4 
For patients randomised to catheter ablation, BNP showed a change of -90 pg/ml (IQR -270 
to +8) at 3 months, -112 pg/ml (-380 to -3) at 6 months, and -120 pg/ml (-285 to +8) at 12 
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months.  Under rate control, the changes were -26 pg/ml (IQR -74 to +22) at 3 months, -24 
pg/ml (-84 to +56) at 6 months, and -16 pg/ml (-88 to +36) at 12 months.  
Comparing the groups, the reduction in BNP in the ablation arm did not reach any 
significance at 3 months (p=0.17) however showed a strong non-significant trend at 6 
(p=0.052) and 12 months (p=0.051).  It is noted that, under the original intention-to-treat 
protocol, the outcome for BNP did reach significance for a reduction with ablation over rate-
control (p=0.038 at 6 months and p=0.045 at 12 months – see chapter 5) and the borderline 
shift of significance level is likely to reflect borderline sufficient power of the sample size 
(reduced in the per-protocol analysis) and/or assay variability rather than a lack of clinical 
effect, when taken in the context of the other outcomes.    
 
7.4.4 Interleukin-6 (IL-6) 
Results for change in IL-6 from baseline are shown graphically in Figure 7-5.  Overall the 
changes were small, and did not significantly vary between groups.  Again, due to outliers 
and skewed distribution, non-parametric analysis is presented.   
In the catheter ablation group, IL-6 showed a median change of +0.07 pg/mL (IQR -0.45 to 
+0.76) at 3 months, +0.06 pg/mL (IQR -0.52 to +1.38) at 6 months, and -0.06 pg/mL (IQR -
0.64 to +1.69) at 12 months.  In the rate control group, the change was -0.1 pg/mL (IQR -0.89 
to 0.51) at 3 months, +0.11 pg/mL (IQR -0.78 to +0.88) at 6 months, and +0.34 pg/mL (IQR -
0.47 to +0.87) at 12 months.   
Comparing the groups, there was no significant difference at 3 (p=0.93), 6 (p=0.32) or 12 
months (p=0.68).  
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Figure 7-5 Interleukin-6 (IL-6) 
Change (Δ) in IL-6 from baseline at follow-up time points, represented as median with 
error bars showing IQR: catheter ablation (solid line) vs. rate control (dashed line). 
 
7.4.5 Correlation of biomarkers with ARC-HF endpoints 
The trends in change for MR-proANP and BNP were visually remarkably similar to the 
observed change in peak VO2 (primary endpoint for the ARC-HF clinical trial) and quality of 
life score (see chapter 5) and left ventricular ejection fraction (LVEF, see chapter 6).  
Correlation analysis showed that MR-proANP correlated best with all 3 endpoints, and was 
the closest correlated with peak VO2.  BNP was most closely correlated with change in LVEF 
(Table 7-2).    
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MR-proANP and BNP also correlated well together (change at 12 months R=0.63, p<0.001).   
MR-proANP also correlated moderately with change in left atrial (area) size (R=0.39, 
p=0.006).   
 
 
 
Table 7-2 Correlation of biomarker measurements with other ARC-HF endpoints 
 For each biomarker, correlation estimations were performed using Spearman Rank 
correlations against change (Δ) from baseline to 12 months follow-up, based on the per-
protocol analysis (see methods). Correlation coefficient values (R) are shown with 
corresponding 2-sided p-values; n = number of patients samples available for analysis 
 
 
ΔMRANP 
n=49 
p 
ΔApelin 
n=49 
p 
ΔBNP 
n=48 
p 
Δ IL-6 
n=49 
p 
ΔVO2 -0.68 <0.001 0.13 0.36 -0.63 <0.001 -0.12 0.40 
ΔLHFQ  0.35 0.015 0.14 0.30 0.22 0.14 -0.04 0.77 
ΔLVEF -0.32 0.025 -0.16 0.28 -0.53 <0.001 -0.03 0.85 
 
BNP = B-type natriuretic peptide, IL-6 = Interleukin 6, LHFQ = Minnesota Living with 
Heart Failure Questionnaire score, LVEF = left ventricular ejection fraction, MRANP = 
Mid-Regional proAtrial Natriuretic Peptide, VO2 = peak oxygen consumption at treadmill 
exercise testing 
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7.5 Discussion 
This study investigated the impact on cardiac biomarker of alternative management strategies, 
namely catheter ablation and medical rate-control, for persistent atrial fibrillation in patients 
with systolic heart failure.  The most significant impact was on MR-proANP, which showed 
an overall trend towards reduction in both groups, but which was significantly greater in the 
ablation arm by 12 months. 
MR-proANP has recently been identified as an important biomarker, with several studies 
indicating its potential role as a predictor or morbidity and mortality.340, 341  Additionally it 
may be superior to BNP for detecting and managing high-risk patients.350  Increases of ≥30% 
have appeared to define patients at highest risk of events, although more modest changes also 
have an impact.350  In the current study, the reduction in MR-proANP after ablation was 
(median) 28%, compared with (median) 7% for rate control at 12 months.  It could be 
hypothesised that such reductions in MR-proANP may have prognostic implications based on 
the recent studies.  Although, in the current study, this is purely speculative, the finding that 
changes in MR-proANP correlate strongly with changes in VO2 (and moderately well with 
changes in LVEF and quality of life score) would lend further weight to the emerging 
evidence that this biomarker could be a useful indicator in assessing the impact of treatment 
and providing information to assist in risk stratification of patients with heart failure.350 
The changes in BNP showed remarkably similar trends to MR-proANP, and indeed the two 
measures were highly correlated.  Furthermore, BNP correlated best with LVEF, which is 
perhaps to be expected given its relationship with ventricular strain and failure.  However, in 
the context of this biomarker sub-study, the reduction in BNP did not quite reach statistical 
significance despite the observed trends and this, in the face of the above data and emerging 
  
197 
evidence, might suggest it is inferior to MR-proANP for detecting changes in cardiovascular 
performance and perhaps in its ability to predict outcome.   
IL-6 did not show a significant change, either from baseline or between groups, in the present 
study.  Another marker of inflammation, C-reactive protein (CRP) was measured at baseline 
and during follow-up in all patients within the ARC-HF study.  CRP was 10±16 mg/L in the 
ablation arm and 3±3 mg/L in the rate control arm at baseline (apparently skewed by patient 
A8, who was on stable therapy for a chronic inflammatory arthritis): at follow up, the change 
in CRP trended towards a reduction in the ablation arm (3 month p=0.029, 6 months p=0.074 
and 12 months p=0.062), however with a very small magnitude of change (median -1, IQR -3 
to +1 mg/L in the ablation arm compared with median 0, IQR -1 to +3 mg/L in the rate 
control arm).  Although the CRP data should be interpreted with caution, due to the baseline 
differences and the post-hoc analysis, taken together with the IL-6 results these findings 
indicate that ablation, versus rate-control, has an overall small and probably neutral effect on 
markers of inflammation in the context of pre-existing persistent atrial fibrillation and heart 
failure.  
Apelin is perhaps the most difficult of the biomarkers to interpret, both in terms of the results 
of this study and their clinical and physiological relevance.  It has been demonstrated that the 
changes in circulating Apelin levels are not linearly related to severity of heart failure. Whilst 
plasma levels of Apelin were shown to be raised in patients with early heart failure and to fall 
in severe disease,332 other studies have shown that Apelin levels are reduced  from normal in 
varying severities of heart failure,330 and are raised by intervention such as biventricular 
pacing.331  In the presence of the former pattern of behaviour, a varied response to restoration 
of improved haemodynamics might be expected, with patients starting from different 
positions on the scale.  Plasma Apelin itself may be an insufficient marker in isolation, 
without considering its binding interaction with the APJ receptor at the cardiac level, which 
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appears to be down-regulated in heart failure and up-regulated during reverse ventricular 
remodelling.332  
 
7.5.1 Limitations 
This study used a per-protocol analysis, thus the treatment arms could in absolute terms be 
regarded as ‘case-control’ and the study ‘observational’ rather than randomised.  However, 
this protocol was pre-specified, and sought to examine the real impact of catheter ablation 
rather than using an intention-to-treat analysis as was appropriate for the main clinical trial 
outcomes.  Data was therefore ‘missing’ for the two patients who ‘crossed-over’ (A1, after 
baseline; RC9, after 3 months) patient who died (A20) and for the patient who spent a 
prolonged period in rehabilitation (A7).  No imputation or sensitivity analysis was used, as 
this could lead to multiple alternative virtual results and potential bias.  The limitation 
resulting from all this therefore largely relates to sample size and (probable) lack of power, 
particularly relating to BNP, where a borderline increase in the p-value rendered the analysis 
non-significant. 
None of the biomarker data-sets were normally distributed, and therefore non-parametric 
testing was used.  This limits conclusive comments to be made about the magnitude of change 
when comparing the treatment arms, although the graphical trends are informative.  
Furthermore, serial measures analysis by summary measures including area-under-curve351 is 
not pragmatically feasible without application of parametric testing. An alternative method to 
deal with outliers is logarithmic transformation.  However, using this for change data has 
significant pitfalls: i) the need to add a constant to negative values to render them >0, and ii) 
difficulty in interpretation of a meaningful clinical effect based upon geometric means in this 
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context.  A further strategy would be outlier exclusion: however this can lead to significant 
bias.  In this study, it was clear that some data was outlying – e.g. interquartile range of 12m 
BNP values was -208 to +26 (median -34pg/ml), and only one patient had a change >1500: 
patient A13 who died of progressive heart failure 2 months after completion of follow-up.  
Exclusion of this data point was tested: changes remained non-normally distributed, although 
BNP was significantly reduced in the ablation arm by parametric and non-parametric testing 
(Mann Whitney p=0.023, t-test p=0.048).  However, such observations should be interpreted 
with caution and such techniques were not used during the presented analysis of the study 
data.  
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7.6 Conclusion 
Catheter ablation-based rhythm control, when compared with rate control, led to a significant 
reduction in MR-proANP, which appeared progressive during follow up, and which may be a 
prognostically relevant marker of improved cardiac function.  There was a similar reduction 
in BNP although this was a non-significant trend.  An ablation strategy was associated with a 
marked reduction of the novel peptide Apelin after 6 months, although by 12 months the two 
groups were converging again.   
The correlation of reduced MR-proANP with improved cardiopulmonary, symptomatic and 
imaging indices was striking.  This novel assay may have a role in surveillance and 
prognostication for patients with heart failure, and its reduction appears to lend further weight 
to the finding that catheter ablation-based rhythm control confers an advantage over optimally 
managed rate control.  
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8 Discussion 
8.1 The ARC-HF trial 
Atrial fibrillation (AF) and heart failure are increasingly common conditions in clinical 
practice, management is challenging, and the search for optimal therapy has an ongoing area 
of research for several years.  Up until 2008, when the ARC-HF trial was designed, no 
randomised trial had examined a non-paroxysmal atrial fibrillation (AF) population, nor 
compared catheter ablation with medical rate control, in those with heart failure.  Even in 
2012, this is the first randomised clinical trial of ablation-based rhythm-control, versus rate-
control, of persistent AF in heart failure to focus on objective cardiopulmonary exercise 
capacity.   
A strategy of catheter ablation as a form of rhythm control, when compared with a rigorous 
rate-control strategy, was associated with improvement in the primary endpoint of peak VO2, 
as well as the secondary endpoints of quality-of-life score and neurohormonal status.  Left 
atrial size was reduced by ablation and was associated with evidence of mechanical atrial 
recovery.  Left ventricular ejection fraction (LVEF), which has greater natural variability in 
AF, showed only a non-significant increase when compared with the rate-control arm, 
although the changes in baseline were highly significant for the catheter ablation arm.  It 
should be noted that, for LVEF and several other parameters, improvement trends were seen 
in the rate control arm also – providing evidence that these patients were well-managed, and 
in many cases benefited significantly from well-adjusted rate control and medical therapy 
within the clinical trial environment.  Overall these results suggest that rhythm-control by 
ablation, maintaining sinus rhythm in the vast majority at 1 year, is a more effective strategy 
than medical rate-control.   
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8.1.1 Management of AF 
In general populations with AF, previous studies found no advantage from drug-based 
rhythm-control over rate-control.82, 120 Although sub-group AFFIRM data showed a trend 
towards favourability of rhythm-control in those with heart failure,82 the results from AF-CHF 
subsequently showed no benefit over rate-control.122  The possible reasons for the negative 
outcomes from drug-based rhythm control include the adverse effects of antiarrhythmic drugs 
and the relatively poor efficacy in maintaining sinus rhythm.123  Secondly, when paroxysmal 
patients were included, many patients in the rate control arm would spontaneously return to 
sinus rhythm.  Third, some studies had significant cross-over rates: for instance, in AF-CHF, 
more than 20% of patients crossed over to rate control from rhythm control, and 10% in the 
opposite direction.  These phenomena reduce the potential for, and the ability to detect, a 
benefit of rhythm control therapy.   
There is evidence that sinus rhythm is beneficial, if it can be maintained.35, 352  Whilst this 
might reflect self-selecting cohorts, a role has been argued for a therapy that can maintain 
sinus rhythm with minimal side effects.  As catheter ablation may be able to achieve both 
these goals and had shown promise in non-randomised studies in the heart failure 
population,133, 134 the next logical step was to prospectively compare an ablation-based 
rhythm-control strategy directly against medical rate-control,122, 208 in a well-defined cohort 
with non-paroxysmal AF and systolic heart failure, which formed the basis for ARC-HF.  
8.1.2 Objective exercise performance 
The primary endpoint, peak VO2, is well established as a prognostic indicator in heart 
failure,214-216 and as an endpoint in clinical trials.295, 353  Recently, Swank et al have shown 
that modest increases in peak VO2 were associated with reduced mortality and 
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hospitalization.  For every 6% increase in VO2 at repeat cardiopulmonary exercise testing 
after 3 months, there was a 7% reduction in all-cause mortality.354  The distinct beneficial 
impact of catheter ablation on cardiopulmonary exercise performance found in our study – of 
the magnitude of 20% (mean 19.9% higher than rate control, 95% CI 3.9 to 35.9%, p=0.016) 
– has potential to have favourable prognostic implications for catheter ablation in persistent 
AF in heart failure.  Although analysing the individual changes from baseline between groups 
could underestimate the real benefit of treatment (based on divergent outcomes), if we include 
the patient who died (A20) before final follow-up and assume his peak VO2 would have 
fallen (see also 8.1.7), then 50% of the catheter ablation arm had a >6% rise in peak VO2, 
compared with 23% in the rate-control arm (p=0.04).  The numbers are almost identical for an 
increase of ≥1 ml/kg/min (50% vs. 19%, p=0.020): this latter value was used as a threshold 
for significance by the investigators in the RethinQ study on cardiac resynchronisation 
therapy (CRT) in patients with QRS ≤ 130ms,247 which found no benefit from CRT in this 
population (which excluded patients with persistent AF).  However, the subgroup with 
QRS≥120ms, the population where there is evidence of mortality (and morbidity) benefit 
from CRT,355 did show a significant increase in VO2, consistent with prior studies.295, 356  
Hence, there is direct and indirect evidence of the importance of changes in VO2  in patients 
with heart failure, with an increasing body of evidence to suggest positive changes are 
associated with reduced morbidity and mortality.   
Whilst some caution might be exercised in extrapolating these data to patients with persistent 
AF, as studies have only had relatively small proportions of these patients or in fact excluded 
them, much of the improvement in exercise capacity seen in the rhythm-control arm of ARC-
HF was seen after sinus rhythm had already been restored.  Indeed, the observed changes at 
interim stages of several measured parameters, particularly quality of life score and 
biomarkers, would suggest progressive development of the effects.  The effect of catheter-
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ablation based rhythm control on exercise capacity, visible clearly at the trial end time of 12 
months was very much smaller at 3 months. Previous studies have shown that restoration of 
sinus rhythm by cardioversion can increase peak VO2224 and that continued maintenance of 
sinus rhythm leads to later improvement after 1-2 years,225 although the studies were not 
specifically in patients with heart failure.  It is unlikely that the exercise capacity advantage of 
catheter ablation arises solely from being in sinus rhythm during the exercise test alone, 
because the same high proportion of patients were in sinus rhythm at 3 months and 12 
months, yet ~¾ of the 12-month advantage developed only in those intervening 9 months: an 
additional increment of 2.55 ml/kg/min (95% CI 0.71 to 4.39, p=0.008).  The most likely 
explanation for this is progressive systemic improvement in cardiovascular physiology during 
the year, largely occurring long after sinus rhythm was restored.    
8.1.3 Secondary endpoints 
In the secondary endpoints, the numerical trends were in the same direction for all four (see 
chapter 5 and 6).  Minnesota LHFQ score and BNP improved in the ablation arm, which 
became more visible as follow-up progressed. LHFQ score, a validated measure of 
therapeutic efficacy,357 was improved by a similar magnitude to that previously associated 
with favourable prognostic outcomes.358  The reduction in BNP, previously demonstrated in a 
non-heart failure population,233 may also have prognostic implications. BNP levels appear not 
to be independently affected by rhythm itself in heart failure and remain prognostically 
important.326, 359  
Our study did not show significant differences in the 6-minute walk test, rather a trend 
towards improvement.  However this, being self-paced, is open to an additional degree of 
variation which is not present on formal cardiopulmonary exercise testing, the latter being the 
variable with more extensively-documented relationship to long-term survival.213-216  
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Additionally, several patients were limited in performing this test without walking aids at 
follow up (3 in the ablation arm and 1 in the rate control arm at 12 months) whereas they 
could support themselves on treadmill; another possible reason is that the 6 minute walk was 
always performed at the end of the assessment visit, and fatigue may have been relevant in 
some patients.  LVEF showed a numerical trend to improvement but had sufficient variability 
to make it not possible to distinguish confidently a genuine sizeable improvement from 
chance alone. Nevertheless in head-to-head comparisons objective cardiopulmonary exercise 
capacity shows stronger prognostic power in heart failure than ejection fraction.215, 360 
8.1.4 The left atrium 
Regression of left atrial size occurred with catheter ablation.  Although this has been reported 
in patients without left ventricular dysfunction,316, 317 this is the first such observation in a 
heart failure cohort where atrial dilatation might be expected to be less reversible.  The effect 
was already detectable at 6 months.  Atrial size is likely to be a dynamic consequence of 
multiple influences including medium term remodelling. Thus despite the advanced substrate 
of heart failure and baseline atrial dilatation, given time the atrium has some potential to 
recover partially. It is conceivable this may contribute to reduction of future arrhythmia 
recurrence although previous studies, albeit in non-heart failure populations, have provided 
conflicting data.316, 317, 322, 361    
8.1.5 Procedural outcome  
For catheter ablation, both single procedure and multi-procedure success was higher than 
initially expected in our cohort of patients with mostly long-standing persistent AF and heart 
failure.  Maintenance of sinus rhythm was achieved at 1 year in 92% of the patients who 
underwent ablation, with single procedure success, off antiarrhythmic medication, of 72%.  
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The success rate may reflect the increasing efficacy that modern equipment and protocols are 
now achieving, building upon the initial multi-procedural success of 78% (69% off drugs), 
with 50% requiring a redo ablation procedure, as reported by the Bordeaux group when 
treating a similar population in 2004 with pulmonary vein isolation (PVI) and linear 
lesions.133  More recently, the PABA-CHF study240 achieved 71% freedom from AF off 
antiarrhythmic drugs (and 88% on drugs) at 6 months, although half of the patients were 
paroxysmal rather than persistent.  A recent international consensus recommends that clinical 
trials should enrol patients with only one type of AF,272 to avoid such ‘mixed bags’ cohorts 
and enable clinicians to understand the true impact of therapy.  Also, the aim should be 
restoration and maintenance of sinus rhythm without the need of antiarrhythmic drugs, which 
was not often reported in earlier studies, and is still sometimes not reported in the headline 
results: for example the high success rates of the Cox-Maze surgical procedure are well 
known, but it should be noted that almost a third of patients from the original Cox-Maze III 
cohort were taking antiarrhyhmic drugs at latest follow up.362  In ARC-HF, antiarrhythmic 
drugs were stopped in all patients (except patient A18 who was on sotalol and amiodarone for 
ventricular arrhythmias, and also required repeat ablation for atrial tachycardia) prior to the 
end of the post-ablation blanking period, and in most cases at the point of the ablation 
procedure.  Only standard beta-blockers were continued, along with other appropriate heart 
failure medications.  Hence, importantly, the single-procedure success (69 or 72% depending 
on whether patient A1 – who withdrew consent for ablation – was included in the analysis) 
was reported in patients entirely free of antiarrhythmics for at least 1 year. 
In comparison with these studies, our protocol involved the addition of a lesion at the 
cavotricuspid isthmus, and in most patients the addition of lesions targeting complex 
fractionated electrogram (CFE) sites, in line with more contemporary approaches to 
longstanding persistent AF ablation.273  Perhaps most importantly, our procedures were long, 
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involving mapping steps that have not been routine in previous eras, and probably resulted in 
extensive debulking of left atrial tissue, which in turn may explain why AT was far more 
common than AF during follow up.  The long procedure times inherent to performing and 
confirming block in multiple linear lesions, together with repeat high-density mapping of the 
LA and PV antra at each stage of the procedure, provided a very long waiting time after initial 
PVI during which loss of isolation could be identified and corrected, which might be an 
additional avenue that improved outcome.287, 363   
Since commencement of ARC-HF, a randomised trial with a different ablation protocol that 
delivered only 50% maintenance of sinus rhythm, and with a shorter follow up of 6 months,300  
has reported no significant difference in the primary endpoint of magnetic resonance left 
ventricular EF (p=0.6), N-terminal pro-BNP (0.45) and quality of life (p=0.65).  As the 
investigators themselves commented, a strategy that delivered only 50% maintenance of sinus 
rhythm in the ablation arm greatly reduced the power of the study, requiring (for example) 4 
times as many patients to detect an effect as would a study that maintained all intervened 
patients in sinus rhythm. A second concern is whether ejection fraction is a sufficiently 
comprehensive marker of physiological state, considering the greater prognostic power of 
integrated markers such as objective exercise capacity.214  A third concern is whether 6 
months would be sufficient for the effect of restoration of sinus rhythm to fully manifest.  
This duration of follow-up was also a limitation identified by the authors of the PABA-CHF 
trial in their own study.240  ARC-HF helps put the Macdonald et al300 study in context: the 
difference in headline results between the studies may be not a contradiction but merely a 
manifestation of the markedly different number of patients required to detect an effect.  
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8.1.6 Clinical Implications 
These data suggest that amongst patients with heart failure and persistent AF, a benefit can be 
expected from catheter ablation on symptoms, neurohormonal status and objective exercise 
capacity. They do, however, suggest that the effect takes many months to develop. In the 
context of other studies, it seems that an extensive and robust protocol of ablation - to give 
high efficacy in maintenance of sinus rhythm – may be worthwhile. 
8.1.7 Study limitations 
ARC-HF was a physiological study and was not designed to evaluate event endpoints.  
Studies specifically designed to evaluate prognostic impact of AF ablation are now underway 
and are scheduled to complete in 3 or 4 years including CASTLE-AF (NCT00643188) with 
primary outcomes of mortality and heart failure hospitalisation, and RAFT AF 
(NCT01420393) with the primary endpoint of cardiovascular mortality.  
Although an intention-to-treat protocol was used, the inevitable consequence of patient death 
prior to final follow up is missing data for the endpoints.  We did not impute any values for 
this analysis, although sensitivity analyses have been performed post-hoc: imputation of a 
‘worst case scenario’ group-lowest resting VO2 as his final peak VO2 result still produced a 
statistically significant primary endpoint (mean benefit of catheter ablation +2.63 ml/kg/min, 
95% CI 0.03-5.23, p=0.048).    
There were some minor imbalances in the baseline characteristics of patients, which would be 
expected in approximately 5% of such characteristics in any randomised study.  For instance, 
aldosterone antagonist prescription rate was higher at baseline in the ablation arm, and there 
was a trend towards more patients with CRT in-situ.  However, in regression analysis, neither 
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of these had a significant impact on the studied endpoints (e.g. for change in peak VO2, 
aldosterone antagonist p=0.14, CRT p =0.56).  
Finally, although the trial complied with the minimal monitoring for persistent AF ablation 
suggested by the international consensus statements of both 2007128 and 2012272, it is possible 
that silent episodes of paroxysmal AF were missed during the remainder of follow up.  
However, in a population of patients with (mostly longstanding) persistent AF, the presence 
of sinus rhythm at multiple time points is highly suggestive of a major impact on and 
reduction of arrhythmia burden.  Silent AF or atrial tachycardia episodes >30 seconds were 
not seen in the patients with implanted devices; however, 4 patients had atrial arrhythmias 
picked up when they attended for review with progressive symptoms and were appropriately 
included as rhythm failures, subsequently undergoing ablation in 3 cases (fourth was patient 
A7 – see chapter 5.4.5.1).  In addition, it should be noted that the primary outcome was not 
freedom from AF, but rather a prognostically relevant physiological endpoint, and assessed 
the strategy of AF ablation rather than its success.  Nevertheless, the strategy appeared highly 
successful in maintaining sinus rhythm, and the longer-term follow-up presented in chapter 4 
is consistent with this.  
8.1.8 The ARC-HF trial: conclusions 
ARC-HF, a randomised controlled trial of patients with persistent atrial fibrillation and heart 
failure, indicates that a catheter ablation protocol which achieves maintenance of sinus 
rhythm in the majority produces, after 1 year, improvements in symptoms, neurohormonal 
status and objective physiological exercise capacity.  Progressive improvement from 3 to 12 
months implies that the effects reflect more than just restoration of sinus rhythm and this 
method of rhythm control therapy allows a period of beneficial cardiac remodelling.  Large-
scale trials have now been begun of the prognostic impact of catheter ablation-based rhythm 
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control of atrial fibrillation in heart failure: the encouraging pointers for now is that, under 
randomised controlled conditions, two powerful prognostic markers (VO2 and BNP) respond 
favourably.  
8.2 Impact of catheter ablation on biomarkers 
Previous data has suggested that there is a significant fall in plasma levels of BNP and ANP 
in the first few days after catheter ablation, and essentially this is maintained out to 3 months. 
In patients without significant structural heart disease, this is associated with a significant 
reduction in left atrial diameter, a recovery of atrial mechanical function and increased 
LVEF.233     Similar findings have been found in BNP after cardioversion, if sinus rhythm is 
maintained, including a reduction of plasma apelin.364  The present study would appear to 
suggest that, although there is indeed an early reduction in the first few months, when 
compared in a randomised study with a robust strategy of rate-control, the improvements in 
the ‘control’ arm mean it takes much longer to detect an effect and, indeed, there is 
progressive ‘improvement’ out towards 6-12 months, at least in MR-proANP and BNP.  This 
is in keeping with the results of the main ARC-HF trial which showed that the improvement 
in VO2 predominantly occurred from 3 to 12 months, and was not i) just a reflection of being 
in sinus rhythm at 3 months testing or ii) an improvement which occurred during the early 
phase after sinus rhythm.  The overall picture is of a progressive amelioration of the heart 
failure syndrome – by a process (catheter ablation) associated with a high degree of 
maintenance of sinus rhythm – the data suggesting such amelioration involves gradual atrial 
and ventricular remodelling.  Interestingly, most of the change in LVEF and LA size had 
occurred by 6 months, whereas the most significant differences in MR-proANP and BNP 
were seen at 12 months.  Although 6 month VO2 data was not collected, both VO2 and the 
trend in 6-minute walk tended towards improvement at 12 months, and this might suggest that 
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the early phase of restoration of sinus rhythm (in the majority) with catheter ablation leads to 
a form of mechanical remodelling, whereas the later improvements may reflect overall 
systemic amelioration, with improved symptoms and exercise performance along with 
neuroendocrine ‘stabilisation’.   
8.3 Mapping and catheter ablation for persistent AF  
The data presented in chapter 4 prompts further discussion.  Whilst the study did not 
prospectively seek to compare strategies of ablation, the high single (and multiple) procedural 
success at 1 year, in this cohort with persistent AF, heart failure and dilated atria, would 
suggest that there was something different in the methods used in this cohort compared with 
the lower single procedure success seen in relatively contemporary series of ablation in 
patients with and without structural heart disease.  
The first question is whether linear lesions could be a beneficial component of AF ablation, in 
this and other cohorts.  Recent evidence in a dog model suggests the roof may play a more 
important role than the pulmonary vein antrum in the persistent AF substrate.365  Also, earlier 
work by our group has shown that the roof may participate in the mechanisms present at the 
onset of paroxysmal AF.366  In the present study on the cohort of patients from ARC-HF 
(chapter 4 and 5), completion of all linear lesions – including the left atrial roof, mitral valve 
isthmus, and cavotricuspid isthmus – was shown to be superior to leaving any one of these 
lines incomplete, although strong conclusions cannot be drawn given only small numbers (3 
out of 30 patients).  More importantly, approximately 50% of the atrial tachycardia 
recurrences were related in some way to gaps in these linear lesions.  
It is often unclear in multicentre clinical trials exactly what went on in terms of ablation 
lesion sets, when studies focus on pulmonary vein isolation and leave the rest to operator 
discretion – a case in point being the PABA-CHF study.240  Even worse, many studies enrol 
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‘mixed bags’ of patients in AF (persistently) and predominantly sinus rhythm (paroxysmal 
AF).  Nevertheless, several studies have addressed the question of which ablation strategies 
are optimal, as outlined in Chapter 1.  Linear lesions have been shown to be antiarrhythmic133, 
170, 171, 175, 176, 178, 180, 202, 367-370 and yet are well recognised to have proarrhythmic potential 
through incomplete or recovered conduction block.167, 179, 180, 368, 371, 372  These apparently 
contradictory observations have, not infrequently, come from the same investigatory 
groups.171, 180, 367, 368  It appears that it depends whether one is examining single procedure 
success or the entire journey towards sinus rhythm, which may indeed include atrial 
tachycardia on the way.171, 180, 367, 368  Taking the pro-arrhythmia (for atrial tachycardia) aside, 
the vast majority of the above series have shown a benefit of adding linear lesions in some 
form or other, although this is not a completely universal finding.373  This, together with the 
desire to maximise procedural success (maintenance of sinus rhythm) and minimise the risk 
of regular, often persistent, macroreentrant atrial tachycardias (which may be poorly tolerated 
in, or indeed worsen, pre-existing cardiac failure), and the fact that ARC-HF patients were 
likely to have an ‘advanced’ substrate with dilated and/or hypertrophied atria capable of 
sustaining multiple macroreentrant drivers (see below), formed the basis for an ablation 
protocol design which included these lesions in the first place. 
Some of the mechanistic possibilities to explain the benefit of linear lesions on the atrial 
substrate in AF were discussed in Chapter 4.  In addition to this, a recent study examined the 
impact of linear lesions on the atrial substrate based upon the change in spectral components 
seen at frequency analysis.  It was found that neither PVI, the undisputed cornerstone of all 
AF ablation procedures, nor CFE ablation had a significant impact, but (complete) linear 
lesions led to reduction and elimination of spectral components separate from – and typically 
lower than – the dominant frequency.374 The findings of that study would support the concept 
that some components of AF are lower frequency, simultaneous atrial tachycardias which 
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respond to linear ablation presumably by interruption of a critical isthmus in the potential 
macroreentrant circuit.  Hence targeting CFE or PVI alone may miss such components: this 
may explain why linear lesions are additionally required in a high proportion of patients in 
order to achieve termination of longstanding persistent atrial fibrillation.273, 375  However, with 
extra ablation may come a price – not only that of proarrhythmia should the lines of block 
recover – but the potential for collateral damage to adjacent structures, for instance the 
circumflex artery when ablating the mitral isthmus.376  In our study, the only major life-
threatening complication was tamponade: whilst a recognised complication of ablation 
procedures, the investigators involved in ARC-HF have never otherwise this complication 
occurring during a ‘routine’ cavotricuspid isthmus ablation, and it serves as a reminder that 
ablation of any type is associated with a small but significant risk of complications.  
Complex fractionated electrograms remain another controversy in AF ablation.  There did not 
appear to be any advantage, in terms of long term freedom from AF, of adding routine CFE 
ablation to PVI in patients with paroxysmal AF,377 or in a cohort of patients with mixed 
paroxysmal and persistent AF.378  Another recent randomised study showed that up to 2 hours 
of conventional CFE mapping and ablation after PVI provided no additional clinical 
benefit.256   In contrast, one multicentre trial did show a benefit of CFE ablation, guided by 
the same semi-automated computer algorithm as used within ARC-HF,277 compared with PVI 
alone, for high-burden paroxysmal and persistent AF.   
Addition of CFE ablation in the right atrium and coronary sinus was shown not to be 
routinely beneficial,286 whereas a strategy guided by AF cycle length – as a marker of the 
location predominantly driving AF (which may however oversimplify the underlying 
mechanisms involved) – showed that the RA was implicated in approximately 20% of 
persistent AF cases, and ablation in this chamber could terminate AF in more than half such 
patients.379  Redo ablations in our study largely focussed on the left atrium: ablation was 
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however performed in the right atrium of 2 patients, one of whom had an atrial septal defect 
identified at pre-procedural imaging (patient A4) and in whom the second procedure included 
intercaval and right peri-septal ablation as well as superior vena cava isolation, which then 
rendered him free of AF, and another in whom giant atria were associated with remarkably 
few CFE but rather apparent slow drivers with long cycle length almost like an atrial 
‘torsades’ (in the presence of sotalol and amiodarone for ventricular arrhythmia; patient A18), 
but who was also rendered free of AF by the second procedure.  So the right atrium certainly 
has a role, but it appears this is in a minority of patients.  Furthermore, evidence from the 
high-density biatrial mapping study (see Figure 4-10) would suggest that fractionation seen at 
baseline within the right atrium can be eliminated or significantly reduced by left atrial 
ablation alone, which would suggest a strategy of targeting the right atrium early during an 
ablation procedure should be avoided, particularly to minimise the risk of collateral damage to 
the phrenic nerve and nodal structures. 
In turn, another controversy is the acute endpoint for AF ablation.  As discussed in chapter 4, 
AF termination is used as procedural endpoint for persistent AF ablation by some centres, but 
the evidence from ARC-HF, albeit in a relatively small cohort, would suggest highly 
favourable outcomes can be achieved in the majority without aiming for this endpoint.  
Indeed, some form of electrical and/or structural remodelling, induced by the combination of 
extensive trigger/substrate ablation, a prolonged period of sinus rhythm, and regression of 
atrial dilatation, may bridge the gap between an endpoint as defined by the ARC-HF protocol 
(complete PVI, linear lesions, and map-guided left atrial CFE ablation) and one which seeks 
to terminate AF, which almost inevitably would require ablation of more (potentially viable) 
atrial tissue.  Such atrial tissue may play an important role in both mechanical recovery, but 
also in electrical interatrial and atrioventricular synchrony.  Excessive ablation in the anterior 
wall may lead to excessive delay to, and even isolation of, the lateral components including 
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the left atrial appendage, which may have a negative impact on long-term mechanical 
recovery and thromboembolic risk.   A notable finding of the present study was that linear 
ablation, even more when complete, led to reduction of fractionation within the left atrium 
and thus reduced the target area for CFE ablation (chapter 4): this may be a further avenue to 
minimise collateral damage, that is, perform PVI, then linear ablation, and then reassess the 
atria for presence of CFE.  The finding that linear ablation did not prolong cycle length is 
consistent with the findings and mechanistic implications of the study by Yokohawa et al374, 
and the fact that cycle length did then prolong with residual CFE ablation provides some 
support for the notion that these sites contributed as drivers of ongoing AF, indeed apparently 
leading to termination of fibrillation in several patients.     
So, what is the optimal AF ablation strategy in heart failure patients?  The data from the 
present study may suggest that this question is not the one that requires answering.  Perhaps 
heart failure itself does not lead to a particularly irreversible substrate, and it is perhaps the 
optimal ablation strategy for longstanding persistent AF that remains elusive.  Indeed, it has 
recent been shown that LV dysfunction itself does not independently influence the outcome of 
AF ablation, whereas left atrial size does,380 and our outcomes are at least as good as series 
treating persistent AF in the general (non-heart failure) population. 
A new technique may however have promise in optimising AF ablation procedures, which 
currently employ – at best – a stepwise approach to dealing with an otherwise unknown 
substrate for AF in the individual patient.  Targeting focal impulses and performing rotor 
modulation (FIRM) is a recently reported technique aimed at tailoring the ablation towards 
each patient, by attempting to find the unique drivers of AF in that individual.  In 92 patients 
undergoing ablation for AF (72% persistent) a computer algorithm was used to analyse data 
from a 64-pole basket catheter inserted in the left, and in some cases right, atrium.  Localised 
rotors or focal impulses were detected in 97% of examined cases, and an endpoint of 
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termination or ‘slowing’ (≥10% prolongation of AF cycle length) was achieved in 86% where 
FIRM ablation (initially alone) was applied; more impressively, AF terminated in 56% (20 of 
36 cases).381  Although its application may be limited in dilated atria due to the structure/size 
of the basket catheter and requirement for electrical contact, the reporting of this new 
technique is currently attracting the attention of many arrhythmologists.  This could possibly 
be because it remains so mysterious (the computer algorithm used is proprietary, and the work 
has yet to be validated and reproduced by other investigators), but it could also provide a way 
to terminate and maintain sinus rhythm without excessive destruction of atrial tissue, and may 
allow a reduction in the long procedure times associated with ablation of longstanding 
persistent atrial fibrillation.  Further investigation of this novel technique is awaited.  
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8.4 Conclusion 
The results of the ARC-HF trial and its sub-studies would support the stated hypothesis that 
“a strategy of rhythm control by catheter ablation, compared with rate-control, for 
management of persistent atrial fibrillation in patients with heart failure, improves 
cardiovascular performance, symptoms, and neuroendocrine status”.   
Overall, this research makes a case to support a change in the contemporary clinical practice, 
of many physicians, from a position of accepting so-called ‘chronic’ atrial fibrillation when it 
occurs in patients with heart failure, to the alternative approach of aiming to pursue 
restoration and maintenance of sinus rhythm, which can be achieved with high levels of 
success via catheter ablation without the need of antiarrhythmic drug therapies.  It appears 
that this strategy can expose the underlying benefit that is already known to exist for being in 
sinus rhythm compared with atrial fibrillation.   
The high-density mapping studies (chapters 3-4) provided insights into both the atrial 
substrate and the basis for a rationale stepwise approach in treating patients with relatively 
advanced syndrome of (often longstanding) persistent atrial fibrillation, systolic heart failure, 
and associated atrial dilatation.  The ablation strategy devised was shown to confer a 
remarkably high level of arrhythmia freedom even after a single procedure, when compared 
with pre-existing studies.  However, with similar protocols, there is no obvious reason why 
these results should not be applicable to other centres, as long as sufficient time and resource 
is given to performing the procedures.  Such resources may be limited, but cost burdens are 
likely to be offset by the improvement in morbidity resulting from the procedure, although 
longer term data is awaited regarding the impact of an ablation strategy upon hospitalisation 
and mortality in patients with persistent atrial fibrillation and advanced heart failure.     
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Catheter ablation for persistent atrial fibrillation continues to evolve, as the strategies become 
more refined, and as new evidence comes to light regarding how best to eradicate this rhythm 
that was once thought untreatable.  Newer techniques of mapping may yet allow further 
minimisation of collateral damage with unnecessary ablative destruction of atrial tissue.  
Based upon the evidence gathered in chapters 5-7, this could in turn maximise the potential 
recovery of both atrial and ventricular mechanical, electrical, and neuroendocrine function.  
Furthermore, there is increasing evidence that the surrogate endpoints examined in these 
investigations carry powerful prognostic information.  Hence, for patients with the combined 
conditions of atrial fibrillation and heart failure, catheter ablation-based rhythm control may 
offer not only improved quality of life but also, when coupled with optimal pharmacological 
and device-based therapy, an amelioration of the heart failure syndrome and an improved 
prognosis. 
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10  Appendix 
10.1  Minnesota Questionnaire 
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10.2 Case report form for ARC-HF 
 
Patient Study ID number ________________ 
 
Name 
Hosp no.  
DOB     
Sex      Male     Female  
 
Date of Enrolment _______________ 
Date of Randomisation  _______________  
 
RANDOMISATION GROUP  
RATE CONTROL  CATHETER ABLATION 
Index date for follow up_______________ 
Date of 3M follow-up   _______________ 
Date of 6M follow-up   _______________ 
Date of 12M follow-up   _______________ 
 
 
Patient Study ID number ________________ 
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PAST MEDICAL HISTORY 
 
Coronary artery disease   Y/N 
Myocardial infarction   Y/N 
Percutaneous coronary intervention (PCI) Y/N 
 
CABG     Y/N 
Valve operation    none, MV repair, MVR, AVR, other_______ 
 
Implantable Device in-situ  Y/N if Y:  PPM, CRT-P, CRT-D, ICD Inserted ____date____ 
Pacing dependent? Y/N 
 
COPD/asthma  Y/N    
Hypertension  Y/N 
Diabetes   Insulin / tablet /diet / N  
Smoking  Current / ex- (>3months) / never  
Thyroid disease     Hyper / Hypo/ N  
Renal disease    Y/N 
CVA   Y/N 
TIA   Y/N 
 
Comments/Other (free text) ________________________________________________________ 
 
HEART FAILURE CHARACTERISTICS 
 
Aetiology Ischaemic   Y/N 
Unknown DCM   Y/N 
  Viral DCM   Y/N 
  Valvular    Y/N 
  Hypertension   Y/N 
  Other (free text)____________ 
 
Date of HF  onset/diagnosis 
 
Recent unplanned hospitalisation (<1y) Y/N 
   
ARRHYTHMIA CHARACTERISTICS 
 
First known AF   ______________ 
Duration of AF   ______________ Persistent ; Long-standing persistent (>1 year) 
 
Past DC cardioversion?  N/  Y - number: 1,2,3, >3 
Previous SVT   Y/N 
Previous typical flutter  Y/N 
Prior AV node ablation  Y/N 
Prior other (non-AF) ablation Y/N 
    If Y details __________________ 
Patient Study ID number ________________ 
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SYMPTOMS 
 
Palpitation   Y/N 
Syncope    Y/N 
Angina    Y/N 
Breathlessness   Y/N 
Comments  _______________________ 
 
Orthopnoea (no. pillows)   (n=____) 
PND    Y/N 
Ankle swelling   Y/N 
Fatigue    Y/N 
 
Other   ____________________________ 
 
MEDICATION 
 
Allergies Y/N     If Y: ________ 
ACEi cough Y/N 
BB wheeze Y/N 
 
Warfarin dose (mg) ___________ 
 
  Y/N (for each) Drug Name  Dose in 24h (mg) 
 
ACEi   Y/N ________________   
ARB   Y/N _________________   
B-blocker  Y/N _________________  
Aldosterone ant.  Y/N _________________    
Loop diuretic  Y/N _________________  
Other diuretic  Y/N _________________   
Statin   Y/N _________________ 
Aspirin   Y/N 
Amiodarone  Y/N 
Digoxin   Y/N 
Diltiazem  Y/N 
 
Other ___________________ 
 
 
Previous/failed AADs: None 
Amiodarone 
Sotalol 
class I 
other 
 
Comments_____________________________________ 
Patient Study ID number ________________ 
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CLINICAL EXAMINATION 
 
 
DATE____________ 
 
Height  ______m  Weight ______kg 
BP (mmHg)   ________/_________ 
Heart rate:      (see 6MW)  ________bpm 
ECG: rhythm  AF SR Flutter     other (______) 
 QRSd  ______ms 
  
JVP:    normal raised  markedly raised (>10cm) 
 
Murmur none   systolic diastolic ____________________ 
 
3rd HS  Y/N  4th HS  Y/N 
 
Chest  normal   
crepitations  wheeze 
reduced breath sounds dull to percussion 
 
P. oedema: none mild (ankle) moderate (knee) severe (thigh-sacral) 
 
Comments: ____________________ 
 
________________________________________________________________________ 
 
BASELINE INVESTIGATIONS 
Date__________ 
Comments (free text)___________________________________________________ 
 
NYHA class     
 
I II III IV 
 
Quality of Life questionnaire.   
 
Score   _______/105 ENDPOINT 
 
Blood tests.   
BNP (pmol/L)  _________________ ENDPOINT 
Apelin   _________________ ENDPOINT 
 
Patient Study ID number ________________ 
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Hb (g/dl)  Plts (x109/L)   WCC (x109/L) 
INR 
Na  (mmol/L)  K (mmol/L)  Urea (mmol/L)  Creat (µmol/L) 
Bili (µmol/L)  ALP (U/L)  ALT (IU/L)  Albumin (g/L) 
CRP (mg/L) 
fT4 (pmol/L) 
TSH (IU/L) 
Urate (µmol/L) 
Ferritin (µg/L)  B12 (ng/L) Folate (µg/L) 
 
ECG    
QRS rate (bpm)   ______ 
Rhythm at evaluation:  sinus, AF, AT, other _______ 
QRSd (ms)   ______ 
Axis (degrees)   ______ 
LBBB/RBBB   no, LBBB, RBBB, other _______ 
 
EXERCISE TREADMILL TEST (MVO2)   
 
ECHOCARDIOGRAM    
 
RADIONUCLIDE VENTRICULOGRAPHY.   
EF (%)    ______________ ENDPOINT  
 
SIX MINUTE WALK TEST. (6MW)   
HRpre (bpm)    ________ 
HRend (bpm)    ________ 
6MWD (metres)   ______________ ENDPOINT  
 
HOLTER         
 
___________________________________________________________________ 
Patient Study ID number ________________ 
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RATE CONTROL GROUP 
 
BASELINE 
Date___________ 
Resting HR (bpm)   ____________ 
6MWD peak HR (30sec average) ____________ 
 
Medication change necessary (tick)?  None 
Addition of beta blocker 
      Increased dose of beta blocker 
      Decreased dose of beta blocker 
      Addition of digoxin 
      Increased dose of digoxin 
      Decreased dose of digoxin 
 
      Other________________ 
 
If no changes START FOLLOW-UP PERIOD (to 3, 6, and 12 months) 
 
Otherwise arrange further visit at 4 weeks: 
 
4 WEEK CHECK 
Date___________ 
Resting HR (bpm) ______ 
Ambulant HR(bpm) ______ 
Comments____________ 
Medication change necessary?   
 
If no changes START FOLLOW-UP PERIOD (to 3, 6, and 12 months) 
Otherwise arrange further visit at 8 weeks: 
 
     8 WEEK CHECK 
Date___________ 
Resting HR (bpm) _____ 
Ambulant HR (bpm) ______ 
Comments____________ 
Medication change necessary?  
 
START FOLLOW-UP PERIOD (to 3, 6, and 12 months) 
 
Rate control achieved?  Y/N 
Patient Study ID number ________________ 
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Follow-up 3 MONTHS 
 
Major adverse event:   Y/N 
(tick one or more – with date where relevant) 
 
Unplanned HF admission 
Unstable angina 
MI 
Stroke 
TIA 
Pulmonary embolism 
Cardiac Transplantation 
Death 
 
Any unplanned hospital admission? Y/N  ________________________ 
Significant clinical event?  Y/N ________________________ 
 
 3 month CLINICAL EXAMINATION 
 
DATE____________ 
 
Height  ______m  Weight ______kg 
BP (mmHg)   ________/_________ 
Heart rate:      (see 6MW)  ________bpm 
ECG: rhythm  AF SR Flutter     other (______) 
 QRSd  ______ms 
  
JVP:    normal raised  markedly raised (>10cm) 
 
Murmur none   systolic diastolic ____________________ 
 
3rd HS  Y/N  4th HS  Y/N 
 
Chest  normal   
crepitations  wheeze 
reduced breath sounds dull to percussion 
 
P. oedema: none mild (ankle) moderate (knee) severe (thigh-sacral) 
 
Comments: ____________________ 
 
 
Patient Study ID number ________________ 
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3 month INVESTIGATIONS 
Date__________ 
Comments (free text)___________________________________________________ 
 
NYHA class     
 
I II III IV 
 
Quality of Life questionnaire.   
Score   _______/105 ENDPOINT 
 
 Blood tests.   
BNP (pmol/L)  _________________ ENDPOINT 
Apelin   _________________ ENDPOINT 
 
ECG    
 
QRS rate (bpm)   ______ 
Rhythm at evaluation:  sinus, AF, AT, other _______ 
 
 EXERCISE TREADMILL TEST (MVO2)   
 
SIX MINUTE WALK TEST. (6MW)   
HRpre (bpm)    ________ 
HRend (bpm)    ________ 
6MWD (metres)   ______________ENDPOINT  
 
Patient Study ID number ________________ 
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Follow-up 6 MONTHS 
 
Major adverse event:   Y/N 
(tick one or more – with date where relevant) 
 
Unplanned HF admission 
Unstable angina 
MI 
Stroke 
TIA 
Pulmonary embolism 
Cardiac Transplantation 
Death 
 
Any unplanned hospital admission? Y/N  ________________________ 
 
Significant clinical event?  Y/N ________________________ 
 
 
6 month CLINICAL EXAMINATION 
 
DATE____________ 
 
Height  ______m  Weight ______kg 
BP (mmHg)   ________/_________ 
Heart rate:      (see 6MW)  ________bpm 
ECG: rhythm  AF SR Flutter     other (______) 
 QRSd  ______ms 
  
JVP:    normal raised  markedly raised (>10cm) 
 
Murmur none   systolic diastolic ____________________ 
 
3rd HS  Y/N  4th HS  Y/N 
 
Chest  normal   
crepitations  wheeze 
reduced breath sounds dull to percussion 
 
P. oedema: none mild (ankle) moderate (knee) severe (thigh-sacral) 
 
Comments: ____________________ 
Patient Study ID number ________________ 
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6 month INVESTIGATIONS 
Date__________ 
Comments (free text)___________________________________________________ 
 
NYHA class     
 
I II III IV 
 
Quality of Life questionnaire.   
Score   _______/105    ENDPOINT 
 
Blood tests.   
DATE___________ 
BNP (pmol/L)  _________________ENDPOINT 
Apelin   _________________ENDPOINT 
 
ECG    
DATE_________ 
QRS rate (bpm)   ______ 
Rhythm at evaluation:  sinus, AF, AT, other _______ 
QRSd (ms)   ______ 
Axis (degrees)   ______ 
LBBB/RBBB   no, LBBB, RBBB, other _______ 
 
ECHOCARDIOGRAM    
 
SIX MINUTE WALK TEST. (6MW)   
DATE____________ 
 
HRpre (bpm)    ________ 
HRend (bpm)    ________ 
6MWD (metres)   ______________ENDPOINT  
 
HOLTER         
Patient Study ID number ________________ 
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Final visit 12 MONTHS 
 
Major adverse event:   Y/N 
(tick one or more – with date where relevant) 
 
Unplanned HF admission 
Unstable angina 
MI 
Stroke 
TIA 
Pulmonary embolism 
Cardiac Transplantation 
Death 
 
Any unplanned hospital admission? Y/N  ________________________ 
Significant clinical event?  Y/N ________________________ 
 
 
12 month CLINICAL EXAMINATION 
DATE____________ 
 
Height  ______m  Weight ______kg 
BP (mmHg)   ________/_________ 
Heart rate:      (see 6MW)  ________bpm 
ECG: rhythm  AF SR Flutter     other (______) 
 QRSd  ______ms 
  
JVP:    normal raised  markedly raised (>10cm) 
 
Murmur none   systolic diastolic ____________________ 
 
3rd HS  Y/N  4th HS  Y/N 
 
Chest  normal   
crepitations  wheeze 
reduced breath sounds dull to percussion 
 
P. oedema: none mild (ankle) moderate (knee) severe (thigh-sacral) 
 
Comments: ____________________ 
 
Patient Study ID number ________________ 
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12 MONTH   INVESTIGATIONS 
Date__________ 
Comments (free text)___________________________________________________ 
 
NYHA class     
 
I II III IV 
 
Quality of Life questionnaire.   
Score   _______/105 ENDPOINT 
 
Blood tests.   
BNP (pmol/L)  _________________ ENDPOINT 
Apelin   _________________ ENDPOINT 
 
ECG    
QRS rate (bpm)   ______ 
Rhythm at evaluation:  sinus, AF, AT, other _______ 
QRSd (ms)   ______ 
Axis (degrees)   ______ 
LBBB/RBBB   no, LBBB, RBBB, other _______ 
 
EXERCISE TREADMILL TEST (MVO2)   
 
ECHOCARDIOGRAM    
 
RADIONUCLIDE VENTRICULOGRAPHY.   
EF (%)    ______________ ENDPOINT  
 
SIX MINUTE WALK TEST. (6MW)   
HRpre (bpm)    ________ 
HRend (bpm)    ________ 
6MWD (metres)   ______________ ENDPOINT  
 
HOLTER         
 
___________________________________________________________________
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10.3 Case report form for ARC-HF ablation procedures 
Case%report%form%for%ARC.HF%RF%ablation%procedures%
%Patient'Study'ID!_______________!! !!!RFA'number!!!!!!!1!!!!!!2!!!!!!3! !!!!!Site''''''''HH!!!/!!RBH!Date'____/____/________! Operator'1'________________'Operator'2'___________________'3D'mapping'system:''''NavX!/!CARTO! ! Navigation'system:'No!/!Stereotaxis!/!Hansen!Procedure'time'(min)'_____________''''Ablation'time'(sec)'____________''''Saline'dose'(ml)___________' 'Heparin'dose'(IU)_______________''''''Fluoroscopy'time'(min)'____________''Dose'Area'Product'(cGycm2)'________'Baseline'rhythm''''AF,!SR,!AT/flutter! Baseline'V1'cycle'length'(ms)'__________________'
!
Start!time'______________''Femoral!access!time'___________________''Transeptal!x2!access!time''_______________'
RA!geo__________J_____________RACFE____________J___________''LA!geo____________J___________'LA!CFE___________J_____________'AFCL'after&stage&(ms)' CFE'regions'(tick'when'acquired)'Time''StartJJJend' ' LAA' RAA'
CFE'map'
Ant' Pos' Sep' Flo' Rf' LAA' MVI'
''''''''''''''' Baseline!
tick'if'done' Block' Cumulative'RF'time'(sec)'
' ' ' ' ' ' ' ' ' '
!!!!!!!!!!!!!!!!! PVI! ' Y/N' ' ' ' ' ' ' ' ' ' ' '
! Roof!line! ' Y/N' ' ' ' ' ' ' ' ' ' ' '
! MVI!line! ' Y/N' ' ' ' ' ' ' ' ' ' ' '' Endo'CS' ' ' ' ' ' ' ' ' ' ' ' ' '' Epi'CS' ' ' ' ' ' ' ' ' ' ' ' ' '
! CFAE' ' ' ' ' ' ' ' ' ' ' ' ' '' Other'___________' ' ' ' ' ' ' ' ' ' ' ' ' '' SVC'iso' ' ' ' ' ' ' ' ' ' ' ' ' '
! CTI!line' ' Y/N' ' ' ' ' ' ' ' ' ' ' '
'End'time'(sheaths'out)'_____________________'Termination'of'AF' No!/!To!AT!/!To!SR' 'DCCV'required'to'restore'SR'' Yes!–!successful!! Yes!–!unsuccessful!! ! No!Comments'(free'text)'________________________________________________________________________________'Procedural'complications'(up'until'discharge'form'hospital)'''
None!/!Stroke!or!TIA!/!Tamponade!/!Vascular!/!other!(free!text)___________________________!
Rhythm!at!discharge!! SR! AF!! AT!! other!________________!ITU'stay'if'needed'(days)______________' ' ' ' Hospital'stay'(days)'_________'
Log!all!time!points!on!Bard!–!annotate!all!geometry!and!CFE!maps!'
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10.4 Patient information sheet for ARC-HF 
 
A randomised trial to assess  
Catheter Ablation versus Rate-Control  
for Management of Persistent Atrial Fibrillation in Patients with Chronic Heart Failure 
ARC-HF 
Patient information sheet 
We invite you to consider taking part in a research project. 
What is the purpose of the research? 
It is still uncertain what the best treatment is for patients who have both atrial fibrillation (AF) and 
heart failure.  The aim of the research study is to help identify the optimal treatment for patients with 
these two significant medical conditions.  This will be done by comparing two different treatments, 
catheter ablation and rate-control, which are alternative strategies for treating AF.  Patients will be 
randomly assigned (like tossing a coin) to one or the other, and the effect of each strategy assessed by 
looking for changes in exercise capacity, symptoms, heart pump function, and quality of life.  
Why have I been invited to participate? 
We are inviting patients with activity-limiting symptoms (such as shortness of breath, tiredness, or 
palpitations), significantly reduced heart function, and AF to consider participating. 
Background to the research study 
What is atrial fibrillation? 
Normal heart rhythm depends on regular electrical activity of your natural pacemaker cells – the sinus 
node, which usually ‘fires’ at about 60-100 beats per minute.  The impulse spreads to create a 
coordinated contraction of the heart and the rate responds to the needs of the body, so the heart speeds 
up with activity and slows down on resting.  In AF, however, the normal sinus rhythm is lost: the 
upper collecting chambers (atria) have a completely chaotic rhythm (fibrillation) and no longer pump 
effectively.  At the connection to the lower pumping chambers, the heart ‘filters out’ many of the 
impulses so the heart still pumps – but with an irregular, often fast, heart beat which may respond 
poorly to the needs of the body.   
What is heart failure?  
The term can be confusing as it does not mean the heart has actually failed.  Heart failure occurs when 
the pump function of the heart is reduced and can lead to symptoms such as tiredness, swollen ankles 
and breathing difficulty.  Heart failure can cause AF, and vice versa. Patients with heart failure are far 
more likely than patients with normal hearts to develop AF, which affects about 10% of those with 
milder forms of heart failure but up to 1 in 2 patients with severe heart failure.   
How is atrial fibrillation treated in patients with heart failure? 
There are two alternative treatment strategies for AF, which doctors may use to try to improve the 
symptoms related to it, as well as longer-term health: 
1. Rate-control. This means patients taking heart-rate slowing tablets to prevent very fast heart 
rates and allow the heart to pump more efficiently.  AF itself is ‘accepted’ as the long-term 
heart rhythm. 
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2. Rhythm-control. This means trying to restore and maintain normal rhythm, by the means of 
electric shock treatment (DC cardioversion) together with long-term tablet medication, or by 
more recently available ‘cauterisation’ therapy (catheter ablation). 
 
All patients with AF and heart failure should ideally be on blood thinning medication, usually 
warfarin, to reduce the risk of stroke.  Also it is important that other conditions, like diabetes, thyroid 
problems, and blood pressure are all optimally treated.   
How might this study help identify the optimal treatment?  
Doctors still do not know how best to treat AF that occurs in patients with heart failure. Some studies 
have shown that patients do better if they get back to normal rhythm, whilst others showed no overall 
long-term benefit from giving tablet-based rhythm control compared with leaving patients in AF and 
just giving rate-control.  DC cardioversion can restore normal rhythm but does not prevent recurrence 
of AF, whilst rhythm-controlling drugs carry a risk of side effects and do not prevent over half of 
patients experiencing further AF.   
The more recent therapy of catheter ablation can treat the abnormalities that cause AF to persist and, 
although like any procedure carries some risk (see page 5), it can offer long-term remission from AF 
and may be a better rhythm-control strategy.  Small studies have shown that catheter ablation for AF is 
beneficial in patients with heart failure, but it has not yet been directly compared with medical rate 
control.  Without head-to-head direct comparison of ablation (to restore normal sinus rhythm) versus 
medical rate-control, doctors will not know which is the better treatment of AF in patients with heart 
failure.  With the aim of answering this important question, we are conducting a randomised clinical 
trial.  This involves assigning patients at random to one of the two treatments, to see if either shows 
benefit.  By randomising patients, there is less chance of unfair bias towards either treatment. 
 
The research study – participant information 
What will happen to me if I agree to take part in this study? 
We will first check that you are on optimal medication for your heart failure. You might also be on 
additional tablets to treat your AF.  If you meet the entry criteria and are willing to participate we will 
arrange for you to have a ‘baseline’ assessment including some standard tests of heart function. The 
aim is see how you are before and after the treatments, using several different methods - as no single 
test can definitely tell us whether you or your heart have improved.  We will arrange with you a day 
for you to attend for the following tests (some of which you might already have had during your recent 
clinic visits and therefore may not need to be repeated).  You should wear comfortable shoes and 
clothing that will allow you to perform the walking/exercise tests. 
! History & clinical examination – like at a normal out-patient clinic visit.  
! Quality of Life questionnaire.  This is a single-page questionnaire consisting of 21 questions 
about your symptoms: you circle a score for each on scale of 0-5. It takes about 5 minutes to 
complete. 
! Blood tests. About 30ml of blood will be taken for routine tests (blood counts, 
kidney/liver/thyroid). Some samples will be stored for tests looking at specific proteins 
relevant to heart function. 
! ECG (Electrocardiogram) and Exercise treadmill test (MVO2) to assess maximum exercise 
capacity and your body’s ability to use oxygen. You will breathe normal air through a mask 
while walking on a treadmill, which gradually increases in speed and steepness (in a way 
designed for patients with weakened hearts). You will be supervised and monitored 
throughout by medical staff, and can stop once you are too tired or if you feel unwell. 
Typically this test takes 10-15 minutes. 
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! Echocardiogram (heart ultrasound scan). You are likely to have already had this scan, which 
looks at the heart muscle and valve function by ultrasound. It takes 15-20 minutes. 
! Radionuclide ventriculography (RNV scan).  This scan involves an injection of a small 
amount of radioactive substance into the bloodstream, which highlights the heart chamber on 
a scanner allowing very accurate measurement of your heart’s pumping function.  It takes 
about 30 minutes, during which time you will be lying on the scanning bed.  
! Six minute walk test.  You will be asked to walk as far as you can in six minutes along a flat 
corridor circuit, resting if necessary at the seats provided.  Your heart rate will be checked.  
! Holter recorder (24-48 hour wearable heart monitor).  You will wear the monitor home so 
we can check your heart rate during routine activities. The recorder should be removed if you 
have a bath or shower; you will be shown how to put it back on.  We will arrange its return 
with you.     
After these tests you will be randomly assigned by computer to one of two groups: medical therapy 
(rate-control) or catheter ablation (rhythm control).  You have an equal chance of being in either 
group. 
 
What will happen if I am assigned to medical therapy (rate control)? 
What is rate-control? 
Rate control is a strategy of preventing excessively fast heart beats during AF, by giving treatment to 
slow down the pumping chambers of the heart. You will probably already be on such rate control 
medication.  Some patients also have a pacemaker to prevent slow heart beats.  Research has shown 
that fast and erratic heart beats caused by AF worsen symptoms, reduce exercise capacity, and trigger 
or worsen heart failure in some cases. Previous large research studies have therefore used heart-rate 
‘targets’ or ‘goals’ for AF patients, with maximum levels for rest and exercise.   
The dose of medicine required to achieve rate control varies widely between patients and needs 
adjusting on an individual basis.  This usually involves a number of repeat medical assessments before 
the medication can be judged ‘optimal’.   
Rate-control treatment   
The aim of treatment will be to control your heart rate (pulse) by optimizing the rate-control 
medication.  We will assess you at several points during the study period to see how this affects your 
symptoms, exercise capacity, and other heart function results. 
! Your baseline assessment will help us establish whether you have satisfactory rate control.  
! Targets for rate control will be a heart rate <80 (beats per minute) at rest and <110 during 
walking  
! If necessary we will see you again after 4-8 weeks to check that rate control has been achieved 
and to fine-tune your medication as necessary. 
 
You will then be seen for follow up as below, undergoing the same assessments and investigations as 
the catheter ablation patients.  Your medication will again be carefully reviewed and adjusted as 
necessary at each of these visits, using the information from the walking and monitoring tests, so that 
we can ensure you are on optimal treatment.  
 
 
What will happen if I am assigned to catheter ablation (rhythm control)? 
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What is catheter ablation? 
Catheter ablation was introduced in the late 1980s and can be used to treat many heart rhythm 
problems.  This minimally invasive procedure has been adapted and developed in the last 10 years to 
treating more complex rhythms such as AF.  It is performed by passing a long wire (catheter) to the 
heart, through a small puncture in a vein in the leg, and using radiofrequency energy to heat up small 
discrete areas of the heart tissue to eliminate abnormal electrical impulses (ablation).  Each treated 
area is very small (3-4mm) so the technique can be applied in an accurate point-by-point fashion.  
During catheter ablation of AF, only a selected part of the upper heart chambers is treated, so the main 
pumping chambers are unaffected.   
The catheter ablation procedure 
We will arrange an admission date with you for the procedure. You will be in hospital for 2 days in 
most cases.  Our institutional protocol for catheter ablation is well established, so none of the below is 
‘experimental’, being used routinely for the patients undergoing these procedures.   
You should continue taking warfarin as normal, aiming for a target of INR 2-3 in the 4 weeks prior to 
the procedure. We will tell you if any medication needs to be stopped before the procedure, otherwise 
continue all tablets as normal.    
You will be admitted to a hospital ward the afternoon before or morning of your procedure, where you 
will be assessed by medical staff including an anaesthetic doctor. A drip-tube (cannula) will be 
inserted in your arm for routine blood tests and for administering medications.  You should not eat or 
drink (except sips of water to take tablets) for 6 hours before your procedure.   
The whole procedure lasts about 3-5 hours and is carried out under general anaesthetic (sometimes 
local anaesthetic and sedative medication), in the cardiac catheter laboratory (a room similar to an 
operating theatre with specialist equipment such as X-ray cameras and other equipment needed for the 
procedure).  Once you are under anaesthetic, we will check there is no blood clot in your heart by 
doing an ultrasound test via your food-pipe.♥  Then the skin in your groin area will be cleaned and 
small plastic tubes placed in the veins and artery.  Thin plastic-coated wires called catheters will be 
inserted through the tubes and steered to the heart.  The left atrium, the main area for treatment, will 
be accessed with a long needle and plastic tube via the groin. You will then receive blood-thinning 
medication (heparin) to prevent blood clot formation during the procedure.  The ablation will then be 
performed to eliminate the abnormal areas of electrical activity.  If you remain in AF afterwards, you 
will undergo a DC cardioversion at the end of the procedure. 
At the end of the procedure, blood thinning will be stopped and the tubes removed from your groin.  
Local anaesthetic will be given to numb the area, and then the anaesthetist will wake you up.  Some 
patients may be looked after in intensive care or ‘recovery’ before returning to the ward.  You will 
need to lie flat for 1-2 hours after the procedure to reduce the chance of groin bleeding.   
You will typically be discharged the day after the procedure unless you require other medical care.♥♥ 
If you experience a recurrence of abnormal heart rhythm in the first 2 months after ablation, we would 
try to restore your normal rhythm by performing DC cardioversion, as a day-case under brief general 
anaesthetic.  Recurrence after 2 months suggests the procedure was not completely effective – we 
would then offer a second ablation procedure, as per standard practice.  Some patients require several 
                                                
♥ If a clot is present it would be unsafe to proceed and you would be woken up; we would increase the dose of your warfarin, 
and bring you back after 2 months for a repeat procedure. 
♥♥ You should not drive for 2 days after the procedure, because of DVLA regulations. 
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ablation procedures to achieve long-term remission from AF (the maximum number you can undergo 
during this study is three).  After ablation, you will be followed up as below. 
 
What follow up will I receive? 
We would like to find out about the effect of each type of treatment on your day-to-day living, 
exercise capacity, and heart function.  Hence we will arrange a follow-up timetable with you (as 
below) for repeat tests, which can again be performed during a daytime visit to the hospital.  At each 
visit you will be carefully assessed and your medical treatments reviewed and adjusted as necessary. 
After this time, the study will be completed, and you will be referred back to your original specialist 
doctor. We will then analyse all the results from the patients who have participated in the study.  Once 
the data analysis is complete, we aim to publish the results in scientific journals and would notify all 
participants of the outcomes, via your GP or in person.  If you continue to require specialist heart-
rhythm care, you will be offered further follow up in an appropriate cardiology clinic at Royal 
Brompton or Harefield Hospital.   
Are these treatments safe? Are there any risks? 
Your safety is of utmost importance to us.  We appreciate that all medical treatments involve some 
degree of risk, and this is offset against potential benefit.  Neither arm of the study involves 
experimental treatments in that both rate-control and catheter ablation therapies are recognised 
treatments for patients with AF.  Royal Brompton and Harefield NHS Foundation Trust carry out 
around 500 AF ablation procedures annually and is one of the largest UK centres.  We also have a 
specialist heart failure team, run by internationally recognised experts in the field; hence your care will 
be overseen by highly experienced health care professionals.  
All procedures involving the heart carry a risk of a significant complication. This may be balanced 
against both the long-term risk of stroke/major bleeding if remaining in AF (on warfarin) – 
approximately 1% per year, the benefits of being back in normal rhythm, and the possibility of side-
effects and adverse reactions on rhythm-control medication.  The catheter ablation procedure is 
associated with the following possible complications, of which you should be aware: 
• Stroke or other major blood clot can occur in 1 in 200 cases (0.5%).  To minimise this risk, 
the presence of a blood clot in the heart will be ruled out by ultrasound assessment before the 
procedure, and also your blood will be carefully thinned during ablation.   
• In 1-2% of cases, blood can leak around the heart during or after the procedure.  This may 
require a small plastic tube to be inserted just under the ribcage at the upper part of the 
tummy. Rarely, in about 1 in 500 cases (0.2%), the leakage has to be operated on by open 
chest surgery. 
• Narrowing of a blood vessel (pulmonary vein) that carries blood from the lungs back to the 
heart is rare with modern ablation techniques, but may require treatment in about 0.5% (1 in 
200 cases).  
3 months 
Quality of Life Questionnaire 
ECG, Blood tests, MVO2 
6 minute walk  
12 months  
Quality of Life Questionnaire  
ECG, Blood tests, MVO2, RNV 
scan, Echocardiogram, 
24-48h Holter, 6 minute walk  
6 months 
Quality of Life Questionnaire 
ECG, Blood tests, 6 minute walk, 
Echocardiogram, 24-48h Holter  
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• Bruising and other problems relating to blood vessel damage may occur in up to 5% of cases.  
Most of these are small haematomas (blood collection larger than a bruise), which usually get 
better in a few days.  Less common is a blood collection communicating directly with the 
artery below (pseudoaneurysm), or formation of an abnormal vein−artery connection (fistula).  
These usually get better by themselves with time; operations are only required in less than 1 
in 100 cases (<1%). 
• The nerve responsible for the movement of one side of the breathing muscle (diaphragm) can 
rarely be damaged by the ablation, in 0.3% of cases, which is only permanent in less than 1 in 
1000.   
• Inadvertent ablation of the specialised conducting tissues of the heart can require insertion of 
a permanent pacemaker.  The risk of this is very low at approximately 0.25% or 1 in 400.   
• Life-threatening complications are rare: according to a worldwide survey, the risk of death 
associated with catheter ablation of AF is 0.1% (1 in 1000). 
 
You will be exposed to some radiation during the RNV scans and ablation procedures.  We are all 
exposed to natural background radiation every day of our lives, and each X-ray or nuclear medicine 
examination adds a small additional dose on top of this.  Such additional exposure may slightly 
increase the risk of developing cancer many years or decades later.  To quantify this, we have worked 
out the maximum exposure you could receive as allowed by this study protocol – that being if a 
patient underwent the RNV scans plus three ablation procedures, each with the maximal permitted X-
ray dose (i.e. the majority of patients will receive a much lower dose, thus the following risk is an 
overestimate).  At this level of exposure, about 1 in 500 people may acquire a cancer during their 
whole lifetime.  We all have about a 1in3 to 1in4 chance of getting cancer during our lives, so the 
actual increase in risk is small (e.g. 33.3% increased to 33.5%). Skin injury such as redness similar to 
sunburn may rarely occur, but should not occur using modern X-ray equipment.  Total radiation dose 
at ablation will be minimised by use of pulsed X-ray and the special mapping system. 
Are there any benefits? 
At present we do not know which treatment group will benefit more, because the reason to perform 
the study is to establish which form of treatment for AF is better for patients in heart failure.  It is 
possible that participants may benefit from being in the clinical trial simply because of undergoing 
more detailed tests and slightly more frequent visits to see doctors than usual (depending on your 
previous circumstances). This might provide the opportunity for us or your doctor to look after any 
heart problems more closely and to pick-up any other health related problems sooner than in routine 
clinical care.  
Do I have a choice? 
Yes. Your participation in this study is entirely voluntary, and there is no obligation to participate. If 
you choose not to join the study your medical care will not be affected.  You may withdraw from the 
study at any time without compromising your future medical treatment. 
 
Are there any financial incentives for participation? 
 
There are no financial incentives for participation.   
 
I’m considering taking part in the research study, but I would like time to consider this 
information further before deciding. By when do I need to inform you? 
 
We are keen for all patients to have a clear understanding of the reasons for the research trial and what 
it will involve, and have the opportunity to ask questions prior to enrolment.  Most will need a few 
days to consider the information in this sheet, discuss it with family members, or perhaps do their own 
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research into the subject via the internet.  We would ask participants to answer if possible within 1-2 
weeks, depending on their circumstances.  See contact details below. 
 
 
Confidentiality 
All aspects of this study, including results, will be strictly confidential and only the researchers will 
have access to your personal information.  Person-identifiable data will be stored on secure non-
portable NHS computer systems.  Investigation data used for analysis spreadsheets will be de-
identified by the use of numerical codes. Publication of the results from this study will only use de-
identified information.  The samples that are frozen on-site for later analysis will only display your 
confidential study code number. 
 
Will my general practitioner be informed of my participation? 
Yes, if you give your permission on the consent form.  Informing your GP is professionally courteous 
on our part, and can help continuity in your medical management.   
 
What if something goes wrong? 
In the event that something does go wrong and you are harmed during the research and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation against the 
Royal Brompton and Harefield NHS Trust, although you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will still be available to you. NHS Indemnity 
does not offer no-fault compensation i.e. for non-negligent harm, and NHS bodies are unable to agree 
in advance to pay compensation for non-negligent harm. 
 
I am told I am not eligible to participate in the trial – could you explain why? 
Patients have to fit the ‘inclusion criteria’: symptoms of heart failure above 18 and under 80 years old, 
confirmation of significant heart impairment on heart scan, and at least 7 days of AF.  It may not be 
appropriate for patients with certain medical conditions to undergo the investigations and/or 
treatments set out within this trial, thus there are also certain ‘exclusion criteria’: these include 
advanced kidney, liver, brain or muscular disease, previous AF ablation treatment, recent surgery 
(including a pacemaker if the leads were implanted less than 6 months ago), or an inability to take 
certain medications like warfarin.  You may ask the research doctor to discuss these further. 
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Contact details 
 
If you require further information before deciding, wish to enrol, or have any questions about 
your treatment during the study, please contact: 
 
 
Dr David Gareth Jones, Fellow in Cardiac Electrophysiology 
 
email  davidgarethjones@nhs.net 
 
mobile (text/voicemail)  07847 095863 
 
telephone via Brompton switchboard (020 7352 8121) 
 
fax 0871 2668748 
 
 
Alexandra Wise, BHF Arrhythmia Nurse Specialist 
 
Ask for bleep 1146 via Brompton switchboard 
 
email a.wise@rbht.nhs.uk  
 
 
For urgent matters outside of normal working hours, you may contact: 
 
On-call cardiology registrar, via Brompton or Harefield switchboard 
 
 
To confidentially discuss any concerns and queries about your experience at the hospital 
while participating in this research, and for advice or support, you may contact: 
 
Royal Brompton and Harefield Patient Advice and Liaison Service (PALS) 
 
Royal Brompton Hospital, Sydney Street, London SW3 6NP 
Tel: 020 7352 8121      Fax: 020 7351 8108 
 
Harefield Hospital, Hill End Road, Harefield, Middlesex UB9 6JH 
Tel: 01895 826 572 
 
Email: patientadviceandliaisonservice@rbht.nhs.uk 
 
 
 
Thank you very much for reading this information sheet. 
 
The ARC-HF Study Investigators 
 
 Principal Investigator     Study coordinator/co-investigator 
 Dr Tom Wong, RBH & HH    Dr David Gareth Jones, RBH & HH 
 
 Co-investigators      
 Dr Shouvik Haldar, RBH & HH 
 Dr Vias Markides, RBH & HH     
 Dr Rakesh Sharma, RBH      
 Dr Theresa McDonagh, RBH 
 Dr Shelley Rahman-Haley, HH 
 Professor Richard Underwood, RBH 
 
